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ABSTRACT 
Justin M. Long 
 
NOVEL REGULATION OF NEURONAL GENES IMPLICATED IN ALZHEIMER 
DISEASE BY MICRORNA 
 
Alzheimer disease (AD) results, in part, from the excess accumulation of the 
amyloid-β peptide (Aβ) as neuritic plaques in the brain. The short Aβ peptide is derived 
from a large transmembrane precursor protein, APP. Two different proteolytic enzymes, 
BACE1 and the gamma-secretase complex, are responsible for cleaving Aβ peptide 
from APP through an intricate processing pathway. Dysregulation of APP and BACE1 
levels leading to excess Aβ deposition has been implicated in various forms of AD. Thus, 
a major goal in this dissertation was to discover novel regulatory pathways that control 
APP and BACE1 expression as a means to identify novel drug targets central to the Aβ-
generating process. MicroRNAs (miRNA) are short, non-coding RNAs that act as post-
transcriptional regulators of gene expression through specific interactions with target 
mRNAs. Global analyses predict that over sixty percent of human transcripts contain 
evolutionarily conserved miRNA target sites. Therefore, the specific hypothesis tested 
was that miRNA are relevant regulators of APP and BACE1 expression.  
In this work, several specific miRNA were identified that regulate APP protein 
expression (miR-101, miR-153 and miR-346) or BACE1 expression (miR-339-5p). These 
miRNAs mediated their post-transcriptional effects via interactions with specific target 
sites in the APP and BACE1 transcripts. Importantly, these miRNA also altered secretion 
of Aβ peptides in primary human fetal brain cultures. Surprisingly, miR-346 stimulated 
APP expression via target sites in the APP 5’-UTR. The mechanism of this effect 
appears to involve other RNA-binding proteins that bind to the APP 5’-UTR. 
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Expression analyses demonstrated that these miRNAs are expressed to varying 
degrees in the human brain. Notably, miR-101, miR-153 and miR-339-5p are 
dysregulated in the AD brain at various stages of the disease. The work in this 
dissertation supports the hypothesis that miRNAs are important regulators of APP and 
BACE1 expression and are capable of altering Aβ homeostasis. Therefore, these miRNA 
may possibly serve as novel therapeutic targets for AD. 
Feng C. Zhou, PhD, Chair 
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CHAPTER 1: INTRODUCTION 
The anatomical and cytoarchitectural complexity of the central nervous system 
(CNS) is a function of an equally sophisticated molecular framework. Derangements in 
tightly regulated molecular pathways underlying this complexity are not surprisingly 
linked to many CNS disorders, including Alzheimer disease (AD), a debilitating 
neurodegenerative disorder of unknown etiology lacking effective therapeutics. Gene 
expression is a critical node at which regulatory influences on molecular pathways are 
exerted. As such, fleshing out the full complement of regulatory schemes responsible 
for control of CNS gene expression should be a priority in the search for novel points of 
intervention against CNS disorders. Elucidating these regulatory networks not only 
provides a reference for comparison to the diseased state but also expands the number 
of functionally validated drug targets that might be critical to developing effective 
therapeutics. In pursuit of this goal, this dissertation describes novel mechanisms 
utilized by human CNS cells to post-transcriptionally regulate expression of two gene 
products implicated in AD etiology and explores dysregulation of these mechanisms in 
the AD brain. 
 
I. Alzheimer Disease (AD) Background  
 
A. Clinical and neuropathological overview 
Dementia is a devastating consequence of aging, and AD accounts for the 
largest proportion of dementia cases in the elderly. An estimated 5.4 million people will 
be afflicted with AD in the United States during 2012 [1,2]. With the expected increase 
in life expectancy and the aging of the baby boomer generation, that number is 
projected to rise to somewhere between 11 – 16 million people by 2050. The disease is 
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not only debilitating to the afflicted patient, but also results in a significant burden to 
caretakers and the national and global health care systems. 
The earliest clinical manifestation of the disease is an anterograde amnesia 
characterized by loss in retention of newly formed memories [3]. Declarative memory 
(esp. episodic memory) is most profoundly affected in the early course of the disease. 
Deficits in language and visuospatial skills also occur early. Impairments in procedural 
memory, learned motor skills, and executive function only arise in more advanced 
stages of the disease. Depression and other mood disorders frequently manifest during 
the course of the disease [4], as do changes in personality [5]. The course of dementia 
is always progressive. Activities of daily living are profoundly affected and ultimately the 
patient becomes bed-ridden. This invariably leads to death, generally secondary to 
dehydration, malnutrition or infection [6]. The average life expectancy following 
diagnosis is generally between 3 to 8 years [7,8].  
While clinical signs and symptoms often provide compelling, suggestive 
antemortem evidence of AD, definitive diagnosis still requires postmortem 
histochemical examination of the brain. The cardinal neuropathological findings of AD in 
the brain were originally described in 1907 in the first report of an early-onset form of 
AD by Alois Alzheimer [9]: extracellular neuritic plaques consisting primarily of fibrillar 
amyloid-β (Aβ) peptide [10] and intraneuronal neurofibrillary tangles (NFT) composed of 
paired helical filaments of hyperphosphorylated tau protein [11]. NFT and amyloid 
pathologies follow a stereotypic pattern of progression in the AD brain that somewhat 
correlates with clinical progression [12]. In fact, Braak staging of AD pathology is based 
upon the level of progression of NFT pathology [13]. NFT generally first affect the 
transentorhinal cortex in the earliest stages of disease, spreading next to the 
hippocampal formation, then the frontal, parietal and occipital cortices, finally affecting 
primary motor and sensory cortices only at the most advanced stage of the disease 
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[13]. Interestingly, the progression of anatomic regions affected by NFT somewhat 
tracks the clinical symptom progression. Areas first invested with NFT (i.e. 
transentorhinal cortex and hippocampal formation) play key roles in consolidating newly 
formed memories [14]. Areas last to be invested with NFT (i.e. primary motor and 
sensory cortices) are the areas to be last affected clinically (i.e. basic motor and 
sensory functions). Amyloid deposits follow a less predictable and correlative 
progression. Plaques generally first appear in the neocortex, spread in middle stages to 
the hippocampal formation, and move on to the primary motor and sensory cortices and 
subcortical structures in late stages of the disease [13,15]. Synaptic loss is another 
important feature of AD pathology and appears to occur early in disease progression 
and in numbers disproportionate to neuron loss. Synapse loss also appears to correlate 
with cognitive decline better than other pathological findings [16]. In end stages of AD, 
there is ultimately complete neuronal loss and frank neurodegeneration leading to 
generalized brain atrophy. 
Cholinergic neurons are lost disproportionately to other transmitter systems in 
early stages of the disease, despite lack of significant pathology in the septal nuclei or 
nucleus basalis of Meynert [17,18]. Given the extensive cholinergic projections 
throughout the neo- and allocortex, this cholinergic loss likely contributes to early 
symptomatology. Intrahippocampal injections of Aβ peptide in animal models promotes 
a similar neurodegenerative phenotype in cholinergic centers, perhaps related to 
cholinergic axons that terminate in the hippocampus [19]. This suggests that early 
cholinergic loss in AD may be mediated by retrograde toxicity originating from axonal 
projections at sites of Aβ pathology. However, given the extent of neurodegeneration, it 
is likely that AD progresses to primarily a glutamatergic deficiency in late stages of the 
disease. 
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It is becoming increasingly clear that AD exists on a continuum, with the earliest 
pathological changes developing in the brain years before any clinical symptoms arise 
(i.e. preclinical AD). Recent efforts have focused on identifying biochemical and imaging 
biomarkers that might identify patients with preclinical findings that portend the eventual 
onset of clinically significant dementia [20–23]. Once the disease does become 
clinically apparent, changes in cognitive function are initially very subtle and do not 
meet the criteria for dementia. This intermediate state is classified as mild cognitive 
impairment (MCI) [24]. Among patients diagnosed with MCI, the rate of conversion to 
AD dementia is significantly higher as compared to age-matched populations that are 
cognitively normal [25]. 
  
B. Molecular mechanisms and genetics 
Molecular mechanisms that underlie pathological findings and clinical symptoms 
in AD are still unclear. The amyloid cascade hypothesis posits that accumulation of Aβ 
either due to enhanced production or decreased clearance initiates a cascade of 
molecular events leading to neurodegeneration and dementia [26,27]. Inflammatory 
responses, mitochondrial dysfunction, oxidative stress, calcium dysregulation, impaired 
axonal transport, membrane damage and tau-based neurotoxicity, among others 
mechanisms, are likely participants in this cascade [28,29].  
Aβ is derived from the parental amyloid-β precursor protein (APP). APP is a 
transmembrane protein that undergoes proteolytic processing by secretase enzymes to 
liberate soluble fragments (described in more detail below). Promiscuous C-terminal 
cleavage of the Aβ domain in APP by the γ-secretase complex is responsible for the 
generation of 40 and 42 amino acid forms of Aβ (Aβ40 and Aβ42). Aβ42 is much more 
hydrophobic than Aβ40 and has a much greater propensity to aggregate and form 
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oligomers [30]. The Aβ42 isoform accumulates to a greater extent than Aβ40 in all 
forms of AD and is the primary component of neuritic plaques [31]. 
AD is generally subdivided into two categories based upon age of onset: early-
onset AD (EOAD) and late-onset AD (LOAD). EOAD, with age of onset prior to 60, 
constitutes less than 5% of all cases of AD. EOAD often results from inheritance of 
autosomal dominant single gene mutations in three different genes (APP, PSEN1 and 
PSEN2) [32]. This type of EOAD is also termed familial AD (FAD). Most mutations are 
located in PSEN1 or PSEN2 genes, with a smaller number localizing to the Aβ-
encoding region of APP. PSEN1 and PSEN2 are components of the γ-secretase 
complex responsible for C-terminal cleavage of Aβ from APP. Mutations in these two 
genes appear to predominantly promote Aβ42 cleavage over Aβ40 [33,34]. Mutations in 
APP promote either enhanced Aβ aggregation or Aβ42 over Aβ40 production [35,36]. 
Therefore, the mechanism of elevated Aβ accumulation in FAD is related to mutations 
that promote elevated Aβ42 processing. 
Most forms of LOAD are not inherited in Mendelian fashion and are termed 
sporadic AD (SAD). SAD is a complex disorder whose onset is influenced by multiple 
factors including genetics, the environment, and gene-environment interactions, with 
the greatest known risk factor being advanced age [37]. Heritability is still quite high for 
SAD, estimated somewhere between 50%-80%, but penetrance for single gene 
mutations is very low [38]. The cause of excess Aβ accumulation in the disease is still 
an enigma. Evidence suggests that both increased Aβ production and decreased Aβ 
clearance may play a role [39–41]. The APOE gene confers the greatest genetic risk for 
developing SAD, with the ε4 allele enhancing AD risk approximately 4-fold [42]. 
Interestingly, ApoE has been shown to promote Aβ proteolytic degradation [43]. The ε4 
allele has diminished capacity to promote Aβ clearance, potentially explaining the risk 
conferred by inheriting this allele [41]. Several genome wide association studies have 
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identified multiple genes (PICALM, CR1, CLU, BIN1) that are associated with SAD at 
genome-wide significance [44–46]. However, the effect size for each of these genes in 
isolation is very small, highlighting the importance that gene-environment interactions 
likely play in SAD. 
 
C. Support for centrality of amyloid-β to AD etiology 
While valid criticisms exist, there is significant evidence supporting the Aβ-
centric view put forward by the amyloid cascade hypothesis. Most prominently, the rare, 
early-onset forms of FAD that are inherited in autosomal dominant fashion are caused 
by single gene mutations that act to increase the ratio of the more amyloidogenic and 
toxic Aβ42 relative to the more benign Aβ40 [32]. The APP locus is contained on 
chromosome 21, and rare duplication events at this locus [47] or full trisomy of 
chromosome 21 in Down syndrome (DS) [30] result in FAD via a gene dosage effect. 
Genetic polymorphisms in the APP promoter that elevate APP expression have also 
been shown to be associated with AD [48,49].  
Therefore, elevation of Aβ alone (or Aβ42, specifically) is sufficient to induce AD 
in these rare forms of AD and most likely in SAD cases. Given the similarity in clinical 
phenotype between FAD and SAD, the presumption is that similar molecular 
mechanisms may underlie both, though this is still an open question. It is important to 
point out that the contribution of various risk-modifying gene variants (e.g. APOE, CLU, 
PICALM, CR1, BIN1) to the elevated Aβ levels observed in SAD is unknown, perhaps 
with the exception of APOE [50]. Other evidence in support of the Aβ-centric position 
includes observations that Aβ has clearly neurotoxic and synaptotoxic effects both in 
vitro and in vivo, especially in its soluble oligomeric forms [51].  
Other amyloid-independent mechanisms have been proposed to contribute to 
FAD and SAD pathogenesis and are reviewed elsewhere [52]. Interestingly, APP is 
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implicated in some of these amyloid-independent pathways. As an example, 
dysfunction of the endosomal system in Down syndrome and models of APP gene 
duplication has been attributed to a gene dosage effect of APP specifically mediated by 
increased levels of the β-cleaved C-terminal fragment of APP, not Aβ [53–55]. The 
evidence suggests that modulating levels of APP may represent an attractive 
therapeutic strategy for SAD and FAD, irrespective of the ultimate validity of the amyloid 
cascade hypothesis. 
 
D. Current therapeutic strategies and limitations 
Current FDA-approved therapeutic options for AD include use of cholinesterase 
inhibitors (donepezil, rivastigmine, and galantamiine) in mild-to-moderate AD and an 
uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist (memantine) in 
moderate-to-severe AD [56]. The goal of cholinesterase inhibition is to support 
cholinergic signaling early in the disease when cholinergic neurons are first lost. The 
mechanism of memantine activity may involve neuroprotection during episodes of 
glutamate neurotoxicity. Other neuroprotective and Aβ-modifying activities have been 
reported for cholinesterase inhibitors and memantine and may contribute to their clinical 
effect [57–59]. Unfortunately, these therapeutic options are only modestly effective at 
reducing symptoms and none modifies disease progression [60,61].  
Newer strategies for treating AD span a wide spectrum, ranging from 
modifications of existing treatment modalities to entirely novel mechanisms. Many of 
these are still in early preclinical stages. For example, several inhibitors of the 
butyrylcholinesterase enzyme, which is increased in AD, decrease Aβ levels in both 
culture and animal models [62]. Alternatively, the potassium channel modulator 
diazoxide, which is currently approved for the treatment of hypoglycemia, has shown 
promise in animal models, perhaps by reversing brain hypometabolism as occurs in AD 
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[63]. Several compounds derived from natural sources are also showing promise in the 
preclinical setting, including S-allyl cysteine (SAC) and curcumin. SAC is a component 
of aged garlic and has been shown to protect cultured neuronal cells from oxidative 
stress and to increase synaptic markers in an animal model of AD [64,65]. Curcumin 
has been viewed as a potential therapeutic agent for AD since the discovery that it can 
dissociate amyloid plaque in vitro [66], although the extreme hydrophobicity of this 
molecule has impeded its development as an AD drug candidate. Recently developed 
nanotechnology has allowed the packaging of curcumin into highly soluble 
nanoparticles leading to greatly improved uptake in an animal model. In this model, 
nanocurcumin reduced oxidative stress and apoptotic markers [67].  
The therapies furthest advanced along the clinical pipeline predominantly target 
Aβ production or Aβ clearance. The APP processing pathway is an obvious target for 
reducing Aβ production. Inhibition of β-secretase enzymatic activity has been actively 
pursued since the discovery of β-site APP cleaving enzyme 1 (BACE1), but the 
competing challenges of finding a candidate drug of sufficient size to target the BACE1 
active site yet small enough to efficiently cross the blood brain barrier (BBB) have 
curtailed the identification of a suitable candidate [68,69]. Recent preclinical studies 
have demonstrated that a bi-specific anti-BACE1 neutralizing antibody inhibits Aβ 
production, thus providing an alternative mechanism for clinically inhibiting β-secretase 
activity [70,71]. The most advanced drugs targeting the APP processing pathway are γ-
secretase inhibitors or modulators [72]. Unfortunately, two prominent candidates 
targeting γ-secretase were discontinued after disappointing phase III clinical trials. 
Tarenflurbil is a γ-secretase modulator that suppresses production of Aβ42 in favor of 
shorter Aβ peptides [73]. A promising phase II trial demonstrated a slower rate of 
cognitive decline in mild AD patients taking the drug as compared to placebo [74]. 
However, a follow-up phase III trial did not demonstrate any effect of the drug on 
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cognitive decline [75]. Similarly, semagacestat is a γ-secretase inhibitor that in a phase 
II trial reduced Aβ production in the human CNS [76]. A phase III follow-up trial was 
discontinued early when in-trail monitoring revealed a decrease in cognitive function 
among those patients receiving the inhibitor [77]. Therefore, targeting the γ-secretase 
complex may not represent a viable strategy for AD, especially given that important 
signaling molecules (e.g. Notch) are also γ-secretase substrates and that the complex 
may play a role in membrane turnover [78].  
Other nascent therapeutics that have entered clinical trials target either Aβ 
aggregation or Aβ clearance. Tramiprosate is a glycosaminoglycan-mimetic that blocks 
Aβ aggregation [79]. A phase II trial showed that the drug reduced CNS Aβ42 levels 
[80]. However, a phase III trial did not show any effects of tramiprosate on cognitive 
decline [81]. Immune-based strategies for the treatment of AD hold great promise as an 
approach that may produce more potent disease-modifying effects than the current 
small molecule-based treatments. Both active immunization strategies and passive 
antibody formulations have been pursued. An initial vaccination clinical trial with Aβ42-
adjuvant was halted, however, when a high incidence of meningoencephalitis was 
observed [82]. Passive immunotherapy with humanized monoclonal antibodies 
(bapineuzumab and solanezumab) is currently in phase III testing. Phase II clinical trials 
demonstrated that these antibodies reduce plasma and CSF Aβ but effects on cognition 
were fairly weak [83,84]. Another immunotherapy approach is the use of intravenous 
immunoglobulins (IVIG) [85,86]. Natural anti-Aβ antibodies are present in these 
preparations but not in high quantities [87]. Further clinical testing on the efficacy of 
IVIG for AD is in progress. 
In summary, many preclinical studies have identified attractive new therapeutic 
targets and strategies. Unfortunately, as many of these treatment modalities have 
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moved into clinical trial testing, the results have been invariably disappointing. 
Therefore, the search for effective disease-modifying therapies continues. 
 
II. Biology of amyloid-β precursor protein (APP) 
 
A. Biochemical processing of APP 
As briefly mentioned above, APP is a type I transmembrane protein that 
undergoes proteolytic processing by secretase enzymes to liberate soluble fragments 
(Figure 1) [88,89]. Amyloidogenic processing begins with proteolytic cleavage at the N-
terminus of the Aβ domain in APP by β-secretase (BACE1). This cleavage event results 
in the release of the secreted beta-form of APP (sAPPβ) and the retention of the 99 
amino acid C-terminal fragment (CTF) C99 in the membrane. Intramembranous 
cleavage of C99 at the C-terminus of the Aβ domain by the γ-secretase complex results 
in the release of both Aβ and the APP intracellular domain (AICD) [90].  
The γ-secretase is a large complex composed of at least four different protein 
subunit substrates (Nicastrin, anterior pharynx defective 1 [APH1], presenilin enhancer 
[PSEN], and presenilin1 or presenilin 2). The proteolytic site appears to be located 
within the presenilin proteins [91]. Promiscuous C-terminal cleavage of the Aβ domain 
in APP by the γ-secretase complex is responsible for the generation of Aβ40 and Aβ42.  
The non-amyloidogenic processing pathway involves initial cleavage by one of 
several α-secretases releasing sAPPα and leaving the C83 CTF [92]. By cleaving within 
the Aβ domain, α-secretase activity precludes Aβ production. Intramembranous 
cleavage of C83 by γ-secretase leads to the release of the non-amyloidogenic p3 
peptide and AICD.  
Both α- and β-secretases cleave APP on the luminal side of the membrane, 
resulting in release of sAPPα and sAPPβ into the extracellular or endosomal 
11 
 
compartments depending on holo-APP trafficking. Following intramembranous γ-
secretase cleavage, Aβ or p3 are likewise released into extracellular or endosomal 
compartments, while AICD is released into the cytosol. 
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Figure 1: Biochemical processing of APP. (A) Schematic of the APP protein 
highlighting the Aβ domain and approximate locations of secretase target sites. The Aβ 
N-terminus is located on the luminal side of the protein and is defined by the presence 
of the β-secretase site. The C-terminus of the Aβ domain is located in the membrane 
and defined by the γ-secretase site. The α-secretase site is internally positioned within 
the Aβ domain. (B) Non-amyloidogenic processing requires sequential cleavage by α-
secretase and the γ-secretase complex, releasing the non-amyloidogenic p3 peptide 
and AICD. Amyloidogenic processing requires sequential cleavage by β-secretase 
(BACE1) and the γ-secretase complex, releasing Aβ and AICD.   
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B. Physiological functions of APP   
The primary physiological function of holo-APP is still unclear. However, 
biological activity of the secreted metabolite of APP is well-established. The first 
recognized biological effect of sAPP was its requirement for the normal proliferation of 
fibroblasts in culture [93] in addition to the promotion of neuronal PC12 cell adhesion to 
culture substratum [94]. Studies on cultured neurons and animals quickly followed and 
have since identified trophic effects that include: 1) the enhancement of neurite 
outgrowth [95–100], 2) stimulation of neural stem cell proliferation [101–103], 
differentiation and migration [104], 3) promotion of synaptogenesis [105–107], and 4) 
modulation of synaptic plasticity, learning and memory [108,109]. Additionally, sAPP 
has been demonstrated to protect neurons against a variety of insults that include 
glucose deprivation and excitotoxicity, Aβ and reactive oxygen species (ROS), and 
ischemic brain injury [110–112]. Following the discovery of multiple secretase activities 
[88,89], sAPPα was found to mediate the majority of neuronal-enhancing effects. 
Specifically, the neuroprotective action of sAPPα against glucose deprivation, 
excitotoxicity, and Aβ toxicity is 100-fold greater than that mediated by sAPPβ [113]. 
Interestingly, a pathological function for sAPPα has been recently suggested in autism, 
where elevated peripheral levels of sAPPα are present in severely autistic children 
[114–116].  
A separate reported role for secreted APP is as a physiological signal for axonal 
degeneration and developmental pruning [117]. In cultured neurons under conditions of 
trophic withdrawal, BACE1 activity is stimulated leading to enhanced release of sAPPβ 
that is further degraded to an active 35 kDa N-terminal fragment (N-APP). This N-APP 
moiety serves to activate the DR6 death receptor. Axonal degeneration is then induced 
by activation of the caspase 6 apoptotic pathway. Therefore, sAPP may contribute to 
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normal neuronal development by both stimulating growth and neurite sprouting and by 
promoting pruning and maturation of newly formed synaptic connections. 
Another APP metabolite with reported functional effects is AICD. This 
intracellular fragment, once released from APP, can act as a transcriptional co-activator 
with Fe65 and Tip60 [118,119]. AICD production may be induced by a Notch-like signal 
transduction system. In this system, APP acts as a receptor for TAG1, whereby binding 
of TAG1 ligand to APP induces γ-secretase cleavage of APP and subsequent release 
of AICD [120].   
 
C. Transcriptional and post-transcriptional control of APP expression 
The network of cis-acting elements and trans-acting factors that govern 
expression of APP is complex and still not fully elucidated. Studies of the APP promoter 
have revealed a complex structure with many proximal and distal regulatory elements 
that mediate constitutive and stimulated regulatory activities [121–125]. Proximal 
promoter elements are necessary for basal transcriptional activation [126–129] and bind 
various nuclear factors [126,130] responsible for mediating this activity, including SP1 
[131], USF [132,133], and CTCF [134,135]. A 30 bp element in this region mediates cell 
type-specific transcriptional activation [136]. Proximal regions further upstream also 
contain regulatory elements important for transcriptional regulation [128]. Negative 
regulatory elements exist in this region [137,138], as do heat shock elements that bind 
HSF-1 and mediate transcriptional activity in response to stress and an enhancer 
element that binds a SP1-like factor [139]. Regulatory elements in the genomic 5’-
untranslated region (UTR) also drive promoter activity through a CAGA box [140], 
thyroid hormone (T3) responsive element [141], and nuclear factor binding domain 
[142], among others. 
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Post-transcriptional regulation is also mediated via regulatory elements in the 
mRNA 5’-UTR, including an iron responsive element (IRE) [143,144] and IL-1 
responsive element [145] involved in regulating stimulated translation of the APP 
transcript. Specifically, the iron responsive element forms a stem-loop that binds to iron 
regulatory protein 1 (IRP1) under low intracellular iron conditions, thereby inhibiting 
APP translation. When intracellular iron levels increase, iron binds to IRP1 promoting its 
release from the APP mRNA 5’-UTR and disinhibiting the translational block [144]. An 
internal ribosomal entry site has also been described in the 5’-UTR that can also 
regulate translation of APP independent of cap-dependent translation [146]. 
The APP 3’-UTR contains several stability control elements that regulate APP 
mRNA stability. 29-nucleotide (nt) and 52-nt control elements exist that destabilize the 
transcript [147–149]. Destabilization is attenuated or promoted in a regulated fashion by 
the binding of various cytosolic factors to these elements, including hnRNP C and 
nucleolin [150–153]. Polyadenylation of the APP 3’-UTR also regulates transcript 
stability through the inclusion or exclusion of a specific GG dinucleotide sequence in the 
various polyadenylated transcripts [154,155]. 
Finally, interactions between the APP mRNA coding sequence (CDS) and 
FMRP and hnRNP C competitively regulate translation of APP in response to 
metabotropic glutamate receptor activity [156,157]. Obviously, regulation of APP 
expression involves a complex, intertwined network of trans-acting factors working on a 
dense landscape of cis-acting elements located throughout the APP gene and 
transcript.  
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III. Biology of BACE1 
 
A. Biochemical and physiological function of BACE1 
The biochemical properties of the β-secretase enzyme had been established 
well before BACE1 was identified by five independent groups as the β-secretase 
enzyme in 1999 [158–161]. BACE1 is a type I transmembrane aspartyl protease. 
Protease activity is optimal when the catalytic site is in a low pH environment. As a 
result, BACE1 tends to localize in acidic compartments, such as endosome and trans-
Golgi network, with its catalytic site oriented towards the lumen [162].  
As described above, BACE1 cleaves APP at the aspartate residue that defines 
the N-terminus of the Aβ domain in the APP protein and is the rate-limiting enzyme for 
Aβ production. Cleavage at this site liberates sAPPβ into the lumen of the vesicular 
organelle where the BACE1 enzyme is localized. The C99 CTF remains in the 
membrane as a substrate for γ-secretase processing. γ-secretase then cleaves at the 
C-terminal end of the Aβ domain, liberating either Aβ40 or Aβ42. Aβ is a normal 
physiological product of BACE1 activity, suggesting that it might have a physiological 
function aside from its pathological role in AD. Indeed, low concentrations of Aβ have 
been shown to enhance synaptic plasticity and memory [163,164]. This response to Aβ 
has been described as hormetic in that the opposite effect is observed at higher 
concentrations [165]. 
BACE1 has other physiological substrates aside from APP. The protease also 
cleaves APP-like protein 1 (APLP1) and APLP2 [166,167], the voltage-gated sodium 
channel β2 subunit (Navβ2) [168], and neuregulin 1 type III and neuregulin 3 (NRG1 and 
NRG3) [169,170]. NRG1 and NRG3 processing by BACE1 plays a critical role in normal 
peripheral myelination [169,170]. Blocking the processing of NRG1 and NRG3 by 
BACE1 produces reduced myelin thickness at the sciatic nerve. Repair of damaged 
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sciatic nerve is also impaired when NRG1 processing by BACE1 is inhibited. Cleavage 
of the Navβ2 subunit, first by BACE1 and then by γ-secretase, results in the release of a 
short β2 intracellular fragment that activates Nav1.1 mRNA expression [171]. However, 
the end result of this process is reduced surface Nav1.1 due to intracellular 
accumulation. Therefore, BACE1 regulates sodium current densities in the cell. 
 
B. Transcriptional and post-transcriptional control of BACE1 expression 
Much like with APP, the spectrum of regulatory schemes utilized by the cell to 
control BACE1 expression is complex and still not fully clear. The BACE1 promoter has 
been fairly well characterized [172,173]. In neurons, the BACE1 promoter activity is 
significantly weaker as compared to the APP promoter [174]. The promoter lacks 
canonical TATA or CAAT boxes and more closely resembles the promoter of a 
“housekeeping gene”. The core or minimal promoter is located proximally and spans 
the transcription start site (TSS) with some aspects of the minimal promoter located in 
the genomic 5’-UTR [172,173]. Both positive and negative regulatory elements have 
been described in more distal segments up to 4 kb from the TSS.  
Multiple predicted transcription factor (TF) binding sites have been reported 
[172]. Of these, several have been validated in terms of physical interactions and 
functional effects. Sp1 interacts with the BACE1 promoter and stimulates BACE1 
expression [173]. 12/15-lipoxygenase expression in the brain has been linked to AD 
and causes increased BACE1 expression and Aβ production. This enzyme mediates 
this effect indirectly by stimulating Sp1 expression [175]. Yin Yang 1 (YY1) binds to a 
more distal section of the rat promoter and also stimulates BACE1 expression [176]. 
NF-κB binds to the rat promoter and normally represses BACE1 expression in neurons 
but activates BACE1 expression in activated astrocytes under AD-type stress 
conditions [177]. Finally, two CpG sites in the genomic 5’-UTR are typically methylated 
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and basally inhibit BACE1 transcription [178]. Treatment with the demethylating agent, 
5-aza-2’-deoxycytidine, results in increased BACE1 expression mediated specifically 
through demethylation of these two CpG sites.  
Several modes of BACE1 post-transcriptional regulation have also been 
discovered. One mechanism is mediated through the BACE1 5’-UTR. The 5’-UTR is 
rather long at 446 nt, has high GC content and multiple predicted upstream AUGs 
(uAUGs) and open reading frames (uORF) [179]. These are all characteristics typical 
for gene products under strict translational control, such as proto-oncogenes and stress 
response proteins. The presence of multiple uAUGs and uORF generally inhibits mRNA 
translation because ribosomal scanning initiated from the cap will result in binding and 
translation of the uORF instead of the authentic ORF. Unless the ribosome re-initiates 
scanning following translational termination of the upstream ORF or simply skips the 
upstream ORF altogether (i.e leaky scanning), then the authentic AUG cannot serve as 
a site of translation initiation [180]. Indeed, multiple studies have identified the second 
uORF in the BACE1 5’-UTR as a potent inhibitor of BACE1 translation [179,181–183]. 
Interestingly, under conditions of energy deprivation, BACE1 translation is induced via a 
mechanism that requires the presence of the 5’-UTR and phosphorylation of the 
translation initiation factor eIF2α [184]. The proposed model for this effect is that 
phosphorylation of eIF2α creates an environment where ribosomes more readily scan 
past the uORF, therby increasing the likelihood that the authentic ORF will be 
recognized. 
Another post-transcriptional mechanism employed by human cells to control 
BACE1 levels is the expression of a BACE1 antisense non-coding RNA [185]. This 
RNA binds to approximately 106 complementary nucleotides from exon 6 in the BACE1 
mRNA and stabilizes the transcript. The mechanism involves protecting a microRNA 
recognition element (MRE) against targeting by miR-485-5p [186]. Despite containing a 
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longer 3’-UTR than APP, no novel regulatory mechanisms targeting the 3’-UTR have 
been described for BACE1.  
It is clear that, as with APP, transcriptional and post-transcriptional mechanisms 
for regulating BACE1 expression in human cells are complex and varied. Our 
understanding of the full regulatory network is still incomplete. Therefore, continued 
study of the mechanisms that regulate BACE1 expression in human cells is warranted. 
 
IV. Targeting APP and BACE1 as a therapeutic strategy 
As described above, many of the anti-amyloid therapeutic strategies being 
pursued in the AD preclinical and clinical pipeline are designed to act on protein targets 
after they have been expressed (e.g. anti-Aβ immunotherapy and small molecule 
secretase inhibitors). Most of these late-phase clinical trials have generated 
disappointing results. While some have taken these clinical trial failures as an 
indictment of the amyloid hypothesis of AD etiology, it is more likely that deficiencies in 
clinical trial design or the treatment strategies themselves are more likely to blame 
[187,188]. Therefore, additional strategies and targets are likely needed before safe and 
effective therapeutics are developed. 
As an alternative strategy, modulating expression of relevant protein drug 
targets may prove equally effective (or superior) in some cases. Specifically, APP and 
BACE1 are attractive candidates for expression modulation. Increased APP expression 
in DS [30], APP gene locus duplication events [47], and as a consequence of APP 
promoter polymorphisms [48,49] is sufficient to cause FAD. BACE1 protein levels are 
known to be increased in some SAD patients [39,40,189]. Reducing APP and BACE1 
expression would be corrective in these cases and would be expected to reduce 
production of Aβ with presumably anti-amyloidogenic effects in cases where APP and 
BACE1 levels are not deranged.  
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It is important to point out that APP has very well established roles in normal 
neurodevelopment as described above. Therefore, therapeutically targeting APP 
expression could potentially have deleterious side effects related to inhibition of these 
neurodevelopmental pathways, aside from the anticipated salutary effects on Aβ 
production. However, given that neurodevelopmental pathways are likely to be most 
active during early CNS development, application of APP targeting in later life when 
amyloid pathology begins to accumulate would presumably have a less malignant 
effect. 
Preclinical studies in rodent animal models using antisense inhibition of APP 
expression have demonstrated salutary effects following the approach outlined above 
[190,191]. Other amyloid-independent roles of APP implicated in AD, such as 
transcriptional effects from the release of AICD and effects on endosomal function [52], 
would also be altered in a beneficial fashion. A small molecule-based approach for 
modulating APP expression post-transcriptionally has already been pursued in at least 
one study [192]. Similarly, knockout of BACE1 expression in the Tg2576 AD mouse 
model reverses cognitive deficits associated with Aβ accumulation [193]. Systemic 
delivery to the brain of both a BACE1 siRNA and BACE1 neutralizing monoclonal 
antibody resulted in decreased BACE1 expression and decreased Aβ levels in the 
brains of animal models [70,71,194]. Therefore, the evidence supports targeting 
expression of APP or BACE1 therapeutically as a means to modify Aβ levels in the 
human brain. 
Certain caveats would certainly have to be addressed before translating such an 
approach to the clinic, such as whether any malignant effects might arise from reducing 
APP and BACE1 expression and their associated physiological functions in the context 
of FAD or SAD. APP and BACE1 gene knockout animals have only subtle phenotypic 
changes, suggesting that side effects of expression reduction would be minimal 
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[193,195]. Whether this would also translate to humans is not clear and would require 
further investigation.  
Before APP and BACE1 expression can be targeted therapeutically, a clear map 
of the regulatory network that governs APP and BACE1 expression in the CNS needs 
to be established. Only then can appropriate targets be selected for therapeutic 
manipulation. As summarized above, this regulatory network appears to be extensive 
for both APP and BACE1, with contributions arising at the transcriptional and post-
transcriptional levels. MicroRNAs (miRNA) are a relatively new class of biological 
molecule that mediate potent post-transcriptional effects on gene expression. This class 
of regulatory molecule will likely be amenable to in vivo therapeutic manipulations in the 
near future and therefore may serve as ideal drug targets for modulating APP and 
BACE1 expression. Prior to expounding upon the rationale for examining the role of 
miRNA in regulating expression of APP and BACE1, a sufficient introduction to basic 
miRNA biology will be presented. 
 
V. Biology of miRNA 
 
A. Discovery, historical perspective and nomenclature 
The first miRNA was discovered in 1993 during studies on the temporal control 
of Caenorrhabditis elegans development [196]. lin-4 was identified as a regulator of the 
heterochronic gene lin-14 and originally termed a small temporal RNA (stRNA). 
Investigators discovered that lin-4 was not expressed as a protein, but instead as a 
small RNA consisting of a 61-nt stem-loop precursor that matured to a 22-nt product. 
This small RNA contained sequences with partial complementarity to sequences in the 
lin-14 3’-UTR known to be important for post-transcriptional regulation of the protein 
product [197]. Thus, many of the prominent structural and functional principles now 
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known to be common to all miRNAs were elucidated in these first reports of a single 
member. A second miRNA (let-7) was not discovered until 2000 [198] and was found to 
be conserved across a number of species, including vertebrates [199]. Large scale 
cloning studies later identified a plethora of miRNA that are expressed across many 
species, including humans, and that fit the miRNA profile: a small RNA sequence that is 
present in both a stem-loop precursor form (pre-miRNA) and mature single stranded 
RNA form [200–202]. Many of these miRNAs were also shown to be conserved across 
numerous species. miRNAs were soon found to negatively regulate both Drosophila 
and vertebrate mRNA targets through complimentary sequence motifs located in the 3’-
UTR, just as in C. elegans [203,204].  
The naming convention adopted in these early studies was to name miRNA 
numerically in the order they were discovered. Nomenclature is now curated by the 
miRBase database [205]. Since many miRNA are conserved across species, the same 
number is given to orthologous miRNA. Species is designated by a three or four letter 
prefix (e.g. hsa-miR-101 for human miR-101). In most cases, mature miRNA are 
generated from one strand of the precursor miRNA (guide strand) while the other strand 
of the stem-loop (passenger strand) is degraded (discussed below). The passenger 
strand is often designated the “star” strand (e.g. hsa-miR-101*). In some cases, mature 
miRNA strands are generated from both arms of the stem-loop. These miRNA are given 
either a -5p or -3p appellation based upon the end of the stem-loop from which they 
were derived (e.g. miR-339-5p). Finally, gene duplication events and subsequent 
sequence evolution have generated miRNA paralogs in some cases. These are 
distinguished by a letter suffix (e.g. hsa-miR-133a and hsa-miR-133b). When the 
mature miRNA sequences derived from paralogous precursor miRNA are identical, the 
gene loci from which they are derived are distinguished by a number suffix (e.g. hsa-
miR-101-1 and hsa-miR-101-2). 
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B. Biogenesis 
Most miRNAs are transcribed by RNA polymerase II as long primary transcripts 
(pri-miRNA) that form local stem-loop structures harboring the mature miRNA sequence 
[206]. Therefore the structure of a transcribed pri-miRNA consists of long ssRNA arms 
flanking small local stem-loops containing a pre-miRNA and mature miRNA sequence. 
The genomic location of the pri-miRNA locus can vary from intergenic regions, to 
intronic or exonic regions of non-coding or protein-coding RNA [207]. When located 
intergenically, Pol II-based transcription is driven by independent promoter elements. 
When located within introns, miRNA are often co-transcribed along with the host gene. 
Following transcription, the pre-miRNA is processed from the intron either before or in 
conjuction with intron splicing just as if the sequence was an independent pri-miRNA. If 
the miRNA locus is hosted within a large intron, it is not unreasonable to speculate that 
distinct internal regulatory elements within the intron may independently drive miRNA 
expression. 
 Following pri-miRNA transcription, the nuclear microprocessor complex, 
consisting of RNaseIII-like Drosha and DiGeorge syndrome critical region 8 (DGCR8) in 
human cells, recognizes the internal stem-loop and cleaves the pri-miRNA 
approximately 11 nt from the dsRNA-ssRNA junction, releasing the stem-loop structure 
(pre-miRNA) from flanking RNA and leaving a 3’ 2-nt overhang [208–210]. This newly 
formed pre-miRNA is exported from the nucleus by exportin-5 [211]. In the cytosol, the 
complex of Dicer and TAR RNA-binding protein (TRBP) in human cells binds the pre-
miRNA at the 2-nt overhang and cleaves the loop approximately 22-nt downstream of 
the stem terminus [212,213]. TRBP then recruits AGO2 to the Dicer-TRBP-miRNA 
complex [212]. The miRNA is then incorporated into a microribonucleoprotein (miRNP) 
complex [214], also termed the RNA induced silencing complex (RISC), via a loading 
complex as described below [215].    
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C. Assembly of microribonucleoprotein complex 
The core protein of the RISC complex in humans is always a member of the 
AGO subfamily of Argonaute proteins (AGO1-4), oftentimes being AGO2. AGO2 is the 
only member of the AGO family to possess “slicer” activity (i.e. endonucleolytic activity). 
The mature RISC consists of a ssRNA loaded onto AGO2, in complex with other 
effector proteins. However, the miRNA product of Dicer processing is a dsRNA with 2 nt 
3’ overhangs on either end. Therefore, three steps are necessary for proper assembly 
of the mature RISC [216]. These steps are facilitated by the RISC loading complex 
(RLC). The RLC can be minimally reconstituted in vitro by combining equal 
stoichiometric amounts of Dicer, TRBP and AGO2 [217]. However, full RLC activity is 
achieved when the RISC activator C3PO is also a part of the RLC [218]. 
The first step in assembling the mature RISC is to load the double stranded 
miRNA onto the AGO protein. Due to the bulky size of the dsRNA, heat shock proteins 
90 and 70 (HSP90 and HSP70) chaperone this process by helping to modify the AGO 
structure such that the dsRNA fits into the AGO protein [219,220]. The 5’ phosphate on 
the duplex miRNA strand is apparently critical for normal loading into AGO proteins 
[221]. The choice of strand to be incorporated into the mature RISC is generally based 
upon the asymmetry rule [222]. The strand with the least thermodynamic stability at its 
5’ end generally is loaded and becomes the guide strand.  
The next step in assembling a mature RISC is to pry apart the duplex miRNA as 
the initial step in unwinding the duplex. Recently the N-terminal domain of AGO2 has 
been implicated in this task [216]. The data suggest that the N-terminal domain either 
actively or passively wedges the duplex apart during loading. 
The final step in assembling a mature RISC is to fully unwind the duplex RNA 
until only the guide strand remains in complex with AGO. If there is no mismatch in the 
duplex complementarity at nucleotides 10 – 11, then slicer-dependent unwinding is 
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employed. AGO2 endonucleolytically nicks the passenger strand while also wedging 
the sequences apart. C3PO then can exonucleolytically degrade the AGO2-knicked 
passenger strand [218]. When mismatches in the double stranded miRNA are present 
at nucleotides 10 – 11, then slicer-independent unwinding is instead employed. Once 
the single stranded guide strand is loaded into the mature RISC, it guides the RISC to 
complementary mRNA targets (biogenesis and RISC assembly summarized in Figure 
2). 
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Figure 2: miRNA biogenesis and RISC assembly in human cells. miRNA are initially 
transcribed as pri-miRNA, processed by the complex of Drosha and DGCR8 to pre-
miRNA, exported to the cytosol by exportin-5, and cleaved to a mature miRNA guide 
strand and passenger strand (miRNA*) by the complex of Dicer and TRBP. For RISC 
loading, the miRNA duplex is loaded onto an AGO protein and unwound. The 
passenger strand is degraded while mature guide strand remains (red strand in 
illustration). The guide strand, AGO and GW182 proteins forms the mature RISC. The 
guide strand guides RISC to target transcripts by interacting with specific target sites in 
the 3’-UTR. Near perfect complementarity between the target transcript and the seed 
sequence of the miRNA is required to effectuate an inhibitory response. GW182 recruits 
deadenylase complexes and other factors to promote target transcript destabilization 
and repress translation. Adapted from Long and Lahiri [223] 
  
28 
 
D. Molecular mechanisms of gene regulation 
Most miRNA target sites appear to be located in the 3’-UTR of target transcripts 
[84], although recent cross-linking experiments suggest interactions with target sites in 
the CDS and 5’-UTR do occur [85-86]. The primary explanation for why the majority of 
target sites are restricted to the 3’-UTR across the genome is that active translation of 
the transcript outside the 3’-UTR reduces the efficacy of target sites in these regions 
[224] .  
Canonical target sites require a near perfect match between the 5’ end of the 
miRNA (seed sequence located at nucleotide 2 – 6 of the miRNA) and target transcript 
[204]. Less stringency is required at the 3’ end of the miRNA. Recently a novel mode for 
target recognition was described [225]. This new form of target site contains a G bulge 
in the target mRNA at position 5 of the seed sequence. Apparently this mode of 
targeting is favored because during the nucleation step, when the miRNA interacts with 
the G bulge target site, a reaction intermediate with favorable thermodynamics is 
formed.  
Once the mature RISC is targeted to a given mRNA, the physiological response 
is typically to suppress protein production, although in some rare cases post-
transcriptional activation has been reported [226]. The original consensus in the field 
was that miRNA suppressed protein output in animals primarily by decreasing 
translational efficiency and occasionally by degrading target mRNA. However, recent 
microarray and ribosome profiling studies have suggested that mRNA destabilization is 
the primary factor driving reduced protein output in animals [227,228]. The most recent 
studies have further clarified the story by suggesting that both decreased translational 
efficiency and mRNA destabilization occur during mRNA targeting, with the former 
preceding and often leading to transcript destabilization [229–231].  
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The mechanisms underlying the repressive effects of RISC targeting are 
beginning to become clear. AGO proteins serve as central hubs to recruit additional 
effector complexes that mediate inhibitory effects. Interaction of AGO with GW182 is 
essential for miRNA-mediated translational repression and, in some cases, mRNA 
destabilization [232,233]. The primary mechanism for mRNA destabilization is 
deadenylation of targets transcripts, followed by transcript decapping mediated by 
DCP2, and then 5’-to-3’ exonucleolytic mRNA decay by XRN1 [234–236]. GW182 
seems to participate in this pathway by recruiting the CCR4-CAF1-NOT and PAN2-
PAN3 deadenylase complexes to the target mRNA [234,237,238]. The mechanisms 
underlying reduced translational efficiency are not as clear but miRNA targeting inhibits 
translation at both initiation and elongation steps [239,240]. The mechanism of miRNA-
mediated gene repression contrasts to that of widely-used synthetic short interfering 
RNAs (siRNAs), which hybridize with perfect complementarity to mRNA targets and 
induce AGO2-mediated endonucleolytic cleavage and degradation of the transcript. 
The precise level of miRNA expression necessary for functional regulation is 
likely to vary for each combination of miRNA and mRNA target and their specific 
environmental context. Titration experiments have demonstrated that miRNA efficacy is 
influenced both by the levels of target expression as well as miRNA levels, such that 
target thresholds are generated around which target levels are highly sensitive to 
miRNA effects [241,242]. Therefore, there is a complex interplay between target 
transcript, targeting miRNA and ensuing regulatory effects. 
Bioinformatic analyses suggest that each miRNA may target hundreds of mRNA 
transcripts and that a single mRNA may be targeted by hundreds of targeting miRNA. In 
fact, more than 60% of all mammalian transcripts appear to have been under 
evolutionary pressure to maintain miRNA target sites [243]. However, global proteomic 
analyses following synthetic miRNA delivery suggest that a majority of miRNA-transcript 
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interactions mediate only subtle effects on protein expression. A much smaller number 
of targets per miRNA experience strong regulatory pressures [244,245]. Therefore, 
miRNAs appear to act more like rheostats to fine-tune expression for a majority of 
targets, with a select few targets under heavier regulatory pressures. Alternative 
theories posit that many of the miRNA-target interactions predicted by bioinformatic 
analyses are not physiologically relevant and instead serve to soak up and sequester 
target miRNAs [246]. By titrating levels of available miRNAs, these sites would control 
interactions of miRNA with physiologically relevant targets. These have been termed 
competing endogenous RNA (ceRNA) [247]. Several examples have been described 
where the presence of ceRNA has significant biological effects [248–250].  
 
E. miRNA stability and turnover 
Control of miRNA steady-state levels is a function of pri-miRNA transcription, 
pri- and pre-miRNA processing by the processing complexes, and regulated turnover of 
mature miRNA. Unlike miRNA, mRNA are stabilized by the presence of a 5’ 7-
methylguanylate cap and 3’ poly(A) tail that protect against exonuclease activity. 
Controls on mRNA stability are tightly regulated and mRNA turnover modulates miRNA 
efficacy. A shorter mRNA half-life generally correlates with reduced miRNA efficacy 
[251]. Conversely, miRNA termini are exposed and appear to rely on interactions with 
AGO proteins [252] to stabilize against exonucleolytic degradation [253].  
Recent studies have explored the half-life of miRNAs in various cell types and 
identified great variability. In one study, miRNA half-life was measured in mouse 
embryonic fibroblasts and bone marrow-derived macrophages following conditional 
Dicer ablation [254]. The predicted half-life after controlling for dilutional effects of cell 
proliferation was much longer than that of mRNAs and averaged around 119 hours. 
Conversely, two recent studies have identified much shorter miRNA half-lives in 
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neuronal cell types following inhibition of RNA polymerase II-based transcription. 
Analysis in primary neuronal cell cultures (HN cells) and frozen human brain specimens 
revealed miRNA half-lives in the range of 1 – 4 hours [255]. Similarly short miRNA half-
lives were observed in retinal photoreceptors and cultured hippocampal and cortical 
neurons [256]. Together, these studies suggest that miRNAs are generally very stable 
in vivo but appear to be under regulatory control in neurons that promotes rapid 
turnover. 
Specific mechanisms by which metazoan cells control miRNA degradation and 
turnover have been described but are just beginning to be explored [257,258]. In C. 
elegans, mature miRNA degradation was recently shown to be mediated by the 5’-to-3’ 
exoribonuclease XRN-2 following dissociation of miRNA from RISC. Interestingly, 
increased levels of target mRNA protected against XRN-2 mediated degradation 
suggesting that duplex formation in RISC may stabilize miRNA. An additional control 
mechanism that appears to influence miRNA stability is the addition of non-templated 
terminal nucleotides. The poly(A) polymerase (PAP) GLD-2 monoadenylates miR-122 
at the 3’ terminus resulting in increased miR-122 stability [259]. Conversely, the non-
canonical PAP Tut4 polyuridylates pre-let-7 at the 3’ terminus resulting in reduced pre-
let-7 stability and reduced mature let-7 levels [260,261]. This interaction requires Lin28 
proteins that act as processivity factors for Tut4 [262]. Two recent studies have 
examined pre-miRNA modifications at the transcriptome level and identified extensive 
mono and polynucleotide additions and novel cleavage patterns indicating post-
transcriptional nuclease modifications [263,264]. These studies demonstrate that post-
transcriptional modifications of pre-miRNA are widespread and suggest they may 
represent a widely employed mechanism for miRNA stability control. 
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F. miRNA dysregulation in AD and contribution to pathophysiology 
Unlike in many cancers, where direct contribution of miRNA dysregulation to 
disease etiology is well described, comparatively little is in known about the role miRNA 
play in the development of AD. A small number of studies have reported that miRNA 
levels are dysregulated in AD brain specimens [189,265–268], in AD CSF [267] and in 
peripheral blood mononuclear cells (PBMC) from AD patients [269] (for review see ref 
[270]). Unfortunately, there is very little reproducibility in detected miRNA between 
these studies. Disease heterogeneity, differences in specimen characteristics and 
methodological limitations likely underlie this lack of inter-lab reproducibility to varying 
degrees.  
A small number of miRNA targets have been validated across multiple studies 
and might represent specific AD-dysregulated miRNA. These include miR-107, miR-
29a/b, miR-181, miR-9, miR-106, miR-16, miR-15 and miR-146. miR-29a/b inhibits 
BACE1 expression [189] and is decreased in AD brain possibly contributing to elevated 
Aβ levels [189,267,268,271,272]. Similarly, miR-107 inhibits BACE1 and cofilin 
expression and is decreased in early AD [266,273,274]. miR-181c is decreased in AD 
brain [189,267,268,271], although the pathological relevance of miR-181c targets is still 
unclear. miR-15a levels are decreased in AD. This is a pro-apoptotic miRNA that 
inhibits expression of Bcl2 [275], an anti-apoptotic protein whose expression is known 
to be elevated in AD. miR-9 is highly expressed in the brain and is either decreased or 
elevated in the AD brain depending on the study [189,255,265,267,268,271]. miR-106b 
is decreased in AD brain and in AD transgenic animal models [276,277]. This miRNA 
also targets APP expression [276], perhaps directly promoting Aβ production. Finally, 
miR-146a is a pro-inflammatory miRNA that is elevated in the AD brain and in AD 
transgenic animal models possibly contributing to the pro-inflammatory state present in 
the AD brain [255,267,278,279]. miR-146a expression is stimulated by NF-κB signaling 
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and, once expressed, inhibits expression of complement factor H, an inflammatory 
response repressor in the brain [278]. Therefore, this is some precedence for miRNA 
dysregulation in the AD brain possibly contributing to AD pathophysiology. 
 
G. Role of miRNA in normal and pathological aging 
miRNA also appear to be implicated in the the process of physiological aging. 
The ultimate quantitative measure for effects on aging is life span. C. elegans is a 
commonly used model to assess effects on aging given the naturally short life spans of 
the worms. Studies have identified a large number of miRNA downregulated in older 
worms compared to young worms and a smaller number of miRNA that are upregulated 
with age (e.g. miR-34, miR-246, miR-271, miR-239a/b and others) [280]. When these 
upregulated miRNA were genetically deleted, the effects on aging varied depending on 
the identity of the miRNA. Therefore, in C. elegans, miRNA can have either promoting 
or antagonistic effects on life span. One miRNA with elevated expression in these 
studies was miR-34, a miRNA separately reported to contribute to brain aging [280–
282]. Expression changes have also been reported in humans, where nine miRNA were 
found to be significantly downregulated in PBMC with increasing age [283]. These 
miRNA were also demonstrated to target gene products with known functions relevant 
to aging and may therefore play a causative or compensatory role in the aging process. 
The miRNA identified in these studies may also indirectly contribute to the 
pathophysiology of AD since the greatest risk factor for developing AD is advanced age. 
Aging is often associated with cognitive decline even in the absence of AD, 
although the molecular processes underlying this phenomenon and general brain aging 
are not well understood [284]. The pathophysiological process for brain aging appears 
to be distinct from that of AD or other neurodegenerative disorders since large-scale 
neuron loss is not a significant component of normal brain aging [285]. Studies in 
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mouse, rat, chimpanzee and human have revealed that gene expression and biological 
pathways are altered during normal brain aging, especially those related to 
inflammatory and stress responses [286–290]. Several recent studies have also 
identified miRNA that appear to have altered expression patterns in the brain during 
aging. In the mouse brain, approximately 75 miRNA were found downregulated in old 
animals compared to young, including miR-34a, mir-101 and miR-124, and a few 
miRNA were upregulated [281]. Another study also examined miRNA expression 
changes with aging in rhesus macaque, chimpanzee and human brain and found that 
only miR-144 was consistently upregulated [291]. The contribution of these miRNA to 
the aging process and the relevance of their gene targets is still uncertain. A recent 
study demonstrated that knockdown of miRNA processing in Drosophila melanogaster 
reduced the fly lifespan and accelerated brain aging and degeneration [282]. 
Interestingly, miR-34a increased with age in these flies and miR-34a knockdown also 
reduced lifespan and promoted an accelerated brain aging phenotype. Therefore, 
expression of this miRNA during the aging process is required for normal rate of aging 
in Drosophila. This study also demonstrated that miR-34a likely mediates this effect by 
inhibiting expression of Eip74EF (E74A isoform), a component of steroid hormone 
signaling pathways [282]. While the data in this field is still preliminary and lacks 
consistency and reproducibility, it does suggest that miRNAs likely play a critical role in 
the normal and pathological aspects of the aging process.     
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VI. Hypothesis and Aims 
Comprehensive knowledge of the physiological state is an essential component 
for elucidating pathogenic mechanisms. As such, the overarching goal of this 
dissertation is to clarify the normal, physiological pathways utilized by human cells to 
control expression of APP and BACE1. Given the hypothesized centrality of the Aβ 
peptide to AD etiology, the expectation is that newly discovered regulatory mechanisms 
that control expression of two gene products critical to Aβ production might serve as 
novel therapeutic targets for modulating disease progression. The current state of 
knowledge suggests that regulation of these two gene products is complex, with 
regulatory mechanisms existing at both the transcriptional and post-transcriptional level. 
miRNA are a class of endogenous non-coding RNA molecule with significant post-
transcriptional gene silencing properties. Given that these molecules are predicted to 
regulate expression of the majority of mammalian genes and participate in nearly every 
biological pathway, it is highly likely that miRNA play an important role in regulating 
normal expression of APP and BACE1. Therefore, the objective of this dissertation is to 
determine whether miRNA participate in the regulatory networks that govern their 
expression. The central hypothesis tested in this dissertation is that specific miRNA 
species regulate APP and BACE1 expression and, by extension, have Aβ-modifying 
properties.   
 
This hypothesis was tested by pursuing the following specific aims: 
1.) Identify miRNA that endogenously regulate APP expression.   
2.) Identify miRNA that endogenously regulate BACE1 expression.  
3.) Investigate the relevance of identified microRNA in normal physiology and in 
pathophysiology of Alzheimer disease. 
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CHAPTER 2: MATERIALS AND METHODS 
 
I. Tissue culture techniques 
 
A. Culture and maintenance of continuous human cell lines 
HeLa, U373, SK-N-SH and NTera2/D1 (NT2) cells were obtained from American 
Tissue Type Culture (ATCC, Manassas, VA). Standard cell culture procedures were 
employed in the culture and maintenance of all cell lines. Cells were grown on tissue-
culture treated plasticware (Corning, Tewsbury, MA) and maintained at 37°C in a 
humidified incubator containing 5% CO2. HeLa, U373 and SK-N-SH were grown in 
minimum essential media (MEM) (Cellgro, Manassas, VA) supplemented with 10% fetal 
bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% penicillin-
streptomycin-amphotericin solution (Cellgro, Manassas, VA). NT2 cells were 
maintained in Dulbecco’s modified eagle’s media (DMEM) (Cellgro, Manassas, VA) 
supplemented with 10% FBS and 1% antibiotic cocktail.  
Cells were routinely subcultured upon reaching 90% – 100% confluence by first 
washing cells twice with sterile phosphate buffered saline (PBS; Cellgro, Manassas, 
VA) and then enzymatically dissociating adherent cells using 0.05% trypsin/0.53 mM 
EDTA solution (Cellgro, Manassas, VA) for approximately 1 minute. Trypsin was then 
deactivated by adding an excess volume of serum-supplemented media and the cell 
suspension centrifuged at 200 g for 2 minutes. Cell pellets were then resuspended in 
serum-supplemented media and replated on new culture plasticware at 5 – 25% original 
density.  
 For certain experiments, precise number of cells were plated as indicated below. 
To obtain precise cell counts, the trypan blue exclusion method was employed. Cells 
were first dissociated with trypsin/EDTA as described above. Cell pellets were 
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resuspended in 1 mL of serum-supplemented media and a small aliquot diluted as 
needed for ease of cell counting. Diluted cell aliquots were mixed 1:1 with 0.4% trypan 
blue solution (Sigma-Aldrich, St. Louis, MO) and incubated for 2 – 5 minutes. Cells 
were then pipetted into a chamber consisting of a hemacytometer slide with an 
overlying coverslip. Number of cells were counted in five out of nine squares on the 
hemacytometer (each containing a volume of 0.1 mm3) and used to estimate the 
concentration of cells in the original solution. Precise cell numbers were than plated by 
applying appropriate cell suspension volume.  
Differentiated, post-mitotic NT2 neurons (NT2N) were prepared using a well-
established protocol [292]. Adherent NT2 cells were cultured in T75 flasks in the 
presence of retinoic acid (RA) for four weeks with media changes every four days. Cells 
were then dissociated with trypsin/EDTA and replated to three T175 flasks (1:7 plating 
density). On each of the next two days, flasks were vigorously tapped along each side 
to detach loosely adherent cells. Recovered cells were replated on 100 mm dishes 
coated with 1:30 Matrigel (BD Biosciences, San Jose, CA) and grown in DMEM 
supplemented with 10% FBS, 1 µM cytosine arabinoside (Sigma-Aldrich, St. Louis, 
MO), 10 µM fluorodeoxyuridine (Sigma-Aldrich, St Louis, MO) and 10 µM uridine 
(Sigma-Aldrich, St. Louis, MO) for 1 week. Cells were then transitioned to DMEM 
supplemented with 10% FBS, 10 µM flurodeoxyuridine and 10 µM uridine for one 
additional week. Cell clumps were then gently dissociated with trypsin/EDTA and plated 
in white-walled 96-well tissue-culture treated plates for reporter transfections (see 
below). Following this protocol, this culture is comprised of greater than 90% post-
mitotic neuronal cells resembling immature CNS neurons [292,293] 
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B. Culture and maintenance of primary human fetal brain cells 
The process for culturing primary human fetal brain cells was established and 
primarily performed by Dr. Balmiki Ray in Dr. Lahiri’s lab with assistance from the 
author. Primary cultures of mixed human fetal brain cells were prepared from the brain 
parenchyma of aborted fetuses (80 – 100 days gestational age). The tissues were 
obtained from the Birth Defects Research Laboratory (BDRL) at the University of 
Washington with approval from the Indiana University Institutional Review Board (IRB). 
Fetal brain materials (10 – 20 g) were shipped overnight in chilled Hibernate-E medium 
(Invitrogen, Grand Island, NY) supplemented with 1x B27 serum-free supplement 
(Invitrogen, Grand Island, NY), 0.5 mM GlutaMAX (Invitrogen, Grand Island, NY) and 
antibiotic-antimycotic solution (Cellgro, Manassas, VA).  
The culture procedures closely followed a similar procedure for establishing 
primary neuronal cultures from rat cortex [294], with some modifications. The tissues 
were digested in 0.05% trypsin/0.53 mM EDTA solution and incubated in a shaking 
water bath (150 RPM) at 37°C for 15 minutes. The trypsin-digested tissues were 
transferred to Hibernate-E medium and triturated several times using a siliconized, fire-
polished pipette followed by centrifugation at 400g for 15 minutes. The cell pellet was 
resuspended in Hibernate-E medium and triturated once more followed by 
centrifugation. The pellet was resuspended in culture medium (see below) and cells 
counted by Trypan blue exclusion method as described above.  
The cells were plated at a density of 2 – 4x105 cells per well on poly-D-lysine 
(Sigma-Aldrich, St Louis, MO) coated 24-well plates in Neurobasal medium (Invitrogen, 
Grand Island, NY), supplemented with 1x B27, 0.5 mM GlutaMAX, 5 ng/mL bFGF 
(Invitrogen, Grand Island, NY) and antibiotic-antimycotic cocktail. Half media changes 
were performed every fourth day of culture. Based on preliminary characterizations, the 
late stage culture (days in vitro (DIV) 16 and beyond) contains a mixture of immature 
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neural stem cells (GFAP-, nestin-, and neuronal marker-positive) and differentiated 
neurons and astrocytes (positive for a single marker). A brief immunocytochemical 
characterization of these cultures is described in the Appendix. 
 
C. Transfection of DNA vectors or RNA oligonucleotides into cell lines and primary 
cultures 
Lipofection was employed in these experiments using two separate cationic lipid 
reagents: Transfectin (Bio-Rad, Hercules, CA) and Lipofectamine RNAiMAX 
(Invitrogen, Grand Island, NY). A full list of all commercially-obtained miRNA and siRNA 
molecules transfected in these experiments is included in Table 1. DNA constructs are 
described in section II below. During all transfections, antibiotics were omitted from cell 
culture media.  
It is important to note that in all experiments where negative control RNA 
oligonucleotides (i.e miRNA mimics, miRNA inhibitors, target protectors) were 
transfected, universal negative controls were used. These commercially available 
universal controls have been designed to be minimally reactive with as few transcripts 
as possible based on complementarity analyses with mammalian transcriptome 
databases. These controls are not scrambled sequences and therefore do not 
necessarily have base composition identical to the experimental oligonucleotides for 
which they serve as controls. 
 In many experiments, changes in analytes levels were observed following 
transfection of negative control constructs as compared to mock transfection conditions. 
One possible explanation in these experiments is that changes in analyte levels 
following negative control transfection represent global non-specific or stress-related 
expression changes secondary to high oligonucleotide burden or interruption of normal 
metabolic pathways. As such, comparing negative control to experimental condition is 
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extremely appropriate in this case. An alternative explanation is that the negative 
control may have an inadvertent effect on analyte levels via sequence-specific 
complementarity or indirectly by modulating expression of an upstream pathway. In this 
case, comparison of experimental condition to negative control is likely not appropriate. 
In general, statistical comparisons were made between the experimental treatment and 
either the negative control or the mock transfection depending on which control 
condition exhibited the smallest difference in analyte levels compared to the 
experimental treatment. This approach was taken to avoid, as much as possible, 
inappropriate comparison between experimental treatments and negative control 
transfections.  
In one set of experiments, DNA reporter constructs containing luciferase-
expressing cassettes were transfected into HeLa, SK-N-SH and NT2N cells. For these 
experiments, HeLa cells (5x104 cells per well), SK-N-SH cells (1x105 cells per well) and 
NT2N cells (1.6x104 cells per well) were cultured in white-walled 96 well plates, with 
each well containing 100 µL of serum-supplemented media per well and transfected 
with 150 ng – 300 ng of reporter constructs using Transfectin. Transfection complexes 
were prepared by incubating DNA in a volume of serum-free media equivalent to 20 µL 
per well with 0.75 µL Transfectin per well for 15 – 20 minutes. Transfection complex-
containing solution was then directly added to cells on-plate in serum-containing media. 
Luciferase assays were normally performed 48 hours after transfection.  
 In a separate set of experiments, HeLa cells were co-transfected with reporter 
constructs and miRIDIAN miRNA mimics (Dharmacon, Lafayette, CA). These co-
transfections were performed by incubating HeLa cells cultured in 96-well plates (5x104 
cells per well) with 150 ng reporter DNA and 40 nM miRNA mimic using 0.2 µL 
Transfectin per well. Transfection complexes were prepared as described above.   
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The remaining experiments were single transfections of Silencer Select siRNA 
(Applied Biosystems, Carlsbad, CA), miRNA mimics, miRNA locked nucleic acid (LNA) 
inhibitors (Exiqon, Woburn, MA), or miRNA Target Protectors (Qiagen, Valencia, CA) 
into HeLa or U373 cells using RNAiMAX reagent (primary human fetal neuron cultures 
discussed below). For most experiments, HeLa cells (1.35x105 cells per well) and U373 
cells (7.5x104 cells per well) were cultured in 24-well plates and reverse transfected. In 
reverse transfections, transfection complexes are added to cultures at the same time as 
cells are plated. So, in this transfection format, cells are initially transfected in 
suspension until they settle and adhere to the plate. HeLa cells were generally 
transfected with 20 nM siRNA, 50 nM miRNA mimic, 100 nM – 1000 nM LNA miRNA 
inhibitor and 100-1000 nM miRNA Target Protector using 0.5 µL RNAiMAX per well. 
Transfection complexes were prepared in 50 µL Opti-MEM serum-free media 
(Invitrogen, Grand Island, NY) with 10 – 15 minute incubation periods prior to mixing 
with cell suspensions. U373 cells were similarly transfected with 75 nM miRNA mimics 
using 3.5 µL RNAiMAX per well. In several cases, miRNA mimics were co-transfected 
into HeLa cells with siRNA or miRNA target protectors. In these cases, RNAiMAX levels 
were boosted to 1µL per well to account for the increase in nucleic acid content. 
Multiple batches of human fetal brain cultures were transfected at DIV 17 in 24-
well plates. Cultures were transfected with 20 nM siRNA, 150 nM miRNA mimics, and 
1000 nM LNA miRNA inhibitors using 1.25 µL RNAiMAX per well. bFGF was omitted 
from media during transfections. In one series of experiments, human fetal brain 
cultures were transfected with miRNA mimics in the presence of 150 µM deferroxamine 
mesylate (DFO) (Sigma-Aldrich, St Louis, MO). The appropriate volume of DFO was 
prepared from a 5 mg/mL stock solution in PBS and added to cell culture plates 
approximately one hour prior to transfection. 
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In all experiments employing transfection of small RNA oligonucleotides, 
transfection efficiency was assessed qualitatively by including a siRNA transfection (20 
nM) against the gene product of interest. These siRNA were validated in HeLa cells as 
capable of reducing APP or BACE1 protein and mRNA expression to less than 5% of 
mock or negative control siRNA transfections.  
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Table 1: List of transfected siRNA and miRNA molecules 
siRNA Reagents 
Targeted mRNA Vendor siRNA ID 
APP Applied Biosystems s1500 
BACE1 Applied Biosystems s24219 
Dicer Applied Biosystems Custom 
AGO2 Applied Biosystems Custom 
IRP1 Applied Biosystems s672 
Negative Control #1 Applied Biosystems 4390843  
miRNA Mimics 
miRNA Name Vendor Catalog Number 
hsa-miR-1 Dharmacon C-300585-05  
hsa-miR-101 Dharmacon C-300518-07 
hsa-miR-153 Dharmacon C-300615-07 
hsa-miR-346 Dharmacon C-300712-03 
hsa-miR-339-5p Dharmacon C-300707-07 
hsa-miR-29b Dharmacon C-300520-05 
Negative Control 
Mimic #1 Dharmacon CN-001000-01  
Negative Control 
Mimic #2 Dharmacon CN-002000-01 
miRNA Antisense LNA Inhibitors 
Targeted miRNA Vendor Catalog Number 
miR-101 Exiqon 412942-08 
miR-153 Exiqon 410076-08  
miR-346 Exiqon 411373-00  
Negative Control A Exiqon 199004-00  
Custom miRNA Target Protectors 
miRNA Target Site Vendor 
miR-346 APP Target Site Qiagen 
miR-339-5p BACE1 Target Site 1 Qiagen 
miR-339-5p BACE1 Target Site 2 Qiagen 
Negative Control Target Protector Qiagen 
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D. Harvest and preparation of cell culture lysate for RNA and protein analyses 
Culture plates were collected, placed on ice, and allowed to equilibrate to 
temperature for a few minutes. Conditioned media (CM) from cell cultures were then 
collected and centrifuged at 200 g for 10 minutes. Cleared supernatant was collected 
and stored at -20°C for later analysis. Culture plates were then washed once briefly with 
5 mL ice-cold PBS followed by aspiration of wash solution.   
For downstream protein analyses, 75 – 100 µL of ice-cold mammalian protein 
extraction reagent (M-PER; Pierce, Rockford, IL) supplemented with 0.1% sodium decyl 
sulfate (SDS) and 1x protease inhibitor cocktail set III (EMD, Billerica, MA) was added 
to each well on the plate with shaking for 15 minutes at 4°C. Crude lysates were 
collected and centrifuged at 30,000 g for 10 minutes. Cleared supernatant was 
collected and either immediately used in downstream applications or stored at -20°C for 
later use. 
For downstream RNA analyses, 300 – 600 µL ice-cold cell lysis/binding buffer 
from the miRVana miRNA Isolation kit (Ambion, Grand Island, NY) was added to each 
well. Cells were immediately washed from the plate by pipette and triturated up and 
down until no visible cell clumps were apparent. Lysates were stored on ice before 
proceeding with RNA extractions (described below). 
For downstream applications that required both RNA and protein analyses from 
the same sample, 125 µL ice-cold cell disruption buffer from the miRVana PARIS kit 
(Ambion, Grand Island, NY) supplemented with 1x protease inhibitor cocktail set III was 
added to each well. Cells were washed from the plate and triturated by pipet until no 
visible clumps were apparent. A 50 µL aliquot of lysate was then immediately mixed 
with equal volume 2x denaturant (from miRVana PARIS kit) supplemented with β-
mercaptoethanol (βME). Denaturant-containing lysate was then used for downstream 
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RNA extraction while the crude lysate was centrifuged at 30,000 g for 10 minutes. 
Cleared supernatant was collected and stored at -20°C for later protein analyses. 
 
II. Molecular biology techniques 
 
A. PCR amplification of DNA insert and purification 
The APP 3’-UTR and BACE1 3’-UTR were amplified by PCR for insertion into 
the psiCHECK-2 reporter vector (Promega, Madison, WI). The APP 3’-UTR was 
amplified in both forward and reverse orientation from the pGALA construct (kindly 
provided by Dr. JT Rogers). The BACE1 3’-UTR was amplified from pooled human 
genomic DNA (Roche Applied Science, Indianapolis, IN). The DNA templates were 
amplified using Platinum Taq (Invitrogen, Hercules, CA). This is a “hot start” enzyme 
mix containing an anti-Taq antibody that must be first heat-denatured during 
thermocycling for full enzyme activity. All PCR reactions were assembled on ice at a 
dedicated PCR/RNA workbench with special supplies to prevent DNA or RNA 
contamination.  
Reactions were assembled by combining 1 ng plasmid DNA or 200 ng human 
genomic DNA with 10x PCR buffer, 1.5 mM MgCl2, 200 µM dNTP mixture, 1 µM 
forward and reverse orientation PCR primers, Platinum Taq enzyme and molecular-
grade water. Reactions were then placed in a thermocyler (Bio-Rad). A preliminary 
denaturation incubation at 94°C for 2 minutes was followed by 30 cycles of the following 
protocol: 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 minute for the APP 3’-
UTR or 4 minutes for the BACE1 3’-UTR. 
PCR reactions were then purified using the spin column-based QIAQuick PCR 
Purification Kit per manufacturer’s protocol (Qiagen, Valencia, CA). This kit selectively 
retains amplicons larger than 100 bp while allowing primers and primer-dimers to wash 
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through the column. Purified PCR amplicons were analyzed by agarose gel 
electrophoresis to confirm specific amplification and efficient removal of primers and 
primer-dimers. Amplicon fragments were quantified by measuring sample absorbance 
at 260 nm (A260) on a Tecan GENios plate reader and utilized in downstream cloning. 
Primers used in PCR reactions in this study were obtained from Integrated DNA 
Technologies (Coralville, IA) and are listed in Table 2. A requirement of the In-Fusion 
cloning technique (discussed below) is the addition of a 5’ extension on each forward 
and reverse primer. These extensions are indicated in the table. 
A separate insert was generated for cloning a miR-1 MRE into a reporter 
construct as a positive control. This was accomplished by obtaining sense and 
antisense oligonucleotides harboring the miR-1 MRE (IDT). These oligonucleotides 
were annealed by combining the oligonucleotides in 100 µL annealing buffer (10 mM 
Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA), heating to 95°C in a thermocycler, 
progressively cooling to 70°C over the course of 5 minutes, and then slowly cooling to 
25°C over the course of two hours. Annealed oligonucleotides were then used in 
downstream cloning. Oligonucleotide sequences included 5’ extensions for In-Fusion 
cloning. Sequences are listed in Table 2. 
  
47 
 
Table 2: List of PCR primers and oligonucleotides used for generating DNA 
inserts  
Primer/Oligo 
Description Orientation Primer/Oligo Sequence 
APP 3’-UTR from 
pGALA Forward 
5’-TAGGCGATCGCTCGAGATAAAGGCCAAGAAGG 
GCGGAA-3’ 
APP 3’-UTR from 
pGALA Reverse 
5’-AATTCCCGGGCTCGAGATCTTATCATGTCTGCT 
CGAAGCGGC-3’ 
BACE1 3’-UTR from 
human genomic 
DNA 
Forward 5’-TAGGCGATCGCTCGAGAGATAGAGATTCCCCT GGAC-3’ 
BACE1 3’-UTR from 
human genomic 
DNA 
Reverse GGCCGCTCTAGGTTTAAACGCCTCAGTATTGTTTTAGCC 
Reverse APP 3’-
UTR from pGALA Forward 
5’-TAGGCGATCGCTCGAGATCTTATCATGTCTGCT 
CGAAGCG-3’ 
Reverse APP 3’-
UTR from pGALA Reverse 
5’-GGCCGCTCTAGGTTTAAACATAAAGGCCAAGA 
AGGGCGGA-3’ 
miR-1 MRE Inserta Sense 5’-TAGGCGATCGCTCGAGACTAAATGAATACATAC TTCTTTACATTCCAACCATATGGACA-3’ 
miR-1 MRE Inserta Antisense 5’-GGCCGCTCTAGGTTTAAACTGTCCATATGGTT GGAATGTAAAGAAGTATGTATTCATTTAGT-3’ 
a= Oligonucleotides that were annealed and cloned into psiCHECK-2 by In-Fusion cloning 
Underlined, italics= 5’ extensions required for In-Fusion cloning 
Bold= miR-1 MRE sequence 
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B. Restriction digest of plasmid DNA or amplicon 
The parental construct used in cloning 3’-UTR reporter constructs was 
psiCHECK-2 (Promega, Madison, WI). This plasmid is 6.2 kb in length and contains a 
Renilla luciferase coding sequence (CDS) driven by the SV40 promoter, a multiple 
cloning site (MCS) located in the Renilla 3’-UTR, and a synthetic polyadenylation signal 
to ensure normal transcript processing in the absence of a 3’-UTR insert. A firefly 
luciferase CDS is located downstream and is driven independently by the HSV-TK 
promoter. An ampicillin resistance CDS is also incorporated in this vector to provide 
ampicillin resistance when transformed into bacteria. 
Both In-Fusion cloning and standard ligation cloning require that the vector 
receiving the insert be linearized by restriction enzyme digestion. The cloning 
procedures used in this study to generate 3’-UTR reporter constructs employed either 
single digestion with XhoI or double digestion with XhoI and PmeI. All restriction 
endonucleases employed in this study were obtained from New England BioLabs 
(Ipswich, MA). Restriction digests were performed in 20 µL final volume by mixing 
psiCHECK-2 DNA with XhoI with or without PmeI, appropriate digest buffer, 1x bovine 
serum albumin (BSA) and water. Reactions were incubated at 37°C for 1 – 2 hours. 
Digests were then resolved by agarose gel electrophoresis using 110V for 45 minutes 
to 1 hour. Gels were visualized using a UV transilluminator and bands corresponding to 
linearized psiCHECK-2 were excised. Linearized vector was then extracted from 
excised gel fragments using QIAquick Gel Extraction kit (Qiagen, Valencia, CA). Eluted 
vector was quantified by A260 values and utilized in downstream cloning applications. 
 
C. Molecular cloning, bacterial transformation and plasmid preparation 
Inserts prepared by PCR amplification or oligonucleotide annealing were cloned 
into linearized psiCHECK-2 by ligation-independent cloning as implemented in the In-
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Fusion cloning system (Clontech, Mountain View, CA). This proprietary enzyme mix 
contains 3’-5’ exonucleolytic activity. Both forward and reverse PCR primers used in 
this system are designed with 15 bp 5’ extensions that are identical in sequence to 15 
bp on either side of the restriction sites used to linearize the host vector. Following PCR 
amplification, amplicons then have 5’ and 3’ ends that are identical in sequence to the 
3’ and 5’ end of the linearized plasmid, respectively. Incubation of the linearized plasmid 
and amplicon with the In-Fusion enzyme results in 3’-5’ exonucleolytic attack on the 
exposed ends of both the amplicon and linearized plasmid. Given the sequence identify 
between the ends of both molecular species, very long complementary sticky ends are 
created that anneal to one another. Due to the high thermodynamic stability of the 
annealed vector and amplicon at the extended sticky ends, ligation is unnecessary prior 
to bacterial transformation. Apparently endogenous nick repair mechanisms in E. coli 
are sufficient to allow propagation of the newly formed recombinant plasmid. A 
significant advantage of this method is that no restriction digests or other treatments of 
the insert are necessary prior to cloning. This is highly advantageous, especially when 
working with long inserts, since the presence of internal restriction sites in the insert 
itself can be limiting when performing standard ligation cloning. 
To perform In-Fusion cloning, insert and linearized psiCHECK-2 (200 ng) were 
mixed together, generally at a 2:1 molar ratio, along with the In-Fusion enzyme mix, In-
Fusion buffer and water in a 10 µL final volume. This reaction mix was incubated at 
50°C for 15 minutes before being placed on ice. In every cloning reaction, a negative 
control reaction with no insert was performed to aid in visual estimation of 
recombination efficiency following bacterial transformation. 
Bacterial transformations were performed using Z-competent DH5α E. coli. Z-
competent cells were prepared using the Z-Competent E. Coli Transformation Kit and 
Buffer Set (Zymo, Irvine, CA) per manufacturer’s protocol. Briefly, an overnight culture 
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of untransformed DH5α cells was used to seed a 50 mL culture grown in Zymobroth. 
This culture was shaken and incubated at 250 rpm and 25° – 30°C for approximately 
seven hours. Culture density was frequently monitored by measuring sample 
absorbance at 600 nm (A600) on a Milton Roy Spectronic spectrophotometer. Once 
A600 measurements were between 0.4 – 0.6, the culture was equilibrated to 0°C and 
spun down at 2500 g for 10 minutes. Cell pellet was washed once with 1x Wash buffer 
and re-spun at 2500 g for 10 minutes. Cell pellet was then resuspended in 1x 
Competency buffer, aliquoted, snap-frozen, and stored at -80°C until use. 
To perform transformations, an aliquot of Z-competent E. coli was first thawed 
gently on ice. Then approximately 1 µL of In-Fusion reaction mixture was added to the 
bacterial suspension and the aliquot was gently mixed and incubated on ice for 
approximately 10 – 15 minutes. Transformed aliquots were plated on pre-warmed LB 
agar plates supplemented with 100 µg/mL ampicillin sodium salt (Sigma-Aldrich, St 
Louis, MO) and incubated for 12 – 18 hours at 37°C. Plates that had considerable 
number of colonies relative to negative control cloning plates were further screened. A 
number of colonies (ranging from 3 – 15) were picked and grown in 3 mL LB cultures 
overnight at 37°C. Overnight cultures were then processed using QIAprep Spin 
Miniprep kits (Qiagen, Valencia, CA) to purify plasmid DNA. Restriction digests were 
then performed as described above with diagnostic enzymes to confirm plasmid 
identity. Digests were analyzed by agarose gel electrophoresis and banding patterns 
visualized by UV transillumination. Expected banding patterns generated from multiple 
restriction digests was used as confirmation of successful cloning. DNA was also 
submitted to the Indiana University Sequencing Core for direct sequencing to confirm 
sequence fidelity. 
To prepare sufficient quantities of plasmid DNA for transfections, 150 – 300 mL 
LB-ampicillin cultures from positive clones were grown overnight at 37°C with shaking 
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at 250 rpm. A small volume of culture was stored as a glycerol stock for future retrieval. 
Depending on culture volume, cultures were processed by either NucleoBond Xtra Maxi 
Plus or Midi Plus kits (Clontech, Mountain View, CA) to purify plasmid DNA per 
manufacturer’s protocol. DNA was then quantified on a Nanodrop 1000 
spectrophotometer (Thermo Scientific, Waltham, MA). Table 3 lists the cloned reporter 
constructs used in this dissertation. 
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Table 3: Summary of reporter constructs generated for this disseration 
Plasmid Insert Insert Size Parental Vector Total Plasmid Size 
None None psiCHECK-2 6273 bp 
APP 3’-UTR 1210 bp psiCHECK-2 7487 bp 
BACE1 3’-UTR 3936 bp psiCHECK-2 10193 bp 
APP 3’-UTR  
Reverse  1210 bp psiCHECK-2 7464 bp 
miR-1 MRE 36 bp psiCHECK-2 6305 bp 
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D. Site-directed and cassette mutagenesis 
To prepare mutants at specific miRNA target sites in the APP and BACE1 3’-
UTR (and APP 5’-UTR), the QuikChange Lightning Site-Directed Mutagenesis kit 
(Agilent, Santa Clara, CA) was employed. This kit utilizes mutagenic primer-directed 
replication to introduce mutations at specific sites. Primers are designed to harbor the 
mutagenic site in the middle of the primer but with long perfectly complementary 
flanking regions on either side to anchor the primer to the target sequence. Plasmid 
amplification with a Pfu polymerase is then used to introduce the mutagenic sequence 
into the original sequence.  
Site-directed mutagenesis was performed by first designing optimized 
mutagenesis primers with the aid of the web-based Agilent QuikChange primer design 
tool. Some primers were designed to introduce a novel restriction site during 
mutagenesis to aid in screening for true clones. Primers were obtained commercially 
(Integrated DNA Technologies, Coralville, IA) and are listed in Table 4. To prepare 
reactions, 25 ng template DNA was mixed with 125 ng sense and antisense mutagenic 
primers, QuikSolution, dNTPs, 10x reaction buffer, QuikChange Lightning enzyme mix 
and water for a final volume of 50 µL. Reactions were placed in the thermocycler and 
initially denatured at 95°C for 2 minutes followed by 18 cycles of the following protocol: 
95°C for 20 seconds, 60°C for 10 seconds, 68°C for 4 minutes for APP 3’-UTR reporter 
and 7 minutes for BACE1 3’-UTR reporter. Hemimethylated plasmids containing an 
original, non-mutagenized strand were degraded by DpnI digestion. DpnI-digested 
samples were then transformed into XL10 ultracompetent DH5α E. coli cells from the 
kit. Cells were heat-shocked followed by a one hour outgrowth in NZY broth prior to 
plating on LB/ampicillin agar plates. Colonies were picked and cultured in 3 mL 
LB/ampicillin overnight at 37°C followed by miniprep DNA purification. To screen for 
true clones, some mutants had newly created restriction sites that were digested to 
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reveal novel banding patterns on agarose gel electrophoresis not observed in wild-type 
plasmids. For all other mutants, confirmation was performed by direct sequencing at the 
Indiana University Sequencing Core. Table 5 lists all sequencing primers utilized to 
confirm successful mutagenesis. 
The pGAL reporter construct was kindly provided by Dr. Jack T Rogers to study 
regulatory effects on the APP 5’-UTR [143]. Mutagenesis at a predicted miR-346 target 
site in this 5’-UTR proved refractory to standard site-directed mutagenesis procedures. 
Therefore, cassette mutagenesis was employed instead. In this form of mutagenesis, 
the region of plasmid DNA to be mutated is excised by restriction digest. A mutagenized 
version of this cassette is synthesized, annealed, digested and ligated into the 
linearized vector. The oligonucletoides to replace the miR-346 target site in the APP 5’-
UTR were obtained from Integrated DNA Technologies (Coralville, IA) and are listed in 
Table 4. To perform cassette mutagenesis, pGAL was first double digested with HindIII 
and NcoI as described above. The digested plasmid was then resolved by agarose gel 
electrophoresis, bands containing linearized plasmid excised, and linearized plasmid 
extracted and purified from gel fragments using QIAQuick Gel Extraction kit. Mutant 
oligonucleotides were designed so that, once annealed, the 5’ and 3’ ends would form 
sticky ends to match the HindIII and NcoI sites in the linearized pGAL. Oligonucleotides 
were annealed as described above and directly ligated into linearized pGAL by 
combining annealed cassette, linearized pGAL, T4 ligase buffer, and T4 ligase in a 20 
µL final volume and incubating at room temperature for 2 hours. Approximately, 1 µL of 
ligase reaction mix was then transformed into Z-competent E. coli and plated overnight. 
True clones were confirmed by direct sequencing of plasmid DNA. 
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Table 4: List of primers and oligonucleotides used for site-directed and cassette 
mutagenesis 
Mutagenic 
Primer/Cassette Oligos Orientation Primer Sequence 
miR-101 APP 3’-UTR 
Target Site 1 Sense 
5’-TACATTTTGGTCTCTATACTACATTATTAATGGG 
TTTTGTGATGACATAAGAATTTAGCTGTATCAAAC
TAGTGCATGAATAGATTCTC3’- 
miR-101 APP 3’-UTR 
Target Site 1 Antisense 
5’-GAGAATCTATTCATGCACTAGTTTGATACAGCT 
AAATTCTTATGTCATCACAAAACCCATTAATAATGT
AGTATAGAGACCAAAATGTA-3’ 
miR-101 APP 3’-UTR 
Target Site 2 Sense 
5’-GTATTTCAGATGCTTTAGAGAGATTTTTTTTCCA 
TGACTGCATTTGTTTAAACAGATTGCTGCTTCTGC
TATAT-3’ 
miR-101 APP 3’-UTR 
Target Site 2 Antisense 
5’-ATATAGCAGAAGCAGCAATCTGTTTAAACAAAT 
GCAGTCATGGAAAAAAAATCTCTCTAAAGCATCTG
AAATAC-3’ 
miR-153 APP 3’-UTR 
Target Site Sense 
5’-CAGCTGCTTCTCTTGCCTAAGTATTCCTTTCCT 
GATCACCGCATGTTTTAAAGTTAAACATTTTTAAGT
ATTTCAGATGCTTTAG-3’ 
miR-153 APP 3’-UTR 
Target Site Antisense 
5’-CTAAAGCATCTGAAATACTTAAAAATGTTTAACT 
TTAAAACATGCGGTGATCAGGAAAGGAATACTTAG
GCAAGAGAAGCAGCTG-3’ 
miR-339-5p APP 3’-UTR 
Target Site 1 Sense 
5’-GGAGAGGATGCACAGTTTGCTATTTGCTTTAGA 
CGGATCCACTGTATAAACAAGCCTAACATTG-3’ 
miR-339-5p APP 3’-UTR 
Target Site 1 Antisense 
5’-CAATGTTAGGCTTGTTTATACAGTGGATCCGTC 
TAAAGCAAATAGCAAACTGTGCATCCTCTCC-3’ 
miR-339-5p APP 3’-UTR 
Target Site 2 Sense 
5’-AAGAGGAGAAGGAGAGGGAGTACAAACGGATC 
CAATAGTGGGATCAAAGCTAGGAAAGG-3’ 
miR-339-5p APP 3’-UTR 
Target Site 2 Antisense 
5’-CCTTTCCTAGCTTTGATCCCACTATTGGATCCG 
TTTGTACTCCCTCTCCTTCTCCTCTT-3’ 
miR-346 APP 5’-UTR 
Target Sitea Sense 
5’-AGCTTAGTTTCCTCGGCAGCGGTAGGCGAGAG 
CACGCGGAGGAGCGTGCGCGGGGGCCCCGGGA
GACGGCGGCGGTGGCGGCGCGAATGAGGCAAG
GACGCGGCGGATCCCACTCGCACAGCAGCGCAC
TCGGTGCCCCGCGCAGGGTCGCGC-3’ 
miR-346 APP 5’-UTR 
Target Sitea Antisense 
5’-CATGGCGCGACCCTGCGCGGGGCACCGAGTG 
CGCTGCTGTGCGAGTGGGATCCGCCGCGTCCTT
GCCTCATTCGCGCCGCCACCGCCGCCGTCTCCC
GGGGCCCCCGCGCACGCTCCTCCGCGTGCTCTC
GCCTACCGCTGCCGAGGAAACTA-3’ 
a = Cassette mutagenesis oligonucleotides 
BOLD RED = target mutation 
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Table 5: List of sequencing primers used for confirming mutagenesis 
Sequencing primer description Orientation Primer Sequence 
miR-101 APP 3’-UTR Target Sites Sense 5’-GATGCCTGAACTTGAATTAATCCACAC-3’ 
miR-153 APP 3’-UTR Target Site Sense 5’-TTTACATATGCTTTAAGAATCGATGG-3’ 
miR-346 APP 5’-UTR Target Site Sense 5’-CTGCTGTGCGAGTGGGAT-3’ 
miR-339-5p APP 3’-UTR Target Sites Sense 5’-GGCGTGTGTCCCTGTGGTA-3’ 
miR-339-5p APP 3’-UTR Target Sites Antisense 5’-AGCCCTTCCCATCTCACTTT-3’ 
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III. Biochemical techniques 
 
A. Luciferase reporter assay 
The normal reaction catalyzed by luciferase exhibits very fast kinetics such that 
the standard dual luciferase reporter assay generates a rapid rise and fall in 
luminescence that spans only a few minutes. This reaction system requires the use of 
an injector system to inject reaction reagents and immediately measure luminescence 
from each well of a plate. The Dual Glo assay system (Promega, Madison, WI) utilizes 
a modified reaction system with stabilized reaction kinetics such that the half-life of the 
luciferase reaction is over 2 hours. This is beneficial when multiple plates are being 
analyzed simultaneously, as in this study. After adding reagents, a significant time gap 
is tolerable before taking luminescence readings. Therefore, the Dual Glo assay was 
employed in these experiments.  
HeLa, SK-N-SH or NT2N cells were transfected with reporter constructs either in 
isolation or in combination with miRNA mimics, as described above. Forty eight hours 
post-transfection, the Renilla and firefly luciferase activity was assayed using the Dual-
Glo Reporter system (Promega, Madison, WI). This assay was performed by first 
removing cell culture media from the plate. 30 µL of PBS was then added, followed by 
30 µL Dual-Glo luciferase reagent. Plates were incubated at room temperature for 10 
minutes before firefly luminescence readings were taken using a Turner Biosystems 
Veritas luminomenter. 30 µL of Stop & Glo reagent was then added to each plate 
followed by 10 minute room temperature incubation. Renilla firefly luminescence 
readings were then taken. Since the reporter constructs contained the APP or BACE1 
3’-UTR downstream of the Renilla coding sequence, ratios of Renilla/firefly 
luminescence values were calculated to control for variability in cell number and 
transfection efficiency. When multiple plates were assessed simultaneously, relative 
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response ratios (RRR) were calculated to control for plate-to-plate variation. The RRR 
was calculated by scaling Renilla/firefly ratios to a positive control reaction (miR-1 co-
transfected with miR-1 MRE-containing construct) and negative control reaction 
(reporter alone without co-transfection) included on every plate. 
 
B. Processing of brain tissue for protein extraction 
Frozen human brain specimens from the Harvard Brain Tissue Resource Center 
and University of Kentucky Alzheimer Disease Center Brain Bank isolated from BA9 of 
the frontal cortex in age-matched control and AD patients were provided by Dr. P. 
Hemachandra Reddy and Dr. Peter Nelson, respectively. Sample demographics and 
post-mortem interval (PMI) are described in more detail in Chapter 3 under Aim 3. 
Specimens were initially pulverized using a stainless steel pulverizing chamber pre-
chilled with liquid nitrogen. Pulverized samples were quickly aliquoted and stored at -
80°C, avoiding sample thawing. 
One aliquot of each sample was processed for protein analysis. This frozen 
aliquot was immersed in M-PER supplemented with 0.1% SDS and protease inhibitor 
cocktail set III and immediately sonicated using a Sonifier Cell Disruptor 350 (Branson, 
St Louis, MO) until visible clumps were no longer apparent. Lysates were then 
incubated with 50 U/mL Benzonase enzyme (EMD, Billerica, MA) for 10 minutes at 
37°C to reduce nucleic acid content and associated viscosity. Lysates were centrifuged 
down at 30,000 g for 2 h to clear debris. Cleared supernatants were collected and 
stored at -80°C for future protein analysis. 
  
C. RNA extraction from cell culture and tissue samples 
All RNA extraction procedures were performed at a dedicated RNA/PCR 
workbench under conditions to protect against ribonuclease contamination. Pulverized 
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brain specimens first underwent a preliminary tissue disruption step. A separate frozen 
aliquot of pulverized tissue from each specimen was immersed in 200 µL – 1100 µL ice-
cold Cell Disruption Buffer from the miRVana miRNA Isolation kit and immediately 
homogenized using a Polytron (Kinematica, Bohemia, NY). Cell culture lysates for RNA 
extraction were prepared as described above using either the miRVana miRNA 
Isolation kit or the miRVana PARIS kit. 
Total RNA was extracted using the miRVana miRNA Isolation kit or PARIS kit 
per manufacturer’s instructions. The basis of total RNA extraction in both kits is 
essentially identical. Lysates are prepared in buffers containing guanidinium salts and 
other denaturants to inhibit RNase activity. Lysates are then extracted with an equal 
volume of acid phenol:chloroform. The aqueous layer is recovered and nucleic acid 
solubility is reduced by the addition of ethanol. Total RNA is then bound to a silica-
based spin column. Multiple washes are applied to remove trace phenol and cellular 
contaminants. Finally, RNA is extracted by adding molecular-grade water preheated to 
70°C.  
RNA quantity and purity were assessed following purification by measuring 
sample absorbance across the ultraviolet spectrum using a Nanodrop 1000 (Thermo 
Scientific, Waltham, MA) and assessing the absorbance ratio of 260 nm versus 280 nm 
(A260/A280). RNA integrity was assessed by the Center for Medical Genomics through 
use of on-chip capillary electrophoresis in a Bioanalyzer (Agilent, Santa Clara, CA). The 
RNA integrity number (RIN) was determined by automated software analysis of the 
electropherogram. The RIN value is calculated from an empirically-derived algorithm 
that assesses multiple features of the sample electropherogram and is superior to the 
ratio of 28S:18S ribosomal RNA for assessing RNA integrity [295]. All cell culture 
samples had acceptable A260/A280 ratios and RIN values greater than 8.5. RNA 
quality of the brain specimens was somewhat variable. Specimens from the University 
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of Kentucky Brain Bank had generally high RIN values, with all but two out of 20 
samples having RIN values greater than 6. Several specimens from the Harvard Tissue 
Resource Center had low RIN values (<6), likely attributable to prior sample processing. 
There was no detectable association between low RIN value and higher Ct values 
obtained from quantitative PCR analyses in this collection. Therefore, all samples were 
included for further analysis. 
 
D. Protein quantification, SDS-PAGE and Western blotting 
Lysate protein concentrations were first measured by BCA (Pierce, Rockford, IL) 
per manufacturer’s instructions. This assay is based upon the biuret reaction, whereby 
Cu2+ is reduced to Cu1+ via interactions with peptide bonds in the protein sample. 
Bicinchoninic acid (BCA) included in the assay reagent then complexes with Cu1+ 
producing a stable chromophore that absorbs maximally at 562 nm [296]. This assay 
has a larger dynamic range and a wider breadth of compatibility with various buffer 
components as compared to Lowery and Bradford assays. Protein concentrations were 
measured by incubating 10 µL of lysate with 200 µL of working reagent at 37°C for 30 
minutes and then measuring absorbance at 570 nM with a microplate reader (Bio-Rad, 
Hercules, CA). All samples were analyzed in duplicates and absorbance values 
averaged. Concentrations were calculated by comparison to a bovine serum albumin 
(BSA) standard curve included with each new assay.     
Lysates were prepared for Western blot analysis by first heating samples to 
95°C for 5 minutes in Laemmli sample buffer [297]. An equal amount of lysate protein 
(ranging from 1 – 5 µg) was loaded onto Bis-Tris XT denaturing 10% polyacrylamide 
gels containing sodium dodecyl sulfate (SDS) (Bio-Rad, Hercules, CA). Proteins were 
resolved by SDS-PAGE by applying 200V across the gels for 1.3 hours. Resolved 
protein bands were then transferred onto PVDF membranes by electroblotting at either 
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30V for 10 hours or 100V for 1.5 hours. To assess for even transfer, blots were stained 
with Ponceau-S. Membranes were blocked for 1 h in 5% non-fat milk and then 
incubated overnight with primary antibodies against APP (22C11, Chemicon, Billerica, 
MA), BACE1 (3D5, gift from Dr. Robert Vassar), IRP1 (Santa Cruz Biotechnology, 
Santa Cruz, CA), Dicer (NeuroMAB, Davis, CA), α-tubulin (B-5-1-2, Sigma-Aldrich, St 
Louis, MO), and β-actin (AC15, Sigma-Aldrich, St Louis, MO). Membranes were then 
incubated with HRP-conjugated goat anti-mouse secondary antibody (Rockland 
Immunochemical, Gilbertsville, PA) or HRP-conjugated rabbit anti-goat secondary 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h. Bands were visualized 
using ECL reagent (Pierce, Rockford, IL), detected on film and scanned for 
densitometric analysis 
. 
E. Aβ ELISA analyses 
Aβ analyses were primarily performed by Dr. Balmiki Ray. Levels of Aβ1-40 
were measured in the CM of U373 cells and primary human fetal brain cultures using a 
sensitive and specific commercially available ELISA kit (IBL America, Minneapolis, MN). 
Equal volume of CM (25μL) was loaded in a plate pre-coated with anti-human Aβ (35 – 
40) antibody (clone 1A10) and incubated overnight. This kit uses HRP-conjugated anti-
human Aβ (11 – 28) as detection antibody. The overall assay was performed according 
to manufacturer’s instructions. Briefly, CM was added to pre-coated plates and 
incubated overnight at 4°C. The next day plates were vigorously washed and then 
incubated with detection antibody for approximately one hour at 4°C. Plates were again 
vigorously washed and then incubated with chromogenic substrate 
tetramethylbenzidine for thirty minutes in the dark. Chromogenic reaction was then 
stopped by the addition of stop solution and absorbance at 450 nm was read using 
Tecan GENios microplate reader. Absolute Aβ1-40 values (in pg/mL of CM) were 
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calculated by comparison to an Aβ1-40 standard curve. This value was normalized to 
the total lysate protein yield from each well to control for variability attributable to 
differences in cell number and scaled relative to mock transfection values.  
  
F. Reverse transcription quantitative PCR (RT-qPCR) analysis of mRNA and miRNA 
Both mRNA and miRNA levels were quantified by reverse transcription 
quantitative PCR (RT-qPCR). Specific qPCR assays used in this dissertation are listed 
in Table 6. All RT and qPCR steps were performed at a dedicated PCR/RNA 
workbench with separate supplies to avoid DNA or RNA contamination. For miRNA 
quantification, stem-loop TaqMan assays were employed (Applied Biosystems, 
Carlsbad, CA). This method utilizes miRNA-specific RT primers with complementarity to 
several ribonucleotides on the 3’ end of the targeted miRNA along with a stem-loop 
structure on the primer 5’ end [298]. Since pre-miRNA species have additional 
nucleotides downstream of the mature sequence, steric hindrance between the RT 
primer secondary structure and pre-miRNA sequence impedes unwanted pre-miRNA 
cDNA synthesis. A miRNA-specific forward primer and reverse primer targeting a 
universal sequence located within the loop of the RT primer are used for qPCR 
amplification. The assay uses a hydrolysis probe for detecting amplification during 
qPCR.  
Total RNA (10 ng) was first converted to cDNA using TaqMan microRNA 
Reverse Transcription kit (Applied Biosystems, Carlsbad, CA) by combining RNA, 
miRNA-specific RT primer, MultiScribe reverse transcriptase, RNase inhibitor enzyme, 
dNTPs, reaction buffer and water per manufacturer’s protocol and incubating reaction 
mix on a thermocycler at 16°C for 30 minutes, 42°C for 30 minutes and 85°C for 5 
minutes. cDNA was then subjected to qPCR analysis using specific TaqMan hydrolysis 
probe assays (Applied Biosystems, Carlsbad, CA). The RT reaction mix (cDNA) was 
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combined with TaqMan miRNA assay and TaqMan Universal PCR master mix (Applied 
Biosystems, Carlsbad, CA) per manufacturer’s protocol and analyzed on a 7300 Real-
Time PCR instrument (Applied Biosystems, Carlsbad, CA). Each sample was analyzed 
in duplicate and signals averaged. 
For mRNA quantification, standard mRNA TaqMan hydrolysis probe assays 
were utilized. Total RNA (10 – 75 ng) was converted to cDNA with the High Capacity 
RNA-to-cDNA kit (Applied Biosystems) by combining total RNA, RT enzyme mix and 
RT reaction buffer per manufacturer’s protocol and incubating reaction mix in a 
thermocycler at 37°C for 60 minutes and then 95°C for 5 minutes. The RT reaction mix 
(cDNA) was combined with TaqMan mRNA assay and TaqMan Universal PCR master 
mix as in miRNA analyses. The PCR reactions were then analyzed on the 7300 Real-
Time PCR instrument. Each sample was analyzed in duplicate and signals averaged. 
Both relative and absolute quantification methods were employed. Relative 
quantification was performed using a modified delta-Cq method. The delta-Cq method 
allows for the determination of relative amplicon levels by first calculating the difference 
in the crossing threshold cycle (Ct) for a gene of interest in an unknown sample relative 
to a calibrator sample, i.e. ΔCt. In the simplest form of the delta-Cq method [299], the 
ΔCt value for the gene of interest in a given sample is then compared to the ΔCt value 
for a stably expressed reference gene in the same sample by taking the difference, i.e 
ΔΔCt. Assuming the PCR amplification efficiencies are 100% for both the genes, i.e. the 
amplicon numbers double after each cycle, then the relative levels of the gene of 
interest is calculated by the formula 2-ΔΔCt. A more sophisticated analysis allows for 
more precise quantification by incorporating exact amplification efficiencies (E) for each 
PCR reaction into the calculation [300]. Relative levels are calculated by taking the ratio 
of ExΔCt,x for the gene of interest to EyΔCt,y for the stable reference gene, where Ex and Ey 
are experimentally-determined PCR amplication efficiencies for the gene of interest and 
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reference gene, respectively. Studies have demonstrated that relative transcript 
quantities derived from qPCR analyses are more accurate when normalized to the 
geometric mean of multiple reference genes [301]. Therefore, the relative quantification 
scheme employed for relative RT-qPCR analyses in this dissertation took into account 
experimentally-derived PCR amplification efficiencies and normalization to the 
geometric mean of multiple reference genes [302]. This scheme is implemented into the 
qBasePLUS software used for RT-qPCR analyses in these studies. In order to 
determine amplification efficiencies for each TaqMan assay, aliquots of every RNA 
sample in a given analysis were pooled and used to create a relative standard curve by 
serial dilution. This standard curve was then converted to cDNA and analyzed by qPCR 
in parallel with unknown samples. The slope of the plot of Ct versus standard curve 
dilutions used to calculate amplification efficiency.  
For miRNA relative quantification studies, RNU48, RNU49, RNU6B, and hsa-
miR-16 were used for normalization. For mRNA relative quantification studies, GAPDH, 
B2M, β-actin and TBP were used for normalization.  
To perform absolute quantification in miRNA analyses, HPLC-purified synthetic 
oligoribonucleotide standards were obtained commercially (Sigma, St Louis, MO and 
Integrated DNA Technologies, Coralville, IA). These oligonucleotides were identical in 
sequence to human miR-101, miR-153, miR-346, miR-339-5p, miR-124 and miR-1. 
These oligoribonucleotides were resuspended and exact concentrations measured by 
A260 measurements. Based on measured concentrations, standard curves with 
absolute copy counts were prepared by serial dilution. These serially diluted standards 
were converted to cDNA and analyzed by qPCR in parallel with unknown samples. 
Copy counts per reaction were then determined based upon standard curve analysis. 
Given that each reaction mix was loaded with a known amount of total RNA (generally 
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10 ng), copy counts were then presented as copy counts/15 pg total RNA. This serves 
as a rough estimate of copy counts per average human cell. 
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Table 6: List of TaqMan assays utilized in qPCR analyses 
miRNA and mRNA qPCR Assays 
Assay Name Assay RNA Target Vendor Assay ID 
hsa-miR-101 hsa-miR-101 Applied Biosystems 002253 
mmu-miR-153 hsa-miR-153 Applied Biosystems 001191 
hsa-miR-346 hsa-miR-346 Applied Biosystems 000553 
hsa-miR-339-5p hsa-miR-339-5p Applied Biosystems 002257 
mmu-miR-124a hsa-miR-124 Applied Biosystems 001182 
hsa-miR-1 hsa-miR-1 Applied Biosystems 002222 
hsa-miR-107 hsa-miR-107 Applied Biosystems 000443 
hsa-miR-29b hsa-miR-29b Applied Biosystems 000413 
hsa-miR-16 hsa-miR-16 Applied Biosystems 000391 
RNU6B Human U6B snRNA Applied Biosystems 001093 
RNU48 Human U48 snoRNA Applied Biosystems 001006 
RNU49 Human U49 snoRNA Applied Biosystems 001005 
APP Human APP Applied Biosystems Hs01552282_m1 
BACE1 Human BACE1 Applied Biosystems Hs00201573_m1 
GAPDH Human GAPDH Applied Biosystems Hs99999905_m1 
ACTB Human β-actin Applied Biosystems 4333762T  
B2M Human β-2-microglobulin Applied Biosystems Hs99999907_m1 
TBP Human TATA-binding protein Applied Biosystems Hs99999910_m1 
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IV. Data Analysis 
Densitometric analysis of Western blots was performed using ImageJ software. 
qPCR data normalization was performed using qbasePLUS software. Fluoresence 
micrograph and Western blot image processing was performed using Adobe 
Photoshop. Western blot images were adjusted for contrast and brightness and some 
extraneous sections of blots between boxed regions were removed for the sake of 
clarity. No manipulations have been made to images that alter data quantification or 
interpretation. All graphs were preared in Prism GraphPad. Error bars represent 
standard error of the mean (SEM). Statistical analyses were performed using Prism 
GraphPad and SPSS. For comparison between two categories, two-tailed Student’s t-
test was performed. For comparison across multiple categories, one-way ANOVA was 
performed. When ANOVA was significant, post-hoc Dunnett’s t-test, Tukey’s Honest 
Significant Difference (HSD) test, or Student-Neuman-Keuls (SNK) test were performed 
as appropriate to correct for multiple comparisons. The α threshold for statistical 
significance was set at 0.05. 
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CHAPTER 3: RESULTS 
 
I. Aim 1: Identify miRNA that endogenously regulate APP expression 
To unequivocally identify specific members of the repertoire of miRNA that 
regulate APP expression, the workflow outlined in Figure 3 was employed throughout 
this study. This workflow starts from a gene of interest (GOI), in this case APP – or 
BACE1 in aim 2 – and proceeds as follows: i) identification of putative miRNA target 
sites within the transcript, ii) functional validation of these putative regulatory 
interactions, iii) testing the effect on a relevant downstream pathway of interest (i.e. Aβ 
production), and iv) assessing the physiological relevance of the putative regulatory 
relationship by blocking endogenous interaction between miRNA and target site. 
 
A. Global knockdown of miRNA function elevates APP expression 
To begin to dissect the role that miRNAs play in the basal regulation of APP 
expression, global miRNA function was inhibited in cultured human fetal brain cells. To 
accomplish this, AGO2 expression was knocked down using siRNA transfection. Given 
that AGO family proteins are the core constituent of RISC as previously discussed, this 
approach would be expected to modulate expression of gene targets that are under 
direct basal regulation by miRNAs. Also, given the acute nature of the knockdown, the 
compensatory effect of homeostatic controls on gene expression would be expected to 
be less vigorous than in long-term or stable AGO2 knock out conditions. Human fetal 
brain cultures were either mock transfected or transfected with a negative control or 
AGO2-specific siRNA at DIV 17. Cultures were harvested 48 hours post-transfection 
(DIV 19) and APP expression assayed by Western blot. APP levels were found to be 
significantly elevated (1.51±0.09 fold change) following knockdown of AGO2 as 
compared to negative control siRNA transfection (p=0.043 by two-tailed Student’s t-
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test) (Figure 4A and B). This suggests that APP expression is basally inhibited by the 
global complement of miRNA in this relevant cell model. 
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Figure 3: Methodological workflow employed to identify novel AD-relevant miRNA 
regulators of APP and BACE1 expression. The workflow utilized in this dissertation 
began with a specific predetermined GOI – in this case APP and BACE1. Putative 
target sites in the 3’-UTR of the APP and BACE1 transcripts were identified by 
bioinformatic analysis. Target sites were then validated by both 3’-UTR reporter assays 
and direct analysis of native protein levels following transfection of putative targeting 
miRNA. The effect of miRNA-mediated regulation of APP and BACE1 on downstream 
biological pathways was assessed by measuring levels of Aβ in conditioned media of 
miRNA-transfected cultures. Endogenous miRNA function was then disrupted to assess 
whether endogenous miRNAs physiologically regulate expression of APP and BACE1. 
Originally published in expanded form in Long and Lahiri (2012) [223].  
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Figure 4: Knockdown of miRNA effector protein AGO2 enhances expression of 
APP in primary human fetal brain cultures. The effect of disrupting global miRNA 
functionality on APP expression in primary human fetal brain cultures was assessed by 
using siRNA-mediated knockdown of AGO2. Cultures were transfected at DIV 17 and 
lysates prepared 48 hours post-transfection (DIV 19). (A) Levels of APP and α-tubulin 
were assayed by Western blot. (B) Blots were quantified by densitometric analysis and 
APP levels normalized to α-tubulin levels and scaled relative to mock transfection (n=4). 
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B. Bioinformatic analysis of putative miRNA targets in the human APP 3’-UTR     
To identify novel miRNA target sites in the human APP 3’-UTR, multiple web-
based bioinformatics algorithms were used to predict favorable miRNA interactions. 
These web-based predictors included TargetScan 6.0 [204,243,303–305], PicTar [306], 
DIANA-microT v4.0 [307–310], miRANDA-mirSVR [311–314], PITA [315] and rna22 
[316]. There are some common parameters that a majority of these algorithms assess 
to varying degrees when predicting putative target sites. These include seed sequence 
complementarity, the free energy of duplex formation, cross-species conservation at the 
target site and local sequence context surrounding the target sites. However, each 
predictor algorithm includes its own unique combination of parameters making each set 
of predictions distinct between the predictors. Specific attributes of each predictor are 
described in Table 7. 
miRNA target site predictions in the APP 3’-UTR were extracted from the 
predictor outputs. Criteria for selecting a given miRNA:target site interaction included 
relatively high predictor score and known brain expression. Preference was also given 
to miRNA-target interactions predicted across multiple algorithmic platforms. Table 8 
summarizes the identity of the predicted targeting miRNA and the location of the 
predicted target site in relation to the human APP 3’-UTR, along with the various 
predictor scores computed for each given target site interaction. In the case of miR-101, 
two distinct target sites were predicted by multiple algorithms. Since each predictor 
utilizes a unique algorithm for scoring favorable target site interactions or target site 
efficacy, it is not meaningful to compare scores between predictors. However, scores 
can be compared within a prediction set produced by a single predictor. As an example, 
among all TargetScan predictions listed, miR-101 produced the most favorable 
context+ score (-0.35) for interaction with the APP 3’-UTR (Table 8). 
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Table 7: Summary of computational predictor algorithms 
Computational Target 
Site Predictor (URL) Summary of Key Algorithm Components References 
TargetScanHuman 6.0  
(http://www.targetscan.org) 
− Perfect seed sequence complementarity 
− High miRNA-target duplex stability favored 
− Favored sequence contexts  
− Target site position within 3’-UTR 
− Target site cross-species conservation 
required 
[204,243,30
3–305] 
PicTar  
(http://pictar.mdc-berlin.de) 
− Imperfect seed sequence complementarity 
tolerated 
− High miRNA-target duplex stability favored 
− Target site cross-species conservation 
required 
− Probability-based combinatorial scoring matrix 
[306] 
DIANA-microT v4.0 
(http://diana.cslab.ece.ntua
.gr/DianaTools/index.php?r
=microtv4) 
− Imperfect seed sequence complementarity 
tolerated 
− High miRNA-target duplex stability favored 
− Target site cross-species conservation 
incorporated into algorithm but not strictly 
required 
[307–310] 
miRanda-mirSVR 
(http://www.microrna.org) 
− Dynamic programming alignment weighted for 
seed sequence complementarity 
− High miRNA-target duplex stability favored 
− Target site cross-species conservation 
required 
− Machine learning algorithm for predicting 
miRNA efficacy  
[311–314] 
PITA 
(http://genie.weizmann.ac.il
/pubs/mir07/index.html) 
− High miRNA-target duplex stability favored  
− Low stability of secondary structure near target 
site favored (i.e. site accessibility favored) 
[315] 
rna22 
(http://cbcsrv.watson.ibm.c
om/rna22.html) 
− Pattern recognition algorithm that identifies 
sequence motifs from miRNA sequences  
− Identifies target islands in 3’-UTR 
complementary to these sequence motifs 
[316] 
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Table 8: Selected APP 3’-UTR miRNA Target Site Predictions and Scores 
miRNA 
Computational Predictor Scores 
Target 
Siteg 
Target 
Scana PicTar
b 
DIANA- 
microT v4c 
miRanda 
miRSVRd PITA
e rna22f 
miR-101h -0.35 5.13 0.307 -1.278 2.45 *** 242-248  
 -0.05 5.13 0.226 -0.150 *** *** 532-538 
miR-153 -0.22 2.50 0.414 -1.256 -3.91 -21.3 457-463 
miR-106a -0.12 2.35 0.436 -0.703 -6.58 -27.4 710-716 
miR-106b -0.12 1.82 0.414 -0.703 0.21 -27.4 710-716 
miR-20a -0.10 2.35 0.414 -0.707 -6.56 -27.5 710-716 
miR-20b -0.10 *** 0.414 -0.707 -6.66 -28.6 710-716 
miR-17-5p -0.12 2.35 0.414 -0.703 -6.58 -29.4 710-716 
miR-483-3p *** *** *** *** -16.99 -43.6 720-740 
miR-520c-3p -0.13 *** 0.467 -0.723 3.18 -28.7 709-715 
let-7g *** *** *** *** *** -37.2 532-553 
Reported scores: acontext+ score, bPicTar score, cSite score, dmirSVR score, eddG 
score, ffolding energy in kCal/mol, M=14, G=0, E=-20 Kcal/mol; gTarget site position 
relative to start of APP 3’-UTR; hmiR-101 has two distinct predicted target sites in APP 
3’-UTR; *** = target site not predicted by algorithm 
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C. APP 3’-UTR reporter validation of putative miRNA targets in APP 3’-UTR 
To rapidly screen the functionality and efficacy of the various predicted 
miRNA:3’-UTR interactions in the APP 3’-UTR, a reporter construct was prepared 
containing the full length APP 3’-UTR. The APP mRNA consists of a 144 bp 5’-UTR, 2.3 
kb coding sequence (CDS) and 1.2 kb 3’-UTR (Figure 5A). The full length APP 3’-UTR 
was PCR-amplified from the pGALA construct [143] (provided by Dr. Jack T Rogers) 
and inserted downstream of a Renilla luciferase CDS in the psiCHECK-2 vector. The 
psiCHECK-2 vector contains the Renilla luciferase cassette driven by the SV40 
promoter and a separate firefly luciferase CDS under independent transcriptional 
control by the HSV-TK promoter that serves as an internal control in dual reporter 
assays (Figure 5B). A positive control vector was also constructed by inserting 
annealed oligonucleotides containing a MRE perfectly complementary to miR-1 into the 
same psiCHECK-2 vector (Figure 2B). This positive control vector was used to confirm 
effective miRNA delivery and repressive activity in subsequent co-transfection 
experiments. 
Prior to performing APP 3’-UTR reporter and miRNA co-transfections to screen 
for functional interactions, the regulatory influence of the APP 3’-UTR on basal reporter 
expression was first tested. Three different human cell lines (human cervical epithelial 
[HeLa], human neuroblastoma [SK-N-SH] and human neuronally differentiated 
embryonal carcinoma [NT2N]) were transfected with either the empty psiCHECK-2 
vector or the APP 3’-UTR reporter vector (Figure 5C). Despite the 3’-UTR being a 
general hub for MREs with inhibitory influences on protein expression, the presence of 
the APP 3’-UTR significantly stimulated reporter expression in HeLa cells (1.42±0.08 
fold change compared to empty; p=0.002 by post-hoc Dunnett’s t-test) and 
differentiated NT2 neurons (2.73±0.39 fold change compared to empty; p=0.003 by 
post-hoc Dunnett’s t-test) (Figure 5C). There was also a trend for increased reporter 
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expression in response to the APP 3’-UTR in SK-N-SH cells but this was not statistically 
significant. To confirm the specificity of this response, cells were also transfected with a 
reporter construct containing the APP 3’-UTR sequence inserted into psiCHECK-2 in 
reverse orientation. This sequence had no stimulatory effect on reporter expression in 
any of cell lines tested (Figure 5C). Therefore, these data suggest that under basal 
transfection conditions the APP 3’-UTR contains response elements that increase 
reporter gene transcription, enhance mRNA stability or stimulate mRNA translation.  
To validate the functionality of putative miRNA:APP 3’-UTR interactions as 
predicted by the various algorithms, a medium-throughput reporter screen was 
employed as schematically illustrated in Figure 6A. HeLa cells were co-transfected with 
both the APP 3’-UTR reporter construct and miRNA mimics listed in Table 8. A negative 
control co-transfection was performed with a commercial mimic not predicted to target 
mammalian mRNA transcripts. A positive control was performed by co-transfecting the 
positive control reporter construct from figure 6B and miR-1 mimic. Forty eight hours 
post-transfection, reporter expression was determined using a dual luciferase reporter 
assay. Reporter expression values were calculated as normalized ratios of Renilla-to-
firefly luciferase activity. HeLa cells were primarily utilized because of high transfection 
efficiencies and highly reproducible cellular responses. Their lack of neuronal 
phenotype was not a significant concern since HeLa cells have a functional 
miRNA:AGO apparatus [317] and both reporter construct and miRNA were 
exogenously supplied in this particular experiment. 
Co-transfection of miR-106a, miR-106b, miR-153, miR-101 and miR-20b with 
the APP 3’-UTR reporter construct all resulted in significantly reduced reporter 
expression compared to co-transfection with negative control miRNA mimic or 
transfection with the APP 3’-UTR reporter vector alone (fold change in comparison to 
reporter alone: miR-106a, 0.788±0.014 fold; miR-106b, 0.652±0.038 fold; miR-153, 
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0.741±0.024; miR-101, 0.572±0.023 fold; miR-20b, 0.825 ± 0.018 fold; p<0.01 in all 
cases as determined by post-hoc Dunnett’s t-test). Co-transfection with miR-520c-3p 
resulted in significantly increased reporter expression compared to co-transfection with 
negative control miRNA mimic (1.219 ± 0.014 fold change compared to negative 
control; p<0.01 by post-hoc Dunnett’s t-test). Data in figure 6B are scaled such that 
transfection of APP 3’-UTR reporter alone is set to one and the co-transfection of the 
positive control construct from Figure 6B and miR-1 is set to zero. Scaling is necessary 
to control for plate-to-plate variation between reporter assays. 
The strongest inhibitory effect on reporter expression was observed following 
co-transfection with miR-101, miR-106b and miR-153. Further, miR-520c-3p co-
transfection significantly elevated reporter expression. Regulatory effects of miR-106b 
on APP expression were previously reported in the literature [276] and APP protein 
expression in response to miR-520c overexpression has been reported to be 
decreased, not increased [318]. Therefore, follow-up experiments from this set of 
miRNA were restricted to miR-101 and miR-153 to focus on novel putative regulatory 
interactions. 
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Figure 5: APP 3’-UTR stimulates basal reporter expression in multiple human cell 
types. (A) Schematic of the APP mRNA demonstrating sizes of the 5’-UTR, CDS and 
3’-UTR. (B) Schematic of the reporter constructs used to validate putative miRNA target 
sites in the APP 3’-UTR. The APP 3’-UTR was PCR-amplified from the pGAL construct 
and inserted into the psiCHECK-2 vector downstream of the Renilla luciferase (luc) 
CDS. A positive control construct containing a site perfectly complementary to miR-1 
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was constructed by inserting annealed oligonucleotides containing this MRE into 
psiCHECK-2 downstream of Renilla luc. prom=promoter (C) The regulatory effect of the 
APP 3’-UTR on reporter expression was tested by transfecting either the empty 
psiCHECK-2 vector, the APP 3’-UTR reporter construct or vector containing the APP 3’-
UTR in reverse orientation into HeLa, SK-N-SH or differentiated NT2 neuronal cells and 
assaying basal reporter expression. Assay values are reported as the ratio of Renilla to 
luciferase luminescence scaled relative to empty vector (n=5; *p<0.01).  
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Figure 6: Multiple miRNA modulate APP3’-UTR reporter expression in HeLa cells. 
(A) Schematic of the methodological workflow employed to validate putative miRNA 
regulatory interactions with target sites in the APP 3’-UTR. The APP 3’-UTR reporter 
construct was co-transfected into HeLa cells along with miRNA mimics predicted to 
target the 3’-UTR. Reporter expression was then assayed using a dual luciferase 
reporter assay and luminescence detected and analyzed as the normalized and scaled 
ratio of Renilla to firefly luciferase. (B) The APP 3’-UTR reporter construct and miRNA 
mimics (40 nM) were co-transfected and Renilla to firefly luciferase ratios computed as 
described above. Data are presented as RRR (see Materials and Methods). 
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D. miR-101 negatively regulates APP expression  
The APP 3’-UTR reporter assay results above demonstrated that co-transfection 
of miR-101 significantly downregulated reporter expression. miR-101 has two predicted 
target sites in the APP 3’-UTR as predicted by TargetScan, PicTar, DIANA-microT, and 
miRanda-miRSVR. PITA predicts only the first site. The approximate locations of these 
two predicted target sites are schematically illustrated in Figure 7A. The precise location 
of each target site in the human APP 3’-UTR, their sequences and predicted 
interactions with miR-101, and a limited mammalian multiple sequence alignment pulled 
from TargetScan are indicated in Figure 7B. The scores for each site prediction where 
the predictor discriminates between multiple target sites gave a “stronger” score for the 
first site (Table 8). Further, the conserved branch length metric employed in TargetScan 
to assess conservation of each site [243] demonstrated stronger conservation at the 
first site as compared to the second site (1.619 for site 1 vs 0.859 for site 2). This 
suggests that the first site has been under heavier evolutionary pressure to maintain 
target site sequence fidelity. 
To confirm that the inhibitory effect of miR-101 on APP 3’-UTR reporter 
expression was mediated specifically via one of two predicted miR-101 target sites 
located in the APP 3’-UTR, mutations were introduced separately in the seed 
sequences of both target sites in the reporter construct (Figure 7C). These mutant 
reporter constructs were then co-transfected along with miR-101 mimic into HeLa cells 
and reporter expression compared to wild-type reporter (Figure 7D). This reporter assay 
replicated the original finding, demonstrating reduced reporter expression when the 
wild-type reporter was co-transfected with miR-101 as compared to co-transfection with 
negative control miRNA (0.604±0.013 fold change; p<0.01 by post-hoc Dunnett’s t-test). 
Mutation of site 1 eliminated the inhibitory effect of miR-101 mimic on reporter 
expression, whereas mutation of site 2 had no effect on this response (0.596±0.062 fold 
82 
 
change compared to co-transfection with negative control miRNA; p<0.01 by post-hoc 
Dunnett’s t-test). Therefore, miR-101 regulates reporter expression specifically via site 
1 in the APP 3’-UTR.  
Reporter assays allow for rapid and sensitive detection of miRNA-mediated 
effects on reporter expression but are indirect measures of the effect on APP 
expression. Therefore, to directly examine whether miR-101 reduces endogenous APP 
levels, miR-101 mimic was transfected into HeLa cells and APP protein levels directly 
assayed by Western blot (Figure 8A and B). In response to miR-101 transfection, APP 
protein levels were significantly reduced as compared to HeLa cells transfected with 
negative control mimic or mock-transfected cells (0.383±0.056 fold change compared to 
mock transfection; p=0.0011 by Student’s t-test). Therefore, endogenous APP levels 
are inhibited by miR-101 in human HeLa cells. Effective delivery of mimic into HeLa 
was confirmed by RT-qPCR (Figure 8D). Notably, APP mRNA levels measured by RT-
qPCR were significantly decreased following miR-101 transfection as compared to 
negative control miRNA (0.663±0.030 fold change; p= 0.0009 by two-tailed Student’s t-
test) (Figure 8C). This response is consistent with that expected from a miRNA that 
mediates strong inhibitory control on gene expression [227]. 
To confirm that the inhibitory effect of miR-101 on APP levels was not limited to 
HeLa cells, the human glioblastoma cell line U373 (Figure 9A and B) and primary 
human fetal brain cultures (Figure 9C and D) were transfected with miR-101 mimic and 
APP levels assayed by Western blot. In both culture systems, APP protein levels were 
significantly reduced following miR-101 transfection (fold change compared to mock 
transfection: U373, 0.715±.025; human fetal brain culture, 0.756±0.038; p<0.05 by 
Student’s t-test). Therefore, the inhibitory effect on APP levels is not limited only to 
human epithelial HeLa cells but is also apparent in transformed human astroglial cells 
and primary human brain cells. 
83 
 
An expected outcome of reducing APP protein output would be a reduction in its 
neurotoxic metabolite – secreted Aβ protein. To test whether miR-101 delivery reduces 
Aβ secretion, primary human fetal brain cultures and U373 cells were transfected with 
miR-101 mimic and conditioned media (CM) collected after 48 hours. Levels of Aβ1-40 
were then assayed by ELISA and absolute values (pg/mL) corrected for well-to-well 
variations in cell number by either normalizing to total protein yield of crude cell lysates 
(human fetal brain cultures) or to a measure of cell viability (Cell Titer Glo for U373). 
Aβ1-40 levels were significantly decreased in the CM of primary human fetal brain 
cultures transfected with miR-101 as compared to cultures transfected with a negative 
control miRNA (0.367±0.031 fold change; p=0.0012 by Student’s t-test) (Figure 10A). 
Aβ1-40 levels were similarly decreased (but not statistically significant) in the CM of 
primary human fetal brain cultures transfected with miR-101 (0.817±0.059 fold change 
compared to negative control transfection; p=0.052 by Student’s t-test) (Figure 10B). 
  
84 
 
 
85 
 
Figure 7: miR-101 targets human APP 3’-UTR via a conserved site. (A) Schematic 
of the APP transcript demonstrating location of two putative miR-101 target sites in the 
3’-UTR predicted by the TargetScan, PicTar, DIANA-microT, rna22, miRanda-mirSVR, 
and PITA algorithms. (B) Sequence and predicted base-pairing of human miR-101 with 
its two predicted target sites in the human APP 3’-UTR, including seed sequence 
interactions (red boxes). To assess site conservation, multiple genome alignments for 
mammalian species were pulled from TargetScan. Sequences from rhesus macaque, 
mouse, rat, and horse from positions orthologous to the predicted miR-101 target site in 
the human APP 3’-UTR are shown. Red text highlights nucleotide differences compared 
to the human sequence. (C) Two predicted target sites in the APP 3’-UTR reporter 
construct were mutated by site-directed mutagenesis. Red text highlights mutations 
introduced in seed sequence. (D) Wild-type and target site mutant reporter constructs 
were transfected into HeLa cells either alone or along with 50 nM negative control and 
miR-101 mimic. Luciferase expression was assessed 48 hours post-transfection. * 
p<0.05, n=6. 
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Figure 8: miR-101 delivery downregulates APP expression in HeLa cells. (A) HeLa 
cells were transfected with 50 nM miR-101 mimic or negative control and APP levels 
assayed 72 hours post-transfection by Western blot. siRNA (20 nM) transfection 
included as delivery control (n=4). (B) Blots were quantified by densitometric analysis 
and APP levels normalized to α-tubulin levels and scaled relative to mock transfection 
(n=4). (C) APP mRNA levels in HeLa cells were assayed by RT-qPCR 48 hours post-
transfection (n=3). RT-qPCR expression levels were normalized to the geometric mean 
of β-actin, B2M, GAPDH and TBP expression levels and further scaled relative to 
mock-transfected levels. (D) Efficient delivery of miR-101 into HeLa cells confirmed by 
RT-qPCR 72 hours post-transfection (two technical replicates). RT-qPCR expression 
levels were normalized to the geometric mean of RNU48, RNU6B and hsa-miR-16 
expression levels and further scaled relative to mock-transfected levels. * p<0.05 
relative to mock-transfected or negative control-trasfected cells.  
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Figure 9: miR-101 delivery downregulates APP expression in U373 cells and 
primary human fetal brain cultures. (A) U373 cells were transfected with 75 nM miR-
101 mimic or negative control and APP levels assayed 72 hours post-transfection by 
Western blot. siRNA (20 nM) transfection included as delivery control (n=4). (B) Blots 
from panel (A) were quantified by densitometric analysis and APP levels normalized to 
β-actin levels and scaled relative to mock transfection. (C) Primary human fetal brain 
cultures were transfected with 150 nM miR-101 mimic or negative control at DIV 17 and 
lysates prepared 48 hours post-transfection (DIV 19). siRNA (20 nM) transfection 
included as delivery control. Levels of APP and α-tubulin were assayed by Western 
blot. (D) Blots from panel (C) were quantified by densitometric analysis and APP levels 
normalized to β-actin levels and scaled relative to mock transfection. * p<0.05 relative 
to mock-transfected cells; n=4  
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Figure 10: miR-101 delivery reduces secretion of Aβ1-40 into the CM of primary 
human fetal brain cultures and U373 cells. Primary human fetal brain cultures at DIV 
17 and U373 cells were either mock-transfected, transfected with 20 nM APP siRNA, 
transfected with negative control or miR-153 mimic (75 nM for U373; 150 nM for human 
fetal brain cultures). CM were collected 48 h post-transfection. Aβ1-40 levels were 
measured in CM by ELISA. Absolute values (pg/mL) were normalized to either the total 
protein yield of crude cell lysates for primary human fetal brain cultures or to Cell Titer 
Glo values for U373 cells and scaled relative to mock transfection to account for  
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variability associated with differences in cell number and viability. (*p<0.01 by Student’s 
t-test; n=4)  
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E. Other predicted targets of miR-101 
A frequent critique of pursuing miRNA modulation as a therapeutic strategy in 
the diseased state is that physiological miRNA targeting is so promiscuous that it would 
surely result in adverse off-targeting effects during therapeutic manipulation. Given the 
promise of miR-101 as a putative therapeutic target for modulating APP expression, the 
extent of possible promiscuity associated with miR-101 was examined. Datasets 
containing human transcriptome-wide miR-101 target site predictions compiled by the 
TargetScan algorithm were pulled from the TargetScan website.The data were filtered 
by context+ score. The context+ scoring system assesses the predicted efficacy of a 
given target site by assessing the seed sequence type, degree of target site 
complementarity to miRNA 3’ end, presence of optimal local AU bases, and position of 
target site along the transcript 3’-UTR. Table 9 lists all transcripts containing miR-101 
target sites with context+ scores suggesting equal or more efficacious (more negative) 
miR-101 targeting than APP. Aggregate PCT (probability of conserved targeting) scores 
are also listed for each target site. The aggregate PCT score is a quantitative measure of 
the level of cross-species conservation across all miR-101 target sites in a given 
transcript. 
One hundred transcripts have putative miR-101 target sites with context+ scores 
equal to or more favorable than the predicted miR-101 target sites in APP transcript. It 
is important to keep in mind that the context+ scoring system considers all predicted 
miR-101 target sites along a given transcript 3’-UTR, even false positive sites such as 
the second predicted miR-101 target site in APP shown above to be non-functional. 
Therefore, the number of true miR-101 targets in this list is likely overestimated. 
Enriched among the listed transcripts are tumor suppressor genes, including validated 
targets MYCN and EZH2 [319–321]. Therefore, therapeutically elevating miR-101 
expression levels would not be expected to promote carcinogenesis. Also of note are 
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validated transcript targets with roles in autophagy (e.g. RAB5A) and spinocerebellar 
ataxia (i.e. ATXN1) [291,322,323]. Inhibition of these transcripts by therapeutically 
elevating miR-101 levels might potentially have synergistic effects on anti-
amyloidogenic APP metabolism as further discussed in the Discussion section. 
Therefore, promiscuity and off-target effects of miRNA targeting are not exclusively 
deleterious and in some cases may prove synergisitic and beneficial. 
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Table 9: List of transcripts containing TargetScan-predicted miR-101 target sites  
Target gene Gene name 
Total 
context+ 
scorea 
Aggregate 
PCT 
FAM108C1 family with sequence similarity 108, member C1 -0.84 0.60 
GLTSCR1 glioma tumor suppressor candidate region gene 1 -0.81 0.98 
ZNF654 zinc finger protein 654 -0.78 0.99 
EYA1 eyes absent homolog 1 (Drosophila) -0.76 0.32 
FLRT3 fibronectin leucine rich transmembrane protein 3 -0.76 0.95 
CDYL chromodomain protein, Y-like -0.76 0.65 
TNPO1 transportin 1 -0.71 0.78 
LCOR ligand dependent nuclear receptor corepressor -0.69 0.97 
MYCN v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) -0.67 0.90 
TET2 tet oncogene family member 2 -0.66 0.67 
UBE2D1 ubiquitin-conjugating enzyme E2D 1 -0.65 0.79 
SIX4 SIX homeobox 4 -0.64 0.97 
MFSD6 major facilitator superfamily domain containing 6 -0.63 0.86 
TSHZ3 teashirt zinc finger homeobox 3 -0.63 0.93 
FZD4 frizzled family receptor 4 -0.58 0.95 
STC1 stanniocalcin 1 -0.58 0.85 
MYRIP myosin VIIA and Rab interacting protein -0.58 0.84 
FAT3 FAT tumor suppressor homolog 3 (Drosophila) -0.57 0.89 
GLCCI1 glucocorticoid induced transcript 1 -0.57 0.47 
SEL1L sel-1 suppressor of lin-12-like (C. elegans) -0.56 0.77 
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta -0.56 > 0.99 
ZBTB41 zinc finger and BTB domain containing 41 -0.56 0.62 
ATXN1 ataxin 1 -0.55 0.98 
TMEM65 transmembrane protein 65 -0.55 0.77 
ZNF295 zinc finger protein 295 -0.55 0.16 
NSD1 nuclear receptor binding SET domain protein 1 -0.55 0.91 
MOBKL3 MOB1, Mps One Binder kinase activator-like 3 (yeast) -0.55 0.87 
HSPE1-MOBKL3 HSPE1-MOBKL3 readthrough -0.55 0.87 
ASPN asporin -0.55 0.65 
KBTBD8 kelch repeat and BTB (POZ) domain containing 8 -0.54 0.79 
SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 2 -0.54 0.56 
FAM73A family with sequence similarity 73, member A -0.54 0.31 
EZH2 enhancer of zeste homolog 2 (Drosophila) -0.54 0.81 
RBM25 RNA binding motif protein 25 -0.54 0.31 
ZMAT3 zinc finger, matrin-type 3 -0.53 0.79 
SLC39A10 solute carrier family 39 (zinc transporter), member 10 -0.51 0.81 
ZFHX4 zinc finger homeobox 4 -0.51 0.83 
BEAN1 brain expressed, associated with NEDD4, 1 -0.51 0.86 
ZNF532 zinc finger protein 532 -0.51 0.63 
PIKFYVE phosphoinositide kinase, FYVE finger containing -0.50 < 0.1 
MKL2 MKL/myocardin-like 2 -0.50 0.93 
PLEKHG1 pleckstrin homology domain containing, family G (with RhoGef domain) member 1 -0.50 0.48 
DCBLD2 discoidin, CUB and LCCL domain containing 2 -0.50 0.99 
NEK7 NIMA (never in mitosis gene a)-related kinase 7 -0.50 0.87 
HTRA3 HtrA serine peptidase 3 -0.49 0.94 
IKZF4 IKAROS family zinc finger 4 (Eos) -0.49 0.90 
ZDHHC21 zinc finger, DHHC-type containing 21 -0.49 0.31 
CBFA2T2 core-binding factor, runt domain, alpha subunit 2; translocated to, 2 -0.48 0.88 
INO80D INO80 complex subunit D -0.48 0.93 
SHISA6 shisa homolog 6 (Xenopus laevis) -0.47 0.91 
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UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 -0.47 0.52 
RAB5A RAB5A, member RAS oncogene family -0.47 0.63 
NPNT nephronectin -0.47 0.87 
FZD6 frizzled family receptor 6 -0.47 0.57 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit -0.47 0.99 
BTBD3 BTB (POZ) domain containing 3 -0.46 0.85 
PBX3 pre-B-cell leukemia homeobox 3 -0.46 0.76 
SUB1 SUB1 homolog (S. cerevisiae) -0.46 0.70 
ZFP36L2 zinc finger protein 36, C3H type-like 2 -0.45 0.81 
C3orf58 chromosome 3 open reading frame 58 -0.45 0.36 
UBE2D2 ubiquitin-conjugating enzyme E2D 2 -0.45 < 0.1 
ACVR2B activin A receptor, type IIB -0.45 0.96 
H2AFV H2A histone family, member V -0.44 0.91 
PDS5B PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae) -0.44 0.30 
USP47 ubiquitin specific peptidase 47 -0.43 0.88 
DIP2B DIP2 disco-interacting protein 2 homolog B (Drosophila) -0.43 0.91 
ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 -0.43 0.60 
ICK intestinal cell (MAK-like) kinase -0.43 0.85 
SGK1 serum/glucocorticoid regulated kinase 1 -0.43 0.63 
TCF4 transcription factor 4 -0.43 0.48 
SH2B3 SH2B adaptor protein 3 -0.43 0.88 
ANKRD11 ankyrin repeat domain 11 -0.43 0.87 
ATXN1L ataxin 1-like -0.43 0.87 
ZNF746 zinc finger protein 746 -0.43 0.84 
NACC2 NACC family member 2, BEN and BTB (POZ) domain containing -0.42 0.91 
AP1S3 adaptor-related protein complex 1, sigma 3 subunit -0.42 0.50 
PROK2 prokineticin 2 -0.42 0.31 
SULT4A1 sulfotransferase family 4A, member 1 -0.42 0.83 
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 -0.42 0.87 
SMARCA5 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 5 
-0.42 0.88 
RAB39B RAB39B, member RAS oncogene family -0.42 0.47 
MTSS1L metastasis suppressor 1-like -0.42 0.31 
TGFA transforming growth factor, alpha -0.42 0.84 
KCNH7 potassium voltage-gated channel, subfamily H (eag-related), member 7 -0.42 0.76 
FAM108B1 family with sequence similarity 108, member B1 -0.41 0.65 
RAB3GAP2 RAB3 GTPase activating protein subunit 2 (non-catalytic) -0.41 < 0.1 
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein -0.41 0.31 
COL10A1 collagen, type X, alpha 1 -0.41 0.68 
NLK nemo-like kinase -0.41 0.76 
CDH5 cadherin 5, type 2 (vascular endothelium) -0.41 0.84 
ADAMTSL3 ADAMTS-like 3 -0.41 0.59 
PRKCE protein kinase C, epsilon -0.41 0.86 
CEP350 centrosomal protein 350kDa -0.40 0.93 
RAP1B RAP1B, member of RAS oncogene family -0.40 0.71 
BEGAIN brain-enriched guanylate kinase-associated homolog (rat) -0.40 0.31 
RORA RAR-related orphan receptor A -0.40 0.97 
FGA fibrinogen alpha chain -0.40 0.86 
GSK3B glycogen synthase kinase 3 beta -0.40 0.86 
SACM1L SAC1 suppressor of actin mutations 1-like (yeast) -0.40 < 0.1 
APP amyloid beta (A4) precursor protein -0.40 0.66 
aContext+ score threshold for inclusion in table set equal to or less than (more favorable) APP score of       
-0.40 
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F. miRNA-153 negatively regulates APP expression  
Unlike miR-101, miR-153 has only one predicted target site in the APP 3’-UTR 
as predicted by TargetScan, PicTar, DIANA-microT, and miRanda-miRSVR, PITA, and 
rna22. Approximate location of the predicted target site is schematically illustrated in 
Figure 11A. Location, exact sequence and predicted interaction of the target site in the 
human APP 3’-UTR with miR-153 are indicated in Figure 11B, as is a limited 
mammalian multiple sequence alignment. Specific scores produced by each predictor 
for this target site are indicated in Table 8. This specific site is considered strongly 
conserved according to the conserved branch length metric employed in TargetScan 
(1.864 vs 1.619 for conserved miR-101 site 1). This suggests that, as with the functional 
miR-101 site, this particular target site has been under heavy evolutionary pressure to 
maintain perfect target site sequence identity. 
To confirm that the inhibitory effect of miR-153 on APP 3’-UTR reporter 
expression was mediated specifically by the predicted miR-153 target site, mutations 
were introduced into the seed sequence of the target site in the reporter construct 
(Figure 11C). The mutant reporter construct was co-transfected along with miR-153 
mimic into HeLa cells and reporter expression compared to wild-type reporter (Figure 
11D). The original finding was replicable – wild-type reporter co-transfection with miR-
153 was significantly reduced as compared to transfection of the reporter alone 
(0.832±0.017 fold change; p<0.0004 by Student’s t-test). Target site mutation 
eliminated the inhibitory effect of miR-153 delivery on reporter expression. Therefore, 
miR-153 regulates reporter expression specifically via the predicted site in the APP 3’-
UTR.  
miR-153 mimic was transfected into HeLa cells and APP protein levels directly 
assayed by Western blot to directly examine whether miR-153 reduces endogenous 
APP levels (Figure 12A and B). APP protein levels were significantly reduced as 
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compared following transfection with miR-153 as compared to HeLa cells transfected 
with negative control mimic (0.661±0.096 fold change; p=0.0059 by Student’s t-test). 
Therefore, endogenous APP levels are inhibited by miR-153 in human HeLa cells. 
Effective delivery of mimic into HeLa was confirmed by RT-qPCR (~220,000 fold 
change relative to mock) (Figure 12D). APP mRNA levels measured by RT-qPCR were 
significantly decreased following miR-153 transfection as compared to negative control 
miRNA or mock transfection (0.601±0.053 fold change compared to mock transfection; 
p=0.0050 by Student’s t-test) (Figure 12C), suggesting a post-transcriptional 
mechanism that does likely involve a degree of mRNA destabilization, perhaps in 
addition to direct inhibition of protein translation. 
As with miR-101, other human cell types were transfected to confirm that the 
inhibitory effect of miR-153 on APP levels was not limited to HeLa cells. U373 cells 
(Figure 13A and B) and primary human fetal brain cultures (Figure 13 and D) were 
transfected with miR-153 mimic and APP levels assayed by Western blot. In both 
culture systems, APP protein levels were significantly reduced following miR-153 
transfection as compared to transfection with a negative control miRNA (fold change 
compared to negative control transfection: U373, 0.762±.039; human fetal brain culture, 
0.790±0.104; p<0.05 by Student’s t-test). Therefore, the inhibitory effect on APP levels 
is not limited only to human epithelial HeLa cells but is also apparent in transformed 
human astroglial cells and highly relevant primary human brain cells. 
To test whether miR-153 also delivery reduces Aβ secretion, primary human 
fetal brain cultures were transfected with miR-153 mimic and CM collected after 48 
hours. Levels of Aβ1-40 were then assayed by ELISA and absolute values (pg/mL) 
corrected for well-to-well variations in cell number by normalizing to total protein yield of 
crude cell lysates. Aβ1-40 levels were significantly decreased in the CM of primary 
human fetal brain cultures transfected with miR-153 as compared to cultures 
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transfected with a negative control miRNA (0.717±0.054 fold change; p=0.0436 by 
Student’s t-test) (Figure14).  
To establish whether miR-153 participates in the regulatory network that 
controls APP expression in human neurons, a miRNA antisense inhibitor was utilized to 
bind to and disrupt the interaction of miR-153 with mRNA targets. Primary human fetal 
brain cultures were transfected with miR-153 inhibitor and APP expression assayed by 
Western blot. Transfection of miR-153 inhibitor significantly increased APP expression 
relative to negative control inhibitor transfection (1.317±0.099 fold change; p=0.026) 
(Figure 15). Therefore, endogenous miR-153 actively inhibits APP expression in human 
fetal brain cultures under physiological culture conditions.
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Figure 11: miR-153 targets human APP 3’-UTR via a conserved site. (A) Schematic 
of the APP transcript demonstrating location of a putative miR-153 target site in the 3’-
UTR predicted by the TargetScan, PicTar, DIANA-microT, rna22, miRanda-mirSVR, 
and PITA algorithms. (B) Sequence and predicted base-pairing of human miR-153 with 
its predicted target site in the human APP 3’-UTR, including the seed sequence 
interaction (red box). To assess site conservation, multiple genome alignments for 
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mammalian species were pulled from TargetScan. Sequences from rhesus macaque, 
mouse, rat, and horse from positions orthologous to the predicted miR-153 target site in 
the human APP 3’-UTR are shown. Red text highlights nucleotide differences compared 
to the human sequence. (C) The predicted target site in the APP 3’-UTR reporter 
construct was mutated by site-directed mutagenesis. Red text highlights mutations 
introduced in seed sequence. (D) Wild-type and target site mutant reporter constructs 
were transfected into HeLa cells either alone or along with 50 nM negative control and 
miR-153 mimic. Luciferase expression was assessed 48 hours post-transfection. * 
p<0.05, n=6. 
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Figure 12: miR-153 delivery downregulates APP expression in HeLa cells. (A) 
HeLa cells were transfected with 50 nM miR-153 mimic or negative control and APP 
levels assayed 72 hours post-transfection by Western blot. siRNA (20 nM) transfection 
included as delivery control (n=4). (B) Blots were quantified by densitometric analysis 
and APP levels normalized to α-tubulin levels and scaled relative to mock transfection 
(n=4). (C) APP mRNA levels in HeLa cells were assayed by RT-qPCR 48 hours post-
transfection (n=3). RT-qPCR expression levels were normalized to the geometric mean 
of β-actin, B2M, GAPDH and TBP expression levels and further scaled relative to 
mock-transfected levels. (D) Efficient delivery of miR-153 into HeLa cells confirmed by 
RT-qPCR 48 hours post-transfection (n=3). RT-qPCR expression levels were 
normalized to the geometric mean of RNU48, RNU6B and hsa-miR-16 expression 
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levels and further scaled relative to mock-transfected levels. RQ=relative quantity; * 
p<0.05 relative to mock-transfected cells. 
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Figure 13: miR-153 delivery downregulates APP expression in U373 cells and 
primary human fetal brain cultures. (A) U373 cells were transfected with 75 nM miR-
153 mimic or negative control and APP levels assayed 72 hours post-transfection by 
Western blot. siRNA (20 nM) transfection included as delivery control (n=4). (B) Blots 
from panel (A) were quantified by densitometric analysis and APP levels normalized to 
α-tubulin levels and scaled relative to mock transfection. (C) Primary human fetal brain 
cultures were transfected with 150 nM miR-153 mimic or negative control at DIV 17 and 
lysates prepared 48 hours post-transfection (DIV 19). siRNA (20 nM) transfection 
included as delivery control. Levels of APP and α-tubulin were assayed by Western 
blot. (D) Blots from panel (C) were quantified by densitometric analysis and APP levels 
normalized to β-actin levels and scaled relative to mock transfection. * p<0.05 relative 
to negative control-transfected cells; n=4  
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Figure 14: miR-153 reduces secretion of Aβ1-40 into the CM of primary human 
fetal brain cultures. Primary human fetal brain cultures at DIV 17 were either mock-
transfected, transfected with 20 nM APP siRNA, transfected with 150 nM negative 
control or miR-153 mimic. CM were collected 48 h post-transfection. Aβ1-40 levels 
were measured in CM by ELISA. Absolute values (pg/mL) were normalized to the total 
protein yield of crude cell lysates and scaled relative to mock transfection to account for 
variability associated with differences in cell number. Transfection of miR-153 
significantly reduced levels of Aβ1-40 released in the CM of primary human fetal brain 
cultures as compared to negative control-transfected cultures. * p<0.05 relative to 
negative control-transfected cells; n=4. 
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Figure 15: Blocking miR-153 interaction with the APP mRNA 3’-UTR elevates 
basal APP protein levels. (A) Western blot analysis of APP and α-tubulin levels in 
transfected primary human fetal brain cultures. Fetal brain cultures at DIV 17 were 
either mock-transfected or transfected with 1000 nM negative control or miR-153 
antisense inhibitor. Cell lysates for proteins were prepared 24 h post-transfecton. (B) 
Densitometric analysis of APP normalized to α-tubulin demonstrated that miR-153 
inhibitor significantly increased APP expression in primary human fetal brain cells. * 
p<0.05 relative to negative control inhibitor-transfected cells; n=3 – 4. 
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G. miRNA-346 positively regulates APP expression 
While the great majority of miRNA:mRNA interactions detected in global 
analyses are restricted to the mRNA 3’-UTR [303,304], there is significant evidence that 
functional regulatory interactions also occur in the 5’-UTR and CDS [186,245,324,325]. 
To expand the scope of potential miRNA:APP mRNA interactions, the complete APP 
transcript sequence was scanned using the miRanda algorithm as implemented on the 
RegRNA web server [326] against a set of complete human miRNA sequences. This 
implementation utilizes the basic features of the miRanda algorithm [311], including the 
dynamic programming local alignment and thermodynamic stability assessment. It does 
not filter for target site cross-species conservation or utilize machine learning algorithms 
to predict site efficacy as implemented in the miRanda-miRSVR web server (this server 
limits searches to 3’-UTR only). 
Many putative miRNA:APP mRNA interactions were predicted by this algorithm, 
including several 3’-UTR interactions predicted by the algorithms in Table 8 (e.g. miR-
101, miR-153, miR-106a/b, miR-20a/b). A predicted interaction between miR-346 and 
the APP 5’-UTR (Figure 16A) was noted due to high overlap with a known IRE stem-
loop structure previously shown to mediate translational control of APP expression in 
response to changes in intracellular iron homeostasis [143,144]. This site is also directly 
upstream of a known IL-1 acute box domain previously shown to post-transcriptionally 
stimulate APP mRNA translation [145]. The predicted interaction of miR-346 with the 
APP 5’-UTR sequence is indicated in Figure 16B, along with a limited mammalian 
multiple sequence alignment. The predicted interaction produced a complementarity 
score of 153 and minimum free energy (ΔG) of -26.3 kcal/mol, indicating high level of 
complementarity and stable duplex formation. Based on high level of complementarity 
and possibility for direct interaction with known functional regulatory elements in the 5’-
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UTR, it was hypothesized that miR-346 regulates APP expression through interaction 
with its predicted site in the APP 5’-UTR. 
To test for regulatory effects of miR-346 mediated via the APP 5’-UTR, the 
pGAL construct was utilized (provided by Dr. Jack T Rogers) [143]. This construct 
contains the complete 144 bp APP 5’-UTR inserted upstream of the firefly luciferase 
CDS in pGL3 (Promega). The predicted miR-346 target site in pGAL was mutated by 
cassette mutagenesis as indicated in Figure 16C. The wild-type and mutant pGAL 
constructs were co-transfected with miR-346. A Renilla luciferase construct (pRLSV40) 
was also co-transfected as an internal control to allow for dual reporter normalization. 
Surprisingly, transfection of miR-346 significantly induced reporter expression as 
compared to transfection with reporter construct alone (1.701±0.034. fold change; 
p<0.0001 by two-tailed Student’s t-test) (Figure 16D). When the putative miR-346 target 
site in the APP 5’-UTR reporter, co-transfection with miR-346 no longer had a 
stimulatory effect on reporter expression and instead repressed reporter expression 
(0.630±0.027 fold change; p<0.0001 by two-tailed Student’s t-test). Since this region of 
the APP 5’-UTR has known promoter activity [140], a separate strategy was employed 
to test the specificity of the putative target site without mutating a known promoter 
sequence. miR-346 was co-transfected with WT reporter along with either a negative 
control target protector or a custom target protector designed to block interaction of 
miR-346 with the putative target site in the APP 5’-UTR.While the negative control 
target protector had minimal effect, the custom miR-346-APP 5’-UTR target protector 
significantly reduced the stimulatory effect of miR-346 on APP 5’-UTR reporter 
expression (0.724±0.024 fold change compared to miR-346 transfection alone; p<0.01) 
(Figure 16E).Therefore,miR-346 stimulates APP 5’-UTR reporter expression in HeLa 
cells through a predicted target site in the APP 5’-UTR. 
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miR-346 mimic was transfected into HeLa cells and APP protein levels directly 
assayed by Western blot to directly examine whether miR-346 stimulates endogenous 
APP levels (Figure 17A and B). APP protein levels were dramatically and significantly 
elevated following transfection with miR-346 as compared to HeLa cells transfected 
with negative control mimic (3.035±0.109 fold change; p<0.0001 by Student’s t-test). 
Therefore, endogenous APP levels are elevated by miR-346 in human HeLa cells. 
Effective delivery of mimic into HeLa was confirmed by RT-qPCR (~29,000 fold change 
relative to negative control miRNA) (Figure 17D). APP mRNA levels measured by RT-
qPCR were not significantly increased following miR-346 transfection as compared to 
negative control miRNA or mock transfection (Figure 17C), suggesting a post-
transcriptional mechanism that does not likely involve mRNA stabilization but instead 
direct stimulation of protein translation. 
Given the non-canonical location of the miR-346 target site and non-canonical 
effect on APP protein expression, an additional experiment was performed to verify the 
specificity of the 5’-UTR target site for mediating this stimulatory effect. The target 
protector designed to block the interaction of miR-346 with its putative target site in the 
APP 5’-UTR was co-transfected into HeLa cells at increasing concentrations (0 nM-
1000 nM) while holding the concentration of miR-346 mimic steady (15 nM). An 
potential unwanted consequence of increasing the concentration of target protector 
while holding the miR-346 mimic concentration steady is that competition for 
transfection reagent could reduce delivery of miR-346 and the resulting effect on APP 
expression. To control for this, negative control target protector was also co-transfected 
at decreasing concentration (1000 nM – 0 nM) such that the total target protector 
concentration was constant in all transfection conditions. Following miR-346 co-
transfection with negative control target protector, APP expression was significantly 
elevated compared to mock transfection (2.574±0.304 fold change; p=0.0021 by 
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Student’s t-test). Co-transfection of miR-346 mimic with miR-346 target protector 
demonstrated a concentration-dependent decrease in APP levels relative to 0 nM miR-
346 target protector. At 1000 nM miR-346 target protector, APP expression was 
significantly decreased relative to 0 nM miR-346 target protector (0.606±0.074 fold 
change; p<0.01 by post-hoc Dunnett’s t-test) (Figure 18A and B). Therefore, the 
stimulatory effect of miR-346 on endogenous APP protein expression at least partially 
requires the specific interaction of miR-346 with the APP 5’-UTR target site.  
While the general mechanisms underlying the inhibitory effects of miRNA on 
target protein output, including mRNA deadenylation, mRNA decay and translational 
repression, are fairly well characterized [227,229,230,238,240,327], there is no 
characterized mechanistic precedent to serve as basis for explaining the stimulatory 
effect of miR-346 on APP expression. To begin to explore underlying mechanism, the 
role of endogenous miRNA processing and effector machinery was examined. HeLa 
cells were co-transfected with miR-346 and siRNA against Dicer or AGO2. Consistent 
with above experiments, co-transfection of miR-346 with negative control siRNA 
resulted in significantly elevated APP levels compared to negative control siRNA 
transfection alone (2.028±0.067 fold change; p<0.0001 by Student’s t-test) (Figure 
19A). To compare the effect of miR-346 delivery on APP levels after Dicer and AGO2 
siRNA knockdown, the fractional increase in APP levels following miR-346 co-
transfection with siRNA was calculated relative to transfection with siRNA alone 
independently for each siRNA. The fractional increase was then expressed as percent 
increase relative to negative control siRNA co-transfection (100±6.5%) (Figure 19B). 
The increase in APP expression following miR-346 delivery was significantly attenuated 
with knockdown of Dicer (61.55±3.90%; p<0.05 by post-hoc Dunnett’s t-test) or AGO2 
(40.03±11.24%; p<0.01 by post-hoc Dunnett’s t-test). Therefore, the presence of both 
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Dicer and AGO2 is at least partially required for the stimulatory effect of miR-346 on 
APP expression. 
As previously mentioned, the miR-346 target site in the APP 5’-UTR directly 
overlaps with a known IRE [143]. This IRE is known to bind IRP1 in the absence of iron, 
resulting in translational inhibition [144]. In the presence of iron, IRP1 dissociates from 
the IRE, thereby promoting APP mRNA translation. Therefore, it was hypothesized that 
miR-346 may partially mediate its stimulatory effect on APP expression by interfering or 
otherwise modulating with the interaction of IRP1 with its regulatory element in the APP 
5’-UTR. To test this hypothesis, IRP1 expression was knocked down in HeLa cells by 
siRNA transfection. Western analysis confirmed successful knockdown in IRP1 
following siRNA transfection (Figure 20). To assess the effect of IRP1 knockdown on 
induced APP expression following miR346 delivery, percent increase in APP levels 
following miR-346 delivery was calculated as discussed in Figure 18, with the exception 
that negative control miRNA mimic was included in place of mock transfection. IRP1 
knockdown significantly attenuated the stimulatory effect of miR-346 on APP 
expression as compared to negative control siRNA co-transfection (55.48±4.39%; 
p=0.0488 by Student’s t-test) (Figure 20A and B). Therefore, in addition to Dicer and 
AGO2, the presence of IRP1 is at least partially required for the stimulatory effect of 
miR-346 on APP expression.  
To test whether the stimulatory effect of miR-346 on APP expression extended 
to primary human brain cells, human fetal brain cultures were transfected at DIV 19 with 
negative control miRNA or miR-346 mimic. No effect on APP expression was observed 
following miR-346 transfection (Figure 21A and B). Given the suggestive evidence in 
Figure 21 that miR-346 may mediate its effect on APP by cross-talking with IRP1 at the 
levels of the APP transcript, one possible explanation for the lack of response in 
primary human fetal brain cultures is that IRP1 binding to APP mRNA may be reduced 
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due to saturated intracellular iron binding to IRP1. To test this hypothesis, intracellular 
iron was first chelated using deferroxamine mesylate (Dfo). APP expression was 
significantly reduced in cultures treated with 150 µM Dfo for 48 hours relative to vehicle-
treated cells (0.639±0.023 fold change; p=0.0477) (Figure 21C and D). This indicates 
that under basal conditions, intracellular iron disinhibits the repressive action of IRP1 on 
APP translation in primary human fetal brain cultures – a finding consistent with 
previous publications [143,144]. To test whether intracellular iron chelation might unveil 
the stimulatory effect of miR-346 on APP expression in human fetal brain cultures, 
negative control and miR-346 mimics were transfected into primary human fetal brain 
cultures at DIV 19 under continuous Dfo co-treatment for 48 hours. APP expression 
following miR-346 delivery was significantly increased relative to negative control 
miRNA transfection (1.235±0.057 fold change; p=0.0122) (Figure 21E and F). 
Therefore, miR-346 delivery does stimulate APP expression in primary human fetal 
brain cultures, but the effect is only apparent after basal intracellular iron concentrations 
are reduced by chelation. 
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Figure 16: miR-346 targets human APP 5’-UTR via a target site overlapping a 
known IRE. (A) Schematic of the APP transcript demonstrating location of a putative 
miR-346 target site in the 5’-UTR directly overlapping with a known IRE stem-loop. The 
APP 5’-UTR was scanned using the miRanda algorithm on the RegRNA web server to 
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identify the putative miR-346 site. Dashed black rectangle encompasses approximate 
location of predicted miR-346 target site in known IRE stem-loop structure. (B) 
Sequence and predicted base-pairing of human miR-346 with its predicted target site in 
the human APP 5’-UTR, including the seed sequence interaction (red box). To assess 
site conservation, multiple genome alignments for mammalian species were pulled from 
the UCSC Genome Browser. Sequences from rhesus macaque, mouse, rat, and horse 
from positions orthologous to the predicted miR-346 target site in the human APP 5’-
UTR are shown. Red text highlights nucleotide differences compared to the human 
sequence. Bold, italicized, black text in human APP 5’-UTR sequence represents 
functional IRE consensus sequence. (C) APP 5’-UTR reporter construct containing the 
APP 5’-UTR sequence inserted upstream of a firefly luciferase CDS was utilized to 
probe sequence specificity. The predicted target site in the 5’-UTR reporter construct 
was mutated by cassette mutagenesis. Red text highlights mutations introduced in seed 
sequence. (D) Wild-type and target site mutant reporter constructs were transfected into 
HeLa cells either alone or along with 50 nM miR-346 mimic. Luciferase expression was 
assessed 48 hours post-transfection and data presented as scaled Firefly/Renilla 
luminescence. (E) As a separate strategy to probe site specificity, the WT 5’-UTR APP 
reporter construct was co-transfected with miR-346 along with either 200 nM negative 
control target protector or putative miR-346-APP 5’-UTR target protector. Luciferase 
expression was assessed 48 hours post-transfection and data presented as scaled 
Firefly/Renilla luminescence. * p<0.05, n=6. 
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Figure 17: miR-346 delivery dramatically stimulates APP expression in HeLa 
cells. (A) HeLa cells were transfected with 50 nM miR-346 mimic or negative control 
and APP levels assayed 72 hours post-transfection by Western blot. siRNA (20 nM) 
transfection included as delivery control (n=4). (B) Blots were quantified by 
densitometric analysis and APP levels normalized to β-actin levels and scaled relative 
to mock transfection (n=4). (C) APP mRNA levels in HeLa cells were assayed by RT-
qPCR 48 hours post-transfection (n=3). RT-qPCR expression levels were normalized to 
the geometric mean of β-actin, B2M, GAPDH and TBP expression levels and further 
scaled relative to mock-transfected levels. (D) Efficient delivery of miR-346 into HeLa 
cells confirmed by RT-qPCR 48 hours post-transfection (two technical replicates). RT-
qPCR expression levels were normalized to the geometric mean of RNU48, RNU6B 
and hsa-miR-16 expression levels and further scaled relative to mock-transfected 
levels. RQ=relative quantity; * p<0.05 relative to negative control-transfected cells.  
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Figure 18: Induction of APP expression in HeLa by miR-346 delivery is reversed 
when interaction with the predicted target site in the APP 5’-UTR is blocked. HeLa 
cells were transfected with 15 nM miR-346 along with increasing concentrations of a 
target protector designed to protect the APP 5’-UTR miR-346 target site from interaction 
with miR-346. Total transfected nucleic acid concentration was held constant by adding 
adjusted amounts of negative control target protector. (A) APP levels were assayed 72 
hours post-transfection by Western blot. (B) Blots were quantified by densitometric 
analysis and APP levels normalized to β-actin levels and scaled relative to mock 
transfection (n=4). *p < 0.01 relative to 0 nM miR-346 target protector. 
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Figure 19: Knockdown of Dicer and AGO2 attenuates the stimulatory effect of 
miR-346 on APP expression. HeLa cells were co-transfected with or without miR-346 
mimic along with either negative control siRNA, Dicer siRNA or AGO2 siRNA. (A) APP 
levels were assayed 72 hours post-transfection by Western blot. (B) Blots were 
quantified by densitometric analysis and APP levels normalized to β-actin levels. 
Percent increase was then calculated by subtracting the average signal of each mock 
condition (without miR-346) from the miR-346-transfected signal for each siRNA 
transfection group and then scaling as percent increase relative to the mock condition. 
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Figure 20: Knockdown of IRP1 attenuates the stimulatory effect of miR-346 on 
APP expression. HeLa cells were co-transfected with negative control miRNA mimic or 
miR-346 mimic along with either negative control siRNA or IRP1 siRNA. (A) APP levels 
were assayed 48 hours post-transfection by Western blot. (B) Blots were quantified by 
densitometric analysis. Percent increase was calculated by subtracting the average 
signal of the negative control mimic transfections from the miR-346-transfected signal 
for both siRNA transfection groups and then scaling as percent increase relative to the 
negative control mimic condition. 
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Figure 21: Stimulatory effect of miR-346 on APP expression in human fetal brain 
cultures only apparent after iron chelation. Human fetal brain cultures were 
transfected with negative control mimic or miR-346 mimic either in the presence of 
vehicle (A) or presence of 150 µM DFO (E). Vehice and DFO treatments were also 
compared in mock-transfected cells (C). APP levels were assayed 48 hours post-
transfection by Western blot. (B, D, F) Blots were quantified by densitometric analysis 
and APP levels normalized to β-actin levels. 
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II. Aim 2: Identify miRNA that endogenously regulate BACE1 expression 
 
A. Global knockdown of miRNA function elevates BACE1 expression 
A similar strategy to that used in the APP-focused studies described above was 
employed for investigating miRNA regulatory effects on BACE1 expression. To begin, 
the effect of inhibiting global miRNA function on BACE1 levels was tested in cultured 
human fetal brain cells. Human fetal brain cultures were either mock transfected or 
transfected with a negative control or AGO2-specific siRNA at DIV 18. Cultures were 
harvested 48 hours post-transfection (DIV 20) and BACE1 expression assayed by 
Western blot. BACE1 levels were significantly elevated following knockdown of AGO2 
as compared to negative control siRNA transfection (1.318±0.051 fold change; p=0.043 
by two-tailed Student’s t-test) (Figure 22A and B). As with APP expression, this 
suggests that the global complement of miRNA act to basally inhibit BACE1 expression 
in cultured human brain cells. 
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Figure 22: Knockdown of miRNA effector protein AGO2 enhances expression of 
BACE1 in primary human fetal brain cultures. The effect of disrupting global miRNA 
functionality on BACE1 expression in primary human fetal brain cultures was assessed 
by using siRNA-mediated knockdown of AGO2. Cultures were transfected at DIV 17 
and lysates prepared 48 hours post-transfection (DIV 19). (A) Levels of BACE1 and β-
actin were assayed by Western blot. (B) Blots were quantified by densitometric analysis 
and BACE1 levels normalized to β-actin levels and scaled relative to negative control 
transfection. BACE1 levels were significantly increased in primary human fetal brain 
cultures transfected with an AGO2 siRNA as compared to transfection with a negative 
control siRNA (n=4). BACE1 siRNA reduced BACE1 expression confirming partial 
delivery of siRNA in these cultures. * p=0.048 by one-tailed Student’s t-test. 
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B. Bioinformatic analysis of putative miRNA targets in BACE1 3’-UTR 
To identify novel miRNA target sites in the human BACE1 3’-UTR, the same set 
of web-based bioinformatics algorithms described in APP-focused studies above and 
summarized in Table 7 were used to predict favorable miRNA interactions. miRNA 
target site predictions in the BACE1 3’-UTR were extracted from the predictor outputs. 
Criteria for selecting a given miRNA:target site interaction included relatively high 
predictor score and known brain expression. Preference was also given to miRNA-
target interactions predicted across multiple algorithmic platforms. Table 10 
summarizes the identity of the predicted targeting miRNA and the location of the 
predicted target site in relation to the human BACE1 3’-UTR, along with the various 
predictor scores computed for each given target site interaction. Two distinct target 
sites were predicted for miR-29a/b, miR-570, miR-133a/b and miR-339-5p by multiple 
algorithms. 
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Table 10: Selected BACE1 3’-UTR miRNA target site predictions and scores 
miRNA 
Computational Predictor Scores 
Target 
Siteg 
Target 
Scana PicTar
b 
DIANA- 
microT v4c 
miRanda 
miRSVRd PITA
e rna22f 
miR-107 *** 6.16 0.307 *** *** -26.2 267-273 
miR-29ah -0.07 2.46 0.281 *** *** -26.2 1052-1058 
 -0.07 2.46 0.234 *** *** *** 1793-1799 
miR-29bh -0.02 3.97 0.281 *** *** *** 1052-1058 
 -0.02 3.97 0.234 *** *** -30.4 1793-1799 
miR-298 *** *** *** *** *** -27.8 466-471 
miR-328 *** *** *** *** *** -30.6 91-96 
miR-570h -0.18 *** *** *** *** *** 720-727 
 -0.14 *** *** *** *** *** 729-735 
miR-339-5ph -0.37 *** *** -0.2873 -5.2 -31.8 484-491 
 -0.34 *** 0.177 -0.6294 *** -33.6 611-618 
miR-133ah -0.06 *** *** *** *** *** 755-761 
 -0.02 *** *** *** -6.58 -38.8 1500-1506 
miR-133bh -0.06 *** *** *** *** *** 755-761 
 -0.02 *** *** *** -6.58 -38.8 1500-1506 
miR-769-3p -0.08 *** *** *** *** -28.7 3423-3429 
Reported scores: acontext+ score, bPicTar score, cSite score, dmirSVR score, eddG 
score, ffolding energy in kCal/mol, M=14, G=0, E=-20 Kcal/mol; gTarget site position 
relative to start of BACE1 3’-UTR; hTwo distinct target sites are predicted in the BACE1 
3’-UTR; *** = target site not predicted by algorithm 
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C. Reporter validation of putative miRNA targets in BACE1 3’-UTR 
The BACE1 mRNA consists of a 460 bp 5’-UTR, 1.5 kb coding sequence (CDS) 
and 3.9 kb 3’-UTR (Figure 23A). To screen for functional miRNA interactions, a reporter 
construct was prepared containing the full length BACE1 3’-UTR. This reporter was 
generated by PCR amplifying the BACE1 3’-UTR from human genomic DNA and 
inserting the amplicon downstream of the Renilla luciferase CDS in the psiCHECK-2 
vector. This reporter has an identical arrangement to the APP 3’-UTR reporter used in 
aim 1 and is schematically illustrated in Figure 23B.  
The regulatory influence of the BACE1 3’-UTR on basal reporter expression was 
tested prior to screening for functional miRNA interactions. HeLa, SK-N-SH and 
differentiated NT2 neurons were transfected with either the empty psiCHECK-2 vector 
or the BACE1 3’-UTR reporter vector (Figure 23C). The presence of the BACE1 3’-UTR 
significantly repressed reporter expression in HeLa cells (0.391±0.009 fold change 
compared to empty; p=0.0001 by Student’s t-test), SK-N-SH cells (0.251±0.091 fold 
change compared to empty; p=0.0002 by Student’s t-test) and differentiated NT2 
neurons (0.425±0.067 fold change compared to empty; p=0.0176 by Student’s t-test) 
(Figure 23C). These data suggest that under basal transfection conditions the BACE1 
3’-UTR contains inhibitory response elements, completely consistent with the presence 
of possible inhibitory MRE.  
To validate the functionality of putative miRNA:BACE1 3’-UTR interactions as 
predicted by the various algorithms, HeLa cells were co-transfected with both the 
BACE1 3’-UTR reporter construct and miRNA mimics listed in Table 10 (Figure 24). 
Negative control and positive control co-transfections were performed identically to the 
experiment previously discussed in Figure 6. Forty eight hours post-transfection, 
reporter expression was determined using a dual luciferase reporter assay. Reporter 
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expression values were calculated as normalized ratios of Renilla-to-firefly luciferase 
activity. 
Co-transfection of miR-339-5p, miR-29a, miR-29b, miR-570, miR-133a, miR-
133b and miR-769-3p with the BACE1 3’-UTR reporter construct all resulted in 
significantly reduced reporter expression compared to co-transfection with negative 
control miRNA mimic (fold change in comparison to negative control miRNA 
transfection: miR-339-5p, 0.551±0.021 fold; miR-29a, 0.880±0.038 fold; miR-29b, 
0.575±0.036; miR-570, 0.717±0.027 fold; miR-133a, 0.803 ± 0.044 fold, miR-133b, 
0.793 ± 0.023 fold, miR-769-3p, 0.816 ± 0.030 fold; p<0.05 in all cases as determined 
by post-hoc Dunnett’s t-test). Data in Figure 24 are presented as RRR to control for 
plate-to-plate variation as previously described in the discussion for Figure 6.  
Co-transfection with miR-29a/b both produced inhibitory effects on reporter 
expression. Importantly, this regulatory interaction has been independently validated 
[189], highlighting the reproducibility and validity of the reporter assessment. The 
strongest inhibitory effect on reporter expression was observed following co-transfection 
with miR-339-5p. Therefore, follow-up experiments from this set of miRNA were 
restricted to 339-5p.  
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Figure 23: BACE1 3’-UTR inhibits basal reporter expression across multiple 
human cell types. (A) Schematic of the BACE1 mRNA demonstrating sizes of the 5’-
UTR, coding sequence (CDS) and 3’-UTR. (B) Schematic of the reporter constructs 
used to validate putative miRNA target sites in the BACE1 3’-UTR. The BACE1 3’-UTR 
was PCR amplified from human genomic DNA and inserted into the psiCHECK-2 vector 
downstream of the Renilla luciferase (luc) CDS. The positive control construct was the 
same as in Figure 3B. (C) The regulatory effect of the BACE1 3’-UTR on reporter 
expression was tested by transfecting either the empty psiCHECK-2 vector or vector 
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containing the BACE1 3’-UTR into HeLa, SK-N-SH or differentiated NT2 neuronal cells 
and assaying basal reporter expression. Assay values are reported as the ratio of 
Renilla to luciferase luminescence scaled relative to empty vector (n=5; *p<0.05). 
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Figure 24: Multiple miRNA modulate BACE1 3’-UTR reporter expression levels in 
HeLa cells. The BACE1 3’-UTR reporter construct and miRNA mimics (40 nM) were 
co-transfected into HeLa cells. Renilla and firefly luciferase activity were assayed 48 
hours post-transfection. Data are presented as scaled relative response ratios of Renilla 
to firefly luciferase (n=5; *p<0.05). 
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D. miR-339-5p negatively regulates BACE1 expression  
miR-339-5p has two predicted target sites in the BACE1 3’-UTR as predicted by 
TargetScan, miRanda-miRSVR, and rna22. Approximate locations of the predicted 
target sites in the BACE1 transcript are schematically illustrated in Figure 25A. The 
predicted interaction of each target site in the human BACE1 3’-UTR with miR-339-5p 
are indicated in Figure 25B, along with a limited mammalian multiple sequence 
alignment. Both sites are considered poorly conserved according to the conserved 
branch length metric employed in TargetScan (0.212 for miR-339-5p site 1 and 0.595 
for miR-339-5p site 2). This suggests a lack of evolutionary pressure to maintain 
sequence identity at these two sites. Therefore, if a physiologically relevant interaction 
exists at either of these sites, the interaction may be an evolutionarily new 
phenomenon. 
To confirm that the inhibitory effect of miR-339-5p on BACE1 3’-UTR reporter 
expression was mediated specifically via one of two predicted miR-339-5p target sites 
located in the BACE1 3’-UTR, mutations were introduced separately in the seed 
sequences of both target sites in the reporter construct (Figure 25C). A double mutant 
reporter was also constructed containing both target site mutations. These mutant 
reporter constructs were then co-transfected along with miR-339-5p mimic into HeLa 
cells and reporter expression compared to wild-type reporter (Figure 25D). This reporter 
assay replicated the original finding, demonstrating reduced reporter expression when 
the wild-type reporter was co-transfected with miR-339-5p as compared to co-
transfection with negative control miRNA (0.53±0.025 fold change; p<0.0001 by two-
tailed Student’s t-test). Due to technical issues with the site 1 mutant clone, the effect of 
miR-339-5p co-transfection on reporter expression could not be determined. Mutation of 
site 2 partially eliminated the inhibitory effect of miR-339-5p mimic on reporter 
expression (0.731±0.011 fold change compared to negative control reporter; p=0.0001 
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by two-tailed Student’s t-test), whereas mutation of both sites completely reversed the 
miR-339-5p response (p=0.2192 by Student’s t-test). Therefore, miR-339-5p most likely 
regulates reporter expression by interacting with two distinct target sites in the BACE1 
3’-UTR. 
The next step was to directly examine whether miR-339-5p reduces 
endogenous BACE1 levels. BACE1 expression is so low in HeLa that it is not readily 
detectable by Western blot using 3D5 antibody. It is readily detected in U373 and 
primary human fetal brain cultures. Therefore, miR-339-5p mimic was transfected into 
both U373 cells (Figure 26A and B) and human fetal brain cultures at DIV 17 (Figure 
26C and D). U373 cells were also transfected with miR-29b as a positive control 
transfection. miR-29b has been previously shown to downregulate endogenous BACE1 
protein expression [189]. BACE1 protein levels were then directly assayed by Western 
blot. BACE1 expression in U373 cells was significantly reduced following transfection 
with both miR-29b (0.125±0.013 fold change; p<0.01 by post-hoc Dunnett’s t-test) and 
miR-339-5p (0.373±0.038 fold change; p<0.01 by post-hoc Dunnett’s t-test) as 
compared to transfection with negative control miRNA mimic. Similarly, BACE1 protein 
levels were significantly reduced following transfection with miR-339-5p in human fetal 
brain cultures as compared to transfection with negative control miRNA mimic 
(0.873±0.019 fold change; p=0.0381 by two-tailed Student’s t-test). Therefore, 
endogenous BACE1 levels are inhibited by miR-339-5p delivery in human U373 and 
primary fetal brain cells. 
To establish whether endogenous miR-339-5p regulates BACE1 expression by 
interacting with the two reporter-validated target sites in human fetal brain cells, two 
separate custom target protectors were utilized to block the interaction of miR-339-5p 
with each validated BACE1 3’-UTR target site. Primary human fetal brain cultures were 
transfected with miR-339-5p target protectors at DIV 17 and BACE1 expression 
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assayed by Western blot 48 hours post-transfection. Transfection of miR-339-5p site 1 
target protector elevated BACE1 expression, but the increase was not statistically 
significant compared to transfection with negative control target protector (1.351±0.139 
fold change). Transfection of miR-339-5p site 2 target protector significantly elevated 
BACE1 expression compared to transfection with negative control target protector 
(1.499±0.101 fold change) (Figure 27). Therefore, endogenous miR-339-5p actively 
inhibits BACE1 expression in human fetal brain cultures under physiological culture 
conditions and does so by potentially interacting with site 1 and definitely interacting 
with site 2 in the BACE1 3’-UTR. Of note is that site 2, though itself poorly conserved by 
TargetScan standards, exhibits a higher level of cross-species conservation than does 
site 1. Therefore, the reduced efficacy of the site 1 target protector in modulating 
BACE1 expression and the lower level of site 1 cross-species conservation may 
suggest that this site is less physiological relevant than site 2. 
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Figure 25: miR-339-5p targets human BACE1 3’-UTR via poorly conserved sites. 
(A) Schematic of the BACE1 transcript demonstrating location of two putative miR-339-
5p target sites in the 3’-UTR predicted by the TargetScan, rna22, miRanda-mirSVR, 
and PITA algorithms. (B) Sequence and predicted base-pairing of human miR-339-5p 
with its two predicted target sites in the human BACE1 3’-UTR, including the seed 
sequence interactions (red boxes). To assess site conservation, multiple genome 
alignments for mammalian species were pulled from TargetScan. Sequences from 
rhesus macaque, mouse, rat, and horse from positions orthologous to the predicted 
miR-339-5p target sites in the human BACE1 3’-UTR are shown. Red text highlights 
nucleotide differences compared to the human sequence. (C) The predicted target sites 
in the BACE1 3’-UTR reporter construct were mutated by site-directed mutagenesis. A 
double mutant containing both mutations was also constructed. Red text highlights 
mutations introduced in seed sequence. (D) Wild-type and target site mutant reporter 
constructs were transfected into HeLa cells either alone or along with 50 nM negative 
control and miR-339-5p mimic. Luciferase expression was assessed 48 hours post-
transfection. * p<0.0005, n=5. 
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Figure 26: miR-339-5p delivery downregulates BACE1 expression in U373 cells 
and primary human fetal brain cultures. (A) U373 cells were transfected with 150 nM 
miR-29b (positive control) and miR-339-5p mimic or negative control and BACE1 levels 
assayed 72 hours post-transfection by Western blot (n=4). (B) Blots from panel (A) 
were quantified by densitometric analysis and BACE1 levels normalized to β-actin 
levels and scaled relative to mock transfection. (C) Primary human fetal brain cultures 
were transfected with 150 nM miR-339-5p mimic or negative control at DIV 17 and 
lysates prepared 48 hours post-transfection (DIV 19). siRNA (20 nM) transfection 
included as delivery control. Levels of BACE1 were assayed by Western blot. (D) Blots 
from panel (C) were quantified by densitometric analysis and BACE1 levels scaled 
relative to mock transfection (n=3 – 4). * p<0.05 
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Figure 27: Blocking miR-339-5p interaction individually with each of two 
predicted target sites in the BACE1 mRNA 3’-UTR elevates basal BACE1 protein 
levels. (A) Western blot analysis of BACE1 and α-tubulin levels in transfected primary 
human fetal brain cultures. Primary human fetal brain cultures at DIV 17 were either 
mock-transfected or transfected with 1000 nM negative control target protector or 
custom-designed target protectors designed to inhibit interaction of miR-339-5p 
specifically with predicted site 1 or site 2 in the BACE1 mRNA 3’-UTR. BACE1 siRNA 
(20 nM) transfection was included as a delivery control. Cell lysates for proteins were 
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prepared 48 h post-transfecton. (B) Densitometric analysis of blots from panel A. * 
p<0.05; n=4. TP = target protector.  
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III. Aim 3: Investigate the relevance of identified miRNA in normal physiology and 
in pathophysiology of Alzheimer disease 
 
A. Expression analysis of miRNA and protein targets in primary human fetal mixed 
brain cultures suggest co-regulation  
One characteristic of a physiologically relevant miRNA:mRNA regulatory 
relationship is concordant changes in miRNA and protein expression during a cellular 
response. Therefore, the next question addressed was whether APP and its targeting 
miRNA identified in aims 1 and 2 are co-regulated during the maturation of a primary 
human fetal brain culture. Mixed brain cultures were established from the brain 
parenchyma of aborted fetuses as previously described. Cultures were maintained for 
7, 10, 14, 18, 22 and 26 DIV before harvest.  
The analysis compared APP protein levels and miR-153 and miR-346 levels as 
measured from the same sample by Western blot and RT-qPCR, respectively. miR-101 
expression analysis was not completed in this experimentdue to technical 
complications. APP expression was significantly higher at DIV 7 as compared to all 
other time points and then rapidly plateaued with lowest expression levels observed at 
DIV 18 (p<0.01 for DIV7 compared to all time points by post-hoc Tukey’s HSD test) 
(Figure 28A and B). Interestingly, miR-153 had a somewhat inverse expression pattern, 
with highest expression levels at DIV 18, though no differences in expression were 
statistically significant (Figure 28C). Correlation analysis of miR-153 levels versus APP 
levels revealed no significant correlation (p=0.4112), though linear regression produced 
a (non-significant) slope consistent with inverse expression patterns (Figure 28D). miR-
346 exhibited an expression pattern similar to that exhibited by APP with highest 
expression at DIV 7 that plateaued with lower expression levels at DIV (p<0.01 for DIV 
7 as compared to DIV 14, 18, 22 and 26 by post-hoc Tukey’s HSD test) (Figure 28E). 
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Correlation analysis revealed significant positive correlation between miR-346 levels 
and APP levels (p=0.001) (Figure 28F). Linear regression also produced a significant 
non-zero slope consistent with increasing APP levels as a function of increasing miR-
346 levels. These data demonstrate that, in maturing human fetal mixed brain cultures, 
both miR-153 and miR-346 exhibit expression patterns that are perfectly concordant 
with their anticipated regulatory effect on APP expression. Therefore, it is reasonable to 
speculate that the regulatory effect of miR-153 and miR-346 may contribute to the 
pattern of APP expression observed in this culture system. 
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Figure 28: Time profile of APP protein levels and miR-153 and miR-346 levels in 
human fetal brain cultures suggests possible co-regulation. (A) Western blot 
analysis of APP and α-tubulin levels across time (DIV 7 to DIV 26) in a primary human 
fetal brain culture. (B) Blot from panel A was densitometrically analyzed and APP levels 
normalized to α-tubulin and scaled relative to DIV 18 levels (*p<0.001 vs. all time points 
by post-hoc Tukey’s HSD; n=3 – 4). (C) RT-qPCR analysis of miR-153 levels across 
time in the same primary human fetal brain culture as in A & B. Expression levels were 
normalized to the geometric mean of expression levels for endogenous controls 
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RNU6B, RUN48 and miR-16. (p values to be determined; n=2 – 4). (D) Scatter plot of 
normalized APP levels versus relative miR-153 levels. miR-153 levels presented as 
percent of highest expressing sample. Pearson’s correlation coefficient analysis used to 
determine R2 and p-value. Data fitted by linear regression. (E) RT-qPCR analysis of 
miR-346 levels as performed in panel (C). (F) Scatter plot of normalized APP levels 
versus relative miR-346 levels. Analysis performed as in panel (D). (*p<0.001 vs. DIV 
14, 18, 22 and 26 by post-hoc Tukey’s HSD; n=2 – 4).  
  
138 
 
B. Expression analysis of miRNA and protein targets in brain specimens from 
unaffected and Alzheimer disease-affected patients  
The miRNA identified in aims 1 and 2 represent putative drug targets based on 
their ability to modulate gene products essential to the production of Aβ. If these miRNA 
are also dysregulated in the AD brain, they become even more attractive drug targets. 
Discovery of their dysregulation might also provide valuable insights into the underlying 
molecular etiology of AD. Therefore, the next set of experiments sought to examine the 
expression patterns of these miRNA in the AD brain as compared to the non-demented 
brain. 
Two independent cohorts of brain specimens were utilized in this study. The first 
set of specimens was provided by Dr. Peter T Nelson from the University of Kentucky 
Alzheimer Disease Brain Bank. These specimens were isolated from BA9 of the frontal 
cortex and consisted of both control (n=5) and AD (n=15) specimens. Demographic 
details for these specimens are listed in Table 11. These specimens were age-matched 
with a mean age for control specimens of 84.0±2.2 years and 80.8±1.7 years for AD 
specimens. All AD specimens had advanced AD neuropathology (Braak stage VI [13] 
and CERAD score C [328]). Importantly, all specimens were collected following a short 
PMI (range 1.75 hr – 8 hr). Finally, the AD component of this cohort consisted of three 
subgroups defined by history of treatment with AD medications: no history of AD 
medication (No Rx; n=5), history of treatment with rivastigmine but not memantine 
(n=5), and history of treatment with memantine but not rivastigmine (n=5). In these 
experiments, analyses were restricted to the full AD cohort or the No Rx cohort. 
The second set of specimens originated from the Harvard Tissue Resource 
Center and was provided by Dr. P Hemachandra Reddy. These specimens were also 
isolated from BA9 of the frontal cortex and consisted of control (n=5) and AD (n=15) 
specimens. Demographic details from this cohort are listed in Table 12 and were 
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previously published [329]. The AD group was further subdivided into three groups 
defined by stage of neurofibrillary pathology: Braak stage I/II (early AD; n=5), Braak 
stage III/IV (definite AD; n=5), and Braak stage V/VI (severe AD; n=5). Therefore, this 
group consisted of specimens spanning the stages of AD progression. Analyses of this 
cohort was performed either by making comparisons across all Braak stages or by 
combining control and stage I/II and stage III – VI into two distinct groupsfor 
comparison. The rationale for consolidating groups was to increase power of analysis 
by increasing sample size. Given that stage I/II specimens have only very mild AD 
pathology and represent a very early stage of the clinical disease, the assumption is 
that control and stage I/II specimens are more biochemically similar to one another than 
to either stage III/IV or V/VI specimens. 
 This cohort was age-matched across groups: controls (77.6±3.8 years), stage 
I/II (73.2±1.7 years), stage III/IV (77.6±2.5 years), stage V/VI (86.0±3.3 years). Only 
stage I/II and stage V/VI subgroups demonstrated any significant difference in age 
(ANOVA p=0.0476) by post hoc Tukey’s HSD test (p<0.05). PMI was significantly 
higher for cohort 2 but did not vary significantly between groups (ANOVA p=0.1409). 
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Table 11: Demographics and neuropathological assessments of post-mortem 
specimensa constituting cohort 1 
Diagnosis Rx Historyb Age Sex PMI (h) Braak Stagec 
CERAD 
Scored 
NIA-Reagan 
Assessmente  
Control No Rx F 79 1.75 I 0 No disease 
Control No Rx F 92 8 II 0 No disease 
Control No Rx F 84 5 III 0 No disease 
Control No Rx M 81 2.83 II A Low likelihood 
Control No Rx M 84 1.5 II C Low likelihood 
AD No Rx M 76 4.25 VI C High likelihood 
AD No Rx F 91 7.5 V C High likelihood 
AD No Rx F 86 4 VI C High likelihood 
AD No Rx F 80 3.83 VI C High likelihood 
AD No Rx M 74 3 VI C High likelihood 
AD Rivastigmine, No memantine M 88 3.75 V C 
High likelihood 
AD Rivastigmine, No memantine M 96 3.5 V C 
High likelihood 
AD Rivastigmine, No memantine F 83 3.5 VI C 
High likelihood 
AD Rivastigmine, No memantine M 65 4 VI C 
High likelihood 
AD Rivastigmine, No memantine M 69 4 VI C 
High likelihood 
AD Memantine, no rivastigmine F 92 3.5 V C 
High likelihood 
AD Memantine, no rivastigmine F 79 3.75 VI C 
High likelihood 
AD Memantine, no rivastigmine M 84 5.25 VI C 
High likelihood 
AD Memantine, no rivastigmine F 65 4.25 VI C 
High likelihood 
AD Memantine, no rivastigmine F 82 6.25 VI C 
High likelihood 
aBrain specimens provided by Dr. Peter T Nelson from the University of Kentucky Alzheimer 
Disease Center Brain Bank 
bHistory of cholinesterase inhibitor or memantine therapy, No Rx means no history of treatment 
with cholinesterase inhibitors or memantine  
c Braak staging of neurofibrillary tangles as described in [13];  
dNeuritic plaque density scores from the Consortium to Establish a Registry for Alzheimer’s 
Disease as described in [328], 0=no disease, A=possible AD, C=definite AD  
eAssessement of AD pathology based on National Institute of Aging-Reagan Institute 
consensus recommendations as described in [330]  
 
  
141 
 
Table 12: Demographics for post-mortem specimensa constituting cohort 2 
Diagnosis Braak Stage Sex Age PMI (h) 
Control 0 M 68 21 
Control 0 M 82 17 
Control 0 F 74 23 
Control 0 M 74 15 
Control 0 F 90 12 
AD I/II F 74 12 
AD I/II F 67 10 
AD I/II F 76 24 
AD I/II M 77 18 
AD I/II F 72 12 
AD III/IV M 69 18 
AD III/IV M 75 24 
AD III/IV M 82 19 
AD III/IV M 80 19 
AD III/IV F 82 18 
AD V/VI M 77 11 
AD V/VI F 83 18 
AD V/VI M 83 19 
AD V/VI F 92 5 
AD V/VI F 95 8 
aSpecimens from the Harvard Tissue Resource Center were 
provided by Dr. P Hemachandra Reddy and demographic 
details previously published [329]. 
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Prior to assessing for dysregulated miRNA expression in pathological 
specimens, miRNA levels were measured by absolute quantification RT-qPCR in 
control specimens from each cohort to test whether basal expression levels in the adult 
human brain are in the range sufficient for mediating regulatory effects. Previous 
studies have demonstated that thresholds for functional miRNA activity in a cell can be 
as low as ~ 100 copies per cell [242]. Absolute miRNA copy counts were measured 
using RT-qPCR by analyzing miRNA standard curves prepared from synthetic 
oligoribonucleotides. miRNA expression levels were measured for miR-101, miR-153, 
miR-346 and miR-339-5p and normalized to copies per 15 pg total RNA. This amount of 
total RNA approximates the amount present in a single human cell. Therefore, miRNA 
copies as presented in Figure 29 roughly approximate the amounts per cell. However, 
post-mortem RNA degradation in brain specimens prior to freezing likely significantly 
underestimates actual copy counts per cell. For comparison to a known highly 
expressed brain miRNA, miR-124 copy counts were also quantified [331,332].  
In cohort 1 (Figure 29A), miR-124 was the most highly expressed (71340±13550 
copies/15 pg total RNA). Expression levels of other miRNA were significantly lower than 
miR-124 and varied in the following order: miR-101 (6195±452 copies/15 pg total RNA), 
miR-153 (994±314 copies/15 pg total RNA), miR-346 (194±77 copies/15 pg total RNA), 
and miR-339-5p (58±19 copies/15 pg total RNA). Cohort 2 was similarly examined, with 
the exception being that miR-124 was not quantified in specimens from this cohort. 
Expression levels for miRNA varied in the same order for cohort 2 as in cohort 1: miR-
101 (1203±225 copies/15 pg total RNA), miR-153 (260 ±52 copies/15 pg total RNA), 
miR-346 (63 ±23 copies/15 pg total RNA), miR-339-5p (26±5 copies/15 pg total RNA). 
Notably, the absolute copy counts were significantly lower for each miRNA assayed in 
cohort 2 specimens relative to cohort 1. This likely reflects the fact that PMI was 
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significantly longer in cohort 2 and is further reflected by the lower RIN values observed 
in some samples from cohort 2. 
In summary, miR-101, miR-153, miR-346 and miR-339-5p are expressed in the 
human brain to varying extents. Given the degree of underestimation of actual copy 
counts per cell inherent in analyzing a post-mortem specimen, the expression levels of 
each tested miRNA in the human brain are expected to be sufficient to mediate 
functional effects on gene expression observed in aims 1 and 2. 
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Figure 29: Absolute quantification of miRNA levels in control human brain 
specimens confirms physiologically relevant expression. Absolute miRNA copy 
counts per 15 pg of total RNA in control brain specimens from two independent cohorts 
were analyzed by RT-qPCR. Copy counts were calculated from standard curves 
prepared from serial dilutions of miRNA oligonucleotide standards with known 
concentrations. Control reactions lacking template did not demonstrate any 
amplification. miR-124 is a highly expressed, brain-expressed miRNA and was 
analyzed for comparison to a known highly expressed brain miRNA. (n=5 for each 
cohort)  
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Specimens from each brain cohort were next examined for dysregulation of 
APP, BACE1 or their targeting miRNA in AD. APP levels were measured by Western 
blot and levels of miRNA by RT-qPCR. Both relative quantification (normalized to the 
geometric mean of RNU6B, RNU48, RNU49 and miR-16 expression levels) and 
absolute quantification (normalized as copy counts per 15 pg total RNA) of miRNA 
levels were performed. In both cohorts, APP levels were not significantly different in the 
AD specimens (or No Rx AD subgroup) as compared to control brain specimens 
(Figure 31A and B). Next, expression of APP-targeting miRNA was assessed. Levels of 
miR-101 were significantly decreased in both the AD specimens (0.688±0.051 fold 
change; p=0.009 by Student’s t-test) and the No Rx subgroup (0.624±0.070 fold 
change; p=0.0176 by Student’s t-test) as compared to control specimens by relative 
quantification (Figure 10A). The same decrease in miR-101 levels in AD (0.588±0.054 
fold change by Student’s t-test) and the No Rx subgroup (0.650±0.010 fold change; 
p=0.0223 by Student’s t-test) were observed when quantified in absolute terms (Figure 
31B). 
Simlarly, miR-346 expression was significantly decreased in both the full AD 
group (0.338±0.077 fold change; p<0.05 by ANOVA and post hoc Dunnett’s t-test) and 
No Rx subgroup (0.228±0.050 fold change; p<0.51 by ANOVA and post-hoc Dunnett’s 
t-test) by relative quantification (Figure 31E). This finding was also apparent when miR-
346 expression levels were compared by absolute quantification between the full AD 
group (0.256±0.023 fold change; p<0.01 by ANOVA and post hoc Dunnett’s t-test) and 
the controls and for the No Rx subgroup (0.228±0.027 fold change) as compared to 
controls (Figure 31F).  
No significant difference in miR-153 (Figure 31Cand D) levels were observed 
between AD (or No Rx) and control specimens, whether quantified in relative or 
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absolute terms. Therefore, miR-101 and miR-346 levels are negatively dysregulated in 
AD specimens from this cohort 
Next, expression levels of BACE1 and BACE1-targeting miRNA were assessed. 
Levels of BACE1 were not significantly different in AD (or No Rx) specimens as 
compared to control specimens (Figure 32A and B). miR-339-5p levels were 
significantly decreased compared to controls but only in the full AD group and onlywith 
absolute quantification (0.549±0.045 fold change; p=0.033 by two-tailed Student’s t-
test) (Figure 33B). Expression levels of several additional miRNA not specifically tested 
for BACE1-regulating effects in these studies but previously reported to regulate 
BACE1 expression were also assessed: miR-124 [333], miR-107 [266], and miR-29b 
[189]. There were no significant differences in miR-124 (Figure 33C and D), miR-107 
(Figure 33E) or miR-29b levels (Figure 33F) in AD or No Rx subgroup specimens as 
compared to negative control specimens. However, all trended toward decreased 
expression despite not reaching statistical significance. Therefore, miR-339-5p levels 
may be negatively dysregulated in AD specimens from this cohort. 
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Figure 30: Analysis APP protein levels in control and AD human brain specimens 
from cohort 1. (A) Western blot analysis of APP and α-tubulin levels in brain 
specimens from AD and control patients in cohort 1. (B) Blot from panel A was 
densitometrically analyzed and APP levels normalized to α-tubulin and scaled relative 
to control APP levels. AD (No Rx) represents a subgroup of patients from the AD group 
that had no history of treatment with cholinesterase inhibitors or memantine. C, control 
group; AD, AD group; AD*, AD (No Rx) subgroup. 
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Figure 31: Analysis of validated APP-regulating miRNA expression levels in 
control and AD human brain specimens from cohort 1. RT-qPCR analysis of 
expression levels for miR-101 (A and B), miR-153 (C and D), and miR-346 (E and F) in 
brain specimens from AD and control patients in cohort 1. AD (No Rx) represents a 
subgroup of patients from the AD group that had no history of treatment with 
cholinesterase inhibitors or memantine. In panels A, C and E, expression levels were 
determined using the modified delta Cq relative quantification method as implemented 
in qBasePLUS software [301,302]. Expression levels were normalized to the geometric 
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mean of four endogenous controls: RNU6B, RNU48, RNU49 and miR-16. In panels B, 
D, and F, expression levels were quantified in absolute terms as miRNA copy counts 
per 15 pg of total RNA. Copy counts were calculated from standard curves prepared 
from serial dilutions of miRNA oligonucleotide standards with known concentrations. 
(*p<0.05; n=5 for controls, n=14 for AD, n=5 for AD (No Rx)).  
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Figure 32: Analysis of BACE1 protein levels in control and AD human brain 
specimens from cohort 1. (A) Western blot analysis of BACE1 and α-tubulin levels in 
brain specimens from AD and control patients in cohort 1. (B) Blot from panel A was 
densitometrically analyzed and BACE1 levels normalized to α-tubulin and scaled 
relative to control BACE1 levels. C, control group; AD, AD group; AD*, AD (No Rx) 
subgroup 
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Figure 33: Analysis of validated BACE1-regulating miRNA expression levels in 
control and AD human brain specimens from cohort 1. RT-qPCR analysis of 
expression levels for miR-339-5p (A and B), miR-124 (C and D), miR-107 (E) and miR-
29b (F) in brain specimens from AD and control patients in cohort 1. In panels A, C, E 
and F, expression levels were determined using the modified comparative Cq relative 
quantification method as implemented in qBasePLUS software [301,302] . Expression 
levels were normalized to the geometric mean of four endogenous controls: RNU6B, 
RNU48, RNU49 and miR-16. In panels B and D, expression levels were quantified in 
absolute terms as miRNA copy counts per 15 pg of total RNA. Copy counts were 
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calculated from standard curves prepared from serial dilutions of miRNA oligonucleotide 
standards with known concentrations. (*p<0.05; n=5 for controls, n=14 for AD, n=5 for 
AD (No Rx)).  
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A similar set of analyses were performed on independent cohort 2. Unlike the 
specimens in the previous cohort that exhibited only severe AD pathology, these 
specimens ranged across the pathological stages of the disease (Braak stage 0, I/II, 
III/IV and V/VI). Specimens were also grouped into two higher level categories for 
analysis: 1) control and Braak stage I/II specimens, and 2) Braak stage III, IV, V and VI 
specimens. The rationale for comparing these two supergroups is that neurofibrillary 
tangle (NFT) pathology (the basis of Braak staging) does not progress into the 
neocortex until Braak stages III and IV [13]. Since specimens analyzed here are from 
BA9 of the neocortex, the progression from Braak stage II to stage III delineates a 
distinct transition in the pathogenic environment of this region of the brain. 
Clinicopathological correlation studies have also demonstrated that the progression of 
NFT in the neocortex better correlates with cognitive decline than stages of disease 
where NFT are restricted to the allocortex [334]. Grouping also served to enhance the 
power of analysis by increasing sample size of each group to ten.  
APP levels were quantified by Western blot (Figure 34). When compared across 
Braak stages, APP levels were significantly increased in Braak stage III/IV AD samples 
(p=0.041 by post-hoc Tukey’s HSD; n=5) (Figure 34B). When compared between the 
two supergroups, APP expression was also significantly elevated in specimens with the 
presence of neocortical NFT pathology (stages III – VI) and a significant increase was 
observed in stage III/IV specimens as compared to stage I/II (p=0.048 by Student’s t-
test) (Figure 34C). Levels of APP-targeting miRNA were investigated next. miR-101 
levels were not found to be significantly altered across any groups by either relative or 
absolute quantification methods (Figure 35 A – D). Interestingly, miR-153 levels were 
significantly decreased in specimens from combined Braak stages III/IV and V/VI as 
compared to combined control and Braak stage I/II specimens following both relative 
quantification (0.460±0.104 fold change; p=0.024 by two-tailed Student’s t-test) (Figure 
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36B and D) and absolute quantification (0.497±0.117 fold change; p=0.035 by two-
tailed Student’s t-test). The inverse pattern of APP and miR-153 dysregulation in Braak 
stage III/IV AD specimens suggests that decreased miR-153 levels may contribute to 
elevated APP in these specimens. 
miR-346 levels were also found to be significantly decreased in combined AD 
specimens from Braak stage III/IV and V/VI as compared to combined control and stage 
I/II specimens by both relative (0.547±0.079 fold change; p=0.0109 by two-tailed 
Student’s t-test) (Figure 37A and B) and absolute quantification methods (0.530±0.088 
fold change; p=0.0038 by two-tailed Student’s t-test) (Figure 37C and D).This is notable 
because the same alteration in miR-346 expression was observed in cohort 1 providing 
extra validitiy to this finding. 
Finally, levels of BACE1 and BACE1-targeting miRNA were assessed in cohort 
2. BACE1 levels demonstrated a trend towards elevated expression in Braak stage 
III/IV specimens, however this trend was not significant (ANOVA p=0.2648) (Figure 38A 
and B). miR-339-5p levels were then quantified by relative (Figure 39A and B) and 
absolute (Figure 39C and D) quantification. No alterations in miR-339-5p levels 
between any groups were detected by any quantification scheme. 
Collectively these data indicate that miR-101, miR-153, miR-346 and potentially 
miR-339-5p are dysregulated in the brains of at least a subset of moderate to severe 
sporadic AD patients. 
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 Figure 34: Analysis of APP protein levels in control and AD human brain 
specimens across Braak stages from cohort 2. (A) Western blot analysis of APP 
and α-tubulin levels in control, early (Braak stage I/II), definite (Braak stage III/IV) and 
severe (Braak stage V/VI) AD brain specimens in cohort 2. In panel (B), expression 
levels were compared across control and Braak stage I/II, III/IV, and V/VI specimens. In 
panel (C), similar groups were combined to increase the power of analysis. Control and 
Braak stage I/II specimens were grouped together and Braak stage III – VI were 
grouped together for analysis. Blot abbreviations: A, control specimens; B, early AD 
specimens (stage I/II); C, definite AD specimens (stage III/IV); D, severe AD specimens 
(stage V/VI). *p<0.05; n=5 – 10 for each group 
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Figure 35: Analysis of miR-101 expression levels in control and AD human brain 
specimens across Braak stages from cohort 2. RT-qPCR analysis of expression 
levels for miR-101. In panel A and B, expression levels were determined relative to the 
geometric mean of four endogenous controls: RNU6B, RNU48, RNU49 and miR-16. In 
panels C and D, expression levels were quantified in absolute terms as miRNA copy 
counts per 15 pg of total RNA using standard curves prepared from serial dilutions of 
miRNA oligonucleotide standards with known concentrations. In panels A and C, 
expression levels were compared across control and Braak stage I/II, III/IV, and V/VI 
specimens. In panels B and D, similar groups were combined to increase the power of 
analysis. Control and Braak stage I/II specimens were grouped together and Braak 
stage III-VI were grouped together for analysis. (*p<0.05; n=5 – 10 for each group).  
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 Figure 36: Analysis of miR-153 expression levels in control and AD human brain 
specimens across Braak stages from cohort 2. RT-qPCR analysis of expression 
levels for miR-153. In panels A and B, expression levels were determined relative to the 
geometric mean of four endogenous controls: RNU6B, RNU48, RNU49 and miR-16. In 
panels C and D, expression levels were quantified in absolute terms as miRNA copy 
counts per 15 pg of total RNA using standard curves prepared from serial dilutions of 
miRNA oligonucleotide standards with known concentrations. In panels A and C, 
expression levels were compared across control and Braak stage I/II, III/IV, and V/VI 
specimens. In panels B and D, similar groups were combined to increase the power of 
analysis. Control and Braak stage I/II specimens were grouped together and Braak 
stage III – VI were grouped together for analysis. (*p<0.05; n=5 – 10 for each group). 
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 Figure 37: Analysis of miR-346 expression levels in control and AD human brain 
specimens across Braak stages from cohort 2. RT-qPCR analysis of expression 
levels for miR-346. In panel A and B, expression levels were determined relative to the 
geometric mean of four endogenous controls: RNU6B, RNU48, RNU49 and miR-16. In 
panels C and D, expression levels were quantified in absolute terms as miRNA copy 
counts per 15 pg of total RNA using standard curves prepared from serial dilutions of 
miRNA oligonucleotide standards with known concentrations. In panels A and C, 
expression levels were compared across control and Braak stage I/II, III/IV, and V/VI 
specimens. In panels B and D, similar groups were combined to increase the power of 
analysis. Control and Braak stage I/II specimens were grouped together and Braak 
stage III – VI were grouped together for analysis (n=5 for each Braak stage). (*p<0.05; 
n=5 for each group).  
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 Figure 38: Analysis of BACE1 protein expression levels in control and AD human 
brain specimens across Braak stages from cohort 2. (A) Western blot analysis of 
BACE1 and α-tubulin levels in control, early (Braak stage I/II), definite (Braak stage 
III/IV) and severe (Braak stage V/VI) AD brain specimens in cohort 2. (B) Blot from 
panel A was densitometrically analyzed and BACE1 levels normalized to α-tubulin and 
scaled relative to control BACE1 levels. Blot abbreviations: A, control specimens; B, 
early AD specimens (stage I/II); C, definite AD specimens (stage III/IV); D, severe AD 
specimens (stage V/VI). 
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Figure 39: Analysis of miR-339-5p expression levels in control and AD human 
brain specimens across Braak stages from cohort 2. RT-qPCR analysis of 
expression levels for miR-339-5p. In panel A and B, expression levels were determined 
relative to the geometric mean of four endogenous controls: RNU6B, RNU48, RNU49 
and miR-16. In panels C and D, expression levels were quantified in absolute terms as 
miRNA copy counts per 15 pg of total RNA using standard curves prepared from serial 
dilutions of miRNA oligonucleotide standards with known concentrations. In panels A 
and C, expression levels were compared across control and Braak stage I/II, III/IV, and 
V/VI specimens. In panels B and D, similar groups were combined to increase the 
power of analysis. Control and Braak stage I/II specimens were grouped together and 
Braak stage III – VI were grouped together for analysis (n=5 for each Braak stage).   
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CHAPTER 4: DISCUSSION 
 
The overarching goal of the studies described in this disseration was to identify 
novel regulators of gene expression for gene products critical to the production of Aβ in 
the human brain. Given the presumed centrality of Aβ to AD pathogenesis [27], these 
novel regulators might then be pursued as novel drug targets based on their Aβ-
modulating activities. APP and BACE1 were chosen as the gene products of interest 
given their role as the Aβ parental molecule [92] and rate-limiting enzyme for Aβ 
production [158], respectively. Also, they both exhibit elevated expression contributing 
to disease in sporadic AD or rare genetic variants of AD [30,47–49,335].The novel 
regulators that were the focus of these studies were miRNA. The hypothesis that 
miRNA regulate the expression of APP and BACE1 was based upon systems-level 
analyses that demonstrate most mammalian transcripts are miRNA targets [243] and by 
the fact that knockdown of a central RISC protein essential for global miRNA function 
(AGO2) resulted in elevated levels of APP and BACE1 protein (Figures 1 and 21). 
Therefore, experiments were pursued that identified physiologically relevant APP and 
BACE1 mRNA:miRNA regulatory interactions, demonstrated the Aβ-modifying 
properties of some of these miRNA, and established dysregulation of several miRNA in 
the AD brain. 
 
I. Novel miRNA interactions with the APP mRNA regulate APP expression 
 
A. The APP 3’-UTR stimulates basal expression 
Reporter expression under the regulatory influence of the APP 3’-UTR was 
elevated as compared to reporter expression in the absence of the APP 3’-UTR, 
suggesting the presence of regulatory elements in the APP 3’-UTR that either stabilize 
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the reporter transcript or promote reporter transcript translation. This stimulatory effect 
is consistent with previous reports [336]. Several trans-acting factors have been 
previously reported to interact with cis-elements in the APP 3’-UTR promoting APP 
mRNA stability. A 29-nt sequence in the 3’-UTR normally acts as an instability element, 
however hnRNP C binding to this element enhances transcript stability [147,150]. A 52-
nt element located immediately downstream of the APP stop codon basally enhances 
transcript stability and appears to do so by binding multiple RNA-binding proteins, 
including rck/p54 [149,151]. An 81-nt element downstream of the two previous elements 
responds to TGF-β1 signaling by significantly enhancing APP transcript stability [337].  
Any or all of these elements might contribute to the stimulatory effect of the APP 
3’-UTR on reporter expression observed in this study. Additional elements not yet 
described may also significantly contribute. Aside from the exact mechanism, it is clear 
that with the reporter system tested here the integrated response of the APP 3’-UTR 
across multiple cellular environments is to enhance expression. Importantly, the 
observed effect does not preclude the possibility of distinct negative regulatory 
influences being mediated by 3’-UTR cis-elements, such as MRE. 
 
B. Bioinformatic analyses reveal putative APP 3’-UTR:miRNA interactions 
As a first step in identifying miRNA that regulate APP expression, bioinformatic 
predictors were employed to predict putative APP 3’-UTR:miRNA interactions. A more 
unbiased workflow would make no assumptions about putative miRNA target sites and 
simply screen a complete library of all known miRNAs for regulatory effects on APP 
expression using an optimized high throughput assay. However, the costs, logistics, 
and time required for assay optimization are extensive. Further, this approach does not 
provide a sorting mechanism to distinguish effects that are indirect from those that are 
mediated by direct interaction with the APP transcript. Therefore, mechanism would be 
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difficult to dissect. Bioinformatic-based predictions are useful in that they provide 
preliminary evidence for direct interaction of a predicted miRNA with the target 
transcript. Thus, once miRNA regulatory effects on target gene expression are 
validated, a hypothesis regarding mechanism can be immediately tested by mutating 
target site sequences. Additionally, recent proteomic analyses of protein expression 
changes following transfection of synthetic miRNAs have demonstrated that 
bioinformatic predictions capture many experimentally confirmed regulatory 
relationships [244,245]. Therefore, in this study, the following predictors were used: 
TargetScan 6.0, PicTar, DIANA-microT v.4.0, miRanda-mirSVR, PITA and rna22 (Table 
7 for summary). These algorithms output a set of miRNA predicted to target the APP 3’-
UTR. The validity of this approach as a starting point for identifying miRNA regulators of 
APP expression is highlighted by the fact that several miRNA in this set were 
subsequently shown in independent labs to mediate inhibitory effects on APP 
expression: miR-20a [338], miR-20b, miR-106a [276] and miR-520c-3p [318]. 
Despite their ease of use and general success in identifying true interactions 
between miRNA and mRNA target sites, predictor algorithms are not unassailable tools 
in the hunt for physiologically relevant regulatory interactions. The same proteomic 
studies cited above also indicate that these tools generate very high levels of false 
positives despite continued improvement in algorithmic design [244,245]. Therefore, a 
set of miRNA predicted to target APP transcript can be expected to include many 
physiologically irrelevant members (false positive) and exclude many physiologically 
relevant members not detected by the predictor algorithm (false negatives). Other 
disadvantages underlying exclusive use of web-based predictors is that most have pre-
assembled prediction sets that are limited to 3’-UTR only. New experimental 
approaches have identified functional interactions with target sites in the CDS and 5’-
UTR of mRNAs [225,325,339]. Therefore, exclusive use of computational methods for 
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target site identification is likely to miss out on some important functional interactions 
that occur outside the 3’-UTR (e.g. miR-346 data presented in this dissertation). Finally, 
the requirement for cross-species conservation at putative target sites serves as a 
useful filter for enriching for functional sites but is also likely to eliminate the detection of 
species-specific miRNA:mRNA target interactions. Therefore, future studies that 
continue the search for miRNA regulators of APP expression might be well served to 
incorporate new state-of-the-art experimental techniques that directly identify physical 
interactions between miRNA and target mRNA. Examples of such techniques include 
RIP-Chip [340], TAP-Tar [341], HITS-CLIP [225] and PAR-CLIP [339]. These 
techniques are based on the pulldown of a ternary complex consisting of AGO2, miRNA 
and target mRNA via immunoprecipitation of AGO2. 
 
C. APP expression is negatively regulated by miR-101 and miR-153 via target sites in 
the APP 3’-UTR 
Efficacy of predicted miRNA:APP 3’-UTR interactions was tested by 3’-UTR 
reporter assays. Multiple miRNA were found to inhibit reporter expression following co-
transfection with an APP 3’-UTR reporter. The focus of subsequent investigations was 
on miR-101 and miR-153 given the strong inhibitory effect on reporter expression. The 
inhibitory effect of both miRNA on reporter expression required seed sequence fidelity 
at the specific predicted target sites in the APP 3’-UTR, suggesting that miR-101 and 
miR-153 mediate their inhibitory effect by direct interaction with these sites. For miR-
101, two target sites were predicted in the APP 3’-UTR but only the most strongly 
conserved site was found to be functionally active. Both miR-101 and miR-153 inhibit 
APP protein expression and Aβ production in multiple human cell types, including AD-
relevant human primary fetal mixed brain cultures. Importantly, endogenous miR-153 
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regulates basal expression in human cells, as evidenced by elevated APP expression 
following delivery of either antisense inhibitors that disrupt interaction of the miRNA with 
their APP 3’-UTR target sites. In toto, these data suggest that miR-101 and miR-153 
are bona fide drug targets that might be targeted therapeutically to reduce APP 
expression in AD by either stimulating their endogenous expression in the brain or by 
direct delivery of synthetic miRNA. 
Both miR-101 and miR-153 have ascribed functions and targets apart from their 
ability to regulate APP expression. miR-153 targets a gene product especially relevant 
to AD and Parkinson’s disease (PD): α-synuclein (SNCA) [342]. In the cited study they 
demonstrate that endogenous miR-153 regulates SNCA in rodent neurons. SNCA is an 
abundant component of the Lewy bodies (LB) found in PD and dementia with Lewy 
bodies (DLB) [343]. Therefore, miR-153 negatively regulates two gene products 
implicated in two of the most common neurodegenerative diseases. LB are also found 
on autopsy in a common subtype of AD known as the Lewy body variant (AD-LBV) 
[344–347]. This subtype has been associated with more rapid cognitive decline 
compared to “pure” AD [348,349], along with lower levels of pre-synaptic proteins [350]. 
A recent animal model of AD-LBV created by crossing 3xTg-AD mice with A53T SNCA 
transgenic mice revealed accelerated amyloid, tau and Lewy body pathology in the AD-
LBV animals as compared to the parental strains, suggesting synergistic effects 
between SNCA, Aβ and tau in promoting pathology [351]. These relationships only 
strengthen the attractiveness of miR-153 as a potential therapeutic target. Enhancing 
miR-153 levels would be expected to reduce the expression of two gene products (APP 
and SNCA) and downstream metabolies (e.g. Aβ peptides) that may have synergistic 
roles in promoting AD pathology and cognitive decline. An interesting question is 
whether miR-153 expression might be decreased more substantially in the brains of 
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AD-LBV patients relative to AD patients. A meaningful follow-up study would measure 
levels of miR-153 levels in these patients.  
miR-101 also targets other gene products or biological pathways with 
neurodegenerative relevance. A recent study demonstrated that miR-101 is a potent 
inhibitor of autophagy, the process utilized by cells to degrade cellular material and 
organelles in lysosomes [322]. In this study, miR-101 inhibited autophagy through 
negative regulation of gene products implicated in various aspects of autophagy 
biology: Stathmin/Oncoprotein18 (STMN1), Rab5a and ATG4D. Interestingly, 
autophagy appears to be impaired in AD. Autophagic vesicles have been found to 
accumulate in dystrophic neurites of the AD brain and in AD animal models [352,353]. 
Further, acutely inducing autophagy in APP-overproducing cells results in excess Aβ 
production, suggesting that Aβ may be produced from APP cleavage in the proteolytic 
environment of the autophagosome [353]. This being the case, enhancing miR-101 
levels might be expected to have synergistic effects on Aβ production by inhibiting both 
APP expression and a cellular process that may promote its production (autophagy). It 
is important to note that there is conflicting data regarding the role of autophagy in AD; 
is it protective or pathological [354]? Some studies suggest that autophagy induction 
protects cells from Aβ neurotoxicity [355]. Others even contradict previous data by 
suggesting that activation of autophagy decreases APP and Aβ levels [356].  
An additional CNS-relevant and validated miR-101 target is ataxin 1 (ATXN1) 
[291,323]. A gain-of-function mutation leading to a polyglutamine (polyQ) tract 
expansion in ATXN1 leads to spinocerebellar ataxia type I, a neurodegenerative 
disorder characterized by ataxia, motor dysfunction and cerebellar Purkinje neuron loss 
[357]. miR-101 antisense inhibition was shown to enhance the toxicity of polyQ-
expanded ATXN1 expression in human cells [323]. A recent genome-wide association 
study identified ATXN1 as a SAD candidate gene [358]. Interestingly, loss of ATXN1 
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function has been shown to promote amyloidogenic processing of APP, thereby 
increasing Aβ production [359]. Therefore, it might be expected that the negative 
regulatory effect mediated by miR-101 on APP (and therefore Aβ production) might be 
negated by the opposing effect mediated by ATXN1 inhibition. However, in the studies 
presented here, the overall response to miR-101 delivery in U373 cells and primary 
human fetal brain cultures was a reduction in Aβ levels in the conditioned media. 
TargetScan predicts that both miR-101 and miR-153 target the APP paralog, 
amyloid precursor-like protein 2 (APLP2). This prediction has significant biological 
implications given the redundancy in function between APP and APLP2. Single gene 
knockout of either APP or APLP2 results in only a subtle phenotype. But an APP-
APLP2 double gene knock-out is perinatal lethal [360]. The exact function and 
pathways in which APP and APLP2 serve redundant roles is still unknown but are likely 
critical for normal CNS development. It is tempting to speculate that miR-101 and miR-
153 may target both of these gene products as an evolutionarily conserved mechanism 
to regulate certain biological pathways in which they both participate. A very recent 
report has validated the regulatory relationship between miR-153 and APLP2 [361]. 
Validation of the miR-101 APLP2 target site is still required. 
Aside from CNS-relevant functions, both miR-101 and miR-153 have tumor 
suppressor functions. miR-101 expression is significantly reduced in multiple types of 
cancers, including prostate [321], colon [362], hepatocellular carcinoma [363], gastric 
[364], anaplastic large cell lymphoma [365] and lung squamous cell carcinoma 
[366,367]. Consistent with these findings, functional studies have clearly demonstrated 
that miR-101 acts as a tumor suppressor by inhibiting expression of the oncogenes 
EZH2, COX2, FOS, MYCN and MCL-1 [319–321,362–364,368,369]. miR-153 also has 
low expression in cancer cell lines versus normal tissue [370,371] and overexpression 
of miR-153 reduces cancer cell line viability [372]. This tumor suppressor activity may 
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be mediated by inhibitory targeting of anti-apoptotic and pro-survival pathways. Two 
demonstrated targets of miR-153 in glioblastoma multiforme cell lines include B-cell 
lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1), two anti-apoptotic 
proteins [372]. miR-153 also downregulates insulin receptor substrate 2 (Irs2), thereby 
inhibiting the pro-survival effect of the PI3K/Akt signaling pathway [373]. In drug-
resistant leukemic cancer cells, miR-153 has been shown to be downregulated. 
Restoring miR-153 levels in these cells was shown to sensitive them to As2O3-induced 
apoptosis [374]. Finally, in an experimental model of pulmonary fibrosis, miR-153 was 
upregulated, with its pro-apoptotic activity hypothesized to contribute to disease etiology 
[375].      
 
D. APP expression is stimulated by miR-346 via a non-canonical target site in the APP 
5’-UTR 
While most miRNA regulatory interactions are limited to the mRNA 3’-UTR 
[245,303,376] primarily due to the abrogating effect of translation on the efficacy of 
miRNA target sites [224], there are many reported examples of effective miRNA 
targeting in the 5’-UTR or CDS [324,325,377–380]. Therefore, the complete APP 3’-
UTR sequence was scanned for potential miRNA target sites using the RegRNA web 
server. A putative target site for miR-346 in the APP 5’-UTR was noted for its exact 
overlap with a known IRE stem-loop sequence previously shown to regulate APP 
translation in response to iron homeostasis [143,144]. miR-346 strongly upregulated 
expression of an APP 5’-UTR reporter and endogenous APP protein in HeLa cells. Site 
mutagenesis and target protector transfections demonstrated that these effects were 
mediated by specific interaction with the predicted 5’-UTR target site. This regulatory 
effect was also observed in primary human fetal brain mixed cultures but only after iron 
chelation with deferroxamine. Therefore, miR-346 has non-canonical regulatory effects 
169 
 
(stimulation) on APP expression via a non-canonical target site in the APP 5’-UTR. 
Inhibiting this interaction might be a viable strategy for reducing APP expression and 
resulting Aβ production in the AD brain. 
While the vast majority of validated miRNA:mRNA target interactions involve 
inhibition of target expression, there are several examples in the literature of stimulatory 
effects on target expression (for review, see [226]). In fact, Tsai et al. report that miR-
346 has a very similar regulatory relationship with receptor interacting protein 140 
(RIP140) as that observed here with APP [380]. Specifically, they demonstrated that the 
RIP140 5’-UTR stimulates RIP140 translation and contains a non-canonical miR-346 
target site. miR-346 antisense inhibition reduced the stimulatory action of this sequence 
segment. They further demonstrated that miR-346 directly binds to the RIP140 5’-UTR 
via the predicted target site. Therefore, positive regulation of mRNA targets by miR-346 
via 5’-UTR target sites may represent a common mechanism employed by human cells 
for regulating gene expression. 
Other examples of stimulatory miRNA interactions have also been reported. The 
transition of proliferative HEK293 and HeLa cells to a quiescent state (i.e. G0 state) 
following serum starvation triggers a switch in the regulatory program for several 
miRNA:mRNA target interactions from translational repression to translational activation 
[381]. This phenomenon of switching between repression and activation depending on 
cell cycle state was observed for interactions between miR-369-3p and TNFα 3’-UTR 
AU-rich element (ARE) and for let-7 and the HMGA2 3’-UTR. The activating state 
requires the interaction of AGO2 with FXR1a [381]. Similarly, in xenopus oocytes (i.e. 
naturally quiescent cells) miR-16 activates Myt1 expression by interacting with the 3’-
UTR [382]. Upregulation of this kinase maintains the induced quiescent state of the 
oocyte. miR-466l interacts with an ARE in the IL-10 3’-UTR of TLR-triggered 
macrophages and upregulates IL-10 expression by stabilizing the transcript [383]. The 
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mechanism of this effect involves the competition of miR-466l with tristetraprolin (TTP), 
a RNA-binding protein that normally binds the ARE and promotes mRNA degradation. 
miR-34a and miR-34b-5p bind to the 3’-UTR of an alternatively polyadenylated mouse 
β-actin transcript and upregulate translation [384]. Finally, many ribosomal protein 
mRNAs harbor a 5’ terminal oligopyrimidine (TOP) motif that mediates inhibitory effects 
on translation during cell cycle arrest or during nutritional deprivation. miR-10a binds to 
the 5’-UTR of many of these transcripts downstream of the 5’TOP motif and stimulates 
translation, a phenomenon with significant implications for global protein synthesis 
[324]. While miRNA:mRNA interactions that activate expression represent only a small 
minority of all miRNA:mRNA regulatory interactions, there are clearly a number of 
precedents for this type of biological function.   
Aside from its role in upregulating APP and RIP140 expression, miR-346 has 
been implicated in other biological pathways. miR-346 inhibits the release of TNFα from 
synovial cells by stimulating the expression of TTP that binds to the TNFα ARE and 
promotes mRNA degradation [385]. miR-346 appears to stimulate TTP expression by 
inhibiting the transcription of Bruton’s tyrosine kinase (Btk), perhaps by negatively 
regulating a transcription factor involved in Btk transcriptional regulation. As a result, 
miR-346 has been ascribed immunomodulatory functions [385,386]. miR-346 is also 
overexpressed in follicular thyroid carcinoma [387]. Overexpression of miR-346 induces 
cell proliferation in human cell lines, suggesting that miR-346 may promote 
carcinogenesis. An analysis of predicted miRNA:mRNA interactions for schizophrenia-
associated gene products revealed that miR-346 contains a higher rate of predicted 
interactions than expected by chance [388]. miR-346 expression was also found to be 
decreased in the brains of schizophrenic and bipolar patients relative to control patients. 
Interestingly, pri-miR-346 is hosted in intron 2 of a known schizophrenia susceptibility 
gene, glutamate receptor delta 1 subunit (GRID1) [389]. However, expression of miR-
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346 appears to be driven independently from GRID1 expression based on miR-346-
GRID1 correlation analyses [386,388].  
Finally, miR-346 has been implicated in the unfolded protein response (UPR) 
[386]. This biological pathway is induced under conditions of ER stress that result in 
accumulation of unfolded proteins in the ER. Activation of this pathway results in the 
inhibition of global protein production (to reduce ER protein load) and targeted induction 
of gene expression for products that increase ER protein folding capacity [390]. The 
expression of miR-346 is increased following the induction of UPR via a mechanism 
involving transcriptional induction by UPR-linked transcription factor XBP1 [386]. 
Interestingly, this leads to decreased expression of TAP1 through direct interactions 
between miR-346 and the TAP1 3’-UTR. TAP1 is an ATP-binding cassette transporter 
that translocates antigens derived from proteasomal processing into the ER lumen for 
loading onto MHC antigen receptors. miR-346 also decreases MHC class I gene 
expression via indirect interactions, further implicating miR-346 as an 
immunomodulatory miRNA.  
Neurons in the AD brain are often invested with NFT consisting of aggregated 
hyperphosphorylated tau protein that might be expected to induce ER stress. Indeed, 
recent studies suggest that UPR is activated in pretangle neurons [391,392]. Given that 
UPR is active in the AD brain and that APP expression is elevated following UPR 
activation [393], it is reasonable to speculate that miR-346 expression may also be 
induced in certain cells of the AD brain and drive APP expression in pretangle neurons. 
Future studies investigating the regulatory relationship between miR-346 and APP 
during UPR are warranted. 
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E. Mechanism underlying stimulatory effect of miR-346 on APP expression 
Mechanisms involved in post-transcriptional miRNA-mediated inhibitory 
regulation are fairly universal and well described [327]. Generally, AGO2 as a member 
of the ternary miRISC recruits GW182 to the target transcript promoting further protein 
interactions that lead to translational inhibition and transcript deadenylation and 
degradation [227,229,230,237,238,240]. However, mechanisms underlying post-
transcriptional miRNA-mediated stimulatory gene regulation are poorly understood and 
each example may invoke a distinct mechanism involving different mediators and 
molecular interactions. 
To explore the mechanism underlying the stimulatory effect of miR-346 on APP 
expression, the involvement of proteins implicated in canonical miRNA biogenesis 
(Dicer) and function (AGO2) was first tested. The stimulatory response of APP to miR-
346 was significantly abrogated when expression of either Dicer or AGO2 was knocked 
down. This is in contrast to RIP140, where AGO2 was dispensable for the stimulatory 
effect mediated by miR-346 [380]. In this study, AGO2 knockdown almost completely 
abolished the increase in APP expression following miR-346 delivery, suggesting that 
AGO2 is required for this effect. Interestingly, AGO2 was originally discovered as a 
component of a molecular complex involved in translation initiation [394]. This function 
has since gone largely unexplored. Given the location of the miR-346 target site in the 
APP 5’-UTR, near the site of ribosome assembly, one possible explanation for the 
requirement of AGO2 is that it may mediate the stimulatory effect via its functionality in 
the process of translation initiation. Another possibility (discussed below) is that AGO2 
may be required to sterically inhibit interactions between trans-factors and the APP 5’-
UTR IRE.  
At first glance it seems curious that Dicer depletion reduced APP stimulation 
following miR-346 delivery since only mature miRNA mimics were transfected (i.e. 
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downstream of Dicer processing). However, Dicer along with TRBP is a component of 
the RISC-loading complex (RLC) involved in loading mature miRNA onto AGO proteins 
[212,395]. In this study, Dicer depletion have may resulted in less efficient loading of 
miR-346 mimic onto AGO proteins, thereby explaining the effect of Dicer knockdown on 
APP stimulation. It should be noted that not all studies are in agreement on the role of 
Dicer as a necessary component for small RNA loading onto AGO proteins [396].  
Since the miR-346 target site in the APP 5’-UTR directly overlaps with a known 
IRE, the hypothesis that miR-346 interferes with normal iron-based regulation of APP 
expression was next tested. Jack Rogers and colleagues previously demonstrated that 
the APP 5’-UTR IRE forms a stem-loop structure that binds to IRP1 but not IRP2 
[143,144]. IRP1 inhibits APP translation when bound to the 5’-UTR IRE. When iron 
levels are increased, IRP1 binds free iron and dissociates from the APP mRNA allowing 
translation to proceed uninhibited. When iron levels are decreased (such as with iron 
chelation), free iron dissociates from IRP1 allowing IRP1 to bind to the APP 5’-UTR IRE 
and inhibit APP translation. IRP1 knockdown significantly (but not completely) 
attenuated the stimulatory effect of miR-346 on APP expression, confirming that 
functional IRP1 is essential for miR-346 stimulation of APP expression. This strongly 
supports the hypothesis that miR-346 stimulates APP expression by competing with 
IRP1 for interaction at the APP 5’-UTR IRE (i.e. relief of repression). A model of this 
posited interaction is illustrated in Figure 40.  
If this hypothesis is correct, one implication is that iron treatment would be 
expected to reduce the stimulatory effect of miR-346, whereas iron chelation would be 
expected to augment the stimulatory effect due to enhanced IRP1 association with IRE. 
Indeed, in primary human fetal brain mixed cultures, miR-346 transfection under normal 
culture conditions had little effect on APP expression. However, after iron chelation, 
miR-346 delivery significantly enhanced APP expression. Again, this is consistent with 
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the hypothesis that miR-346 stimulates APP expression via interactions with IRP1. 
While this data is highly suggestive, it does not directly confirm the validity of the model 
presented in Figure 40. Future experiments to confirm that IRP1 interaction with the 
APP IRE is disrupted by miR-346 delivery and to test whether miR-346 inhibition alters 
APP expression under conditions of iron treatment or chelation are warranted. 
One explanation as to why iron homeostasis might regulate APP levels is that 
APP has ferroxidase activity [397]. This activity oxidizes ferrous iron (Fe2+), the form 
that participates in the Fenton reaction producing hydroxyl radicals, to the less toxic 
ferric form (Fe3+) without producing reactive oxygen species (ROS). Additionally, this 
ferroxidase activity promotes the export of iron from the cytosol to the extracellular 
space. Therefore, enhancing APP expression in the presence of elevated iron levels 
would help to maintain iron homeostasis and prevent oxidative stress. Aside from the 
role of iron in regulating APP expression, iron is known to accumulate in amyloid 
plaques of the AD brain [398,399]. Iron binds to Aβ and slows the normal ordered 
progression of Aβ to higher ordered aggregates, such as fibrils. This altered 
aggregation process in the presence of iron promotes Aβ toxicity in neuronal cells [400]. 
Iron bound to Aβ also accelerates the formation of ROS through various redox 
chemistries resulting in lipid peroxidation and other oxidative insults [401–403]. As 
such, therapies that modulate iron homeostasis in the AD brain have been proposed as 
a means of reducing Aβ-associated iron toxicity and reducing APP translation and Aβ 
production [404,405].  
General iron chelation therapy in AD is likely a poor strategy since global effects 
are likely to arise, such as iron-deficiency anemia. However, metal-complexing agents 
that have more targeted and less systemic effects on metal ion binding and 
redistribution have been synthesized and are termed metal-protein attenuating 
compounds (MPAC) [404,406]. As an example, XH1 is a compound containing both Aβ-
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binding moieties and metal chelating moieties that are covalently linked. Therefore, 
chelating properties of XH1 are targeted to regions where this activity is salutary. XH1 
has been shown to reduce APP protein expression in neuronal cells [407]. 
 Based on the results presented in this dissertation, it is reasonable to speculate 
that therapeutic reduction of intracellular iron in the AD brain as a means to reduce APP 
translation might be mitigated by endogenous miR-346 expression and its competitive 
interactions with IRP1 binding at the APP 5’-UTR IRE. Therefore, miR-346 inhibition is 
likely to synergize with therapeutic strategies to modulate intracellular iron homeostasis 
as a means to reduce APP translation. 
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Figure 40: Speculative model of predicted miR-346 interaction with IRP1 in the 
APP 5’-UTR. (A) Schematic of APP 5’-UTR with the approximate locations of the miR-
346 target site and IRE along with other molecular players including miR-346 loaded 
into RISC, IRP1 and free iron (Fe). (B) In the case when free intracellular iron levels 
and miR-346 levels are low, IRP1 binds to the IRE and inhibits mRNA translation. (C) 
When iron is present, IRP1 dissociates from the APP IRE and translation is disinhibited. 
(D) When iron is absent, IRP1 would normally bind and inhibit translation. But when 
miR-346 levels are appreciable, its interactionwith the 5’-UTR target site might sterically 
interfere with IRP1 binding and promote translation. 
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F. Other APP-targeting miRNA 
miR-101, miR-153 and miR-346 are not likely to mediate their regulatory effects 
on APP expression in isolation. Indeed, regulatory interactions between APP and other 
miRNA have already been reported (as reviewed in [408,409]). The studies presented 
in this dissertation focused on miR-101 and miR-153 have been previously published in 
part [410,411]. Importantly other labs have independently verified the results presented 
here for miR-101 and miR-153 [361,412,413]. Other miRNAs reported to negatively 
regulate APP expression include miR-147 [413], the miR-20a family (miR-20a, -17, -
106b) [276,338], miR-106a, miR-520c [318], and miR-16 [414]. Some, but not all, of 
these studies have demonstrated physiological regulation of APP expression by these 
miRNA. The presence of AD-specific SNPs in the APP 3’-UTR has been shown to 
interfere with the ability of several miRNA to regulate APP expression [413]. Finally, 
miR-124 has been shown to direct neuron-specific APP mRNA alternative splicing 
[274]. Apparently human cells utilize an extensive repertoire of miRNA, including miR-
101, miR-153 and miR-346, to regulate APP expression and processing. Elucidating 
this complete network is still an ongoing effort.  
 
II. Novel miRNA interactions with the APP mRNA regulate BACE1 expression 
 
A. The BACE1 3’-UTR inhibits basal expression 
The presence of the human BACE1 3’-UTR inhibited reporter expression in 
three different human cell lines tested, consistent with reports on the mouse BACE1 3’-
UTR [415]. This is in contrast to the APP 3’-UTR, which stimulated reporter expression. 
One possible explanation for the regulatory effect of the BACE1 3’-UTR on reporter 
expression is the presence of multiple MRE located in the 3’-UTR interacting in a 
synergistic fashion with endogenously expressed miRNA. The presence of other 
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inhibitory or stimulatory regulatory elements in the 3’-UTR cannot be ruled out but none 
have been reported thus far in the literature. An important distinction between the APP 
3’-UTR and BACE1 3’-UTR is length. The BACE1 3’-UTR is significantly longer than the 
APP 3’-UTR (3.9 kb vs 1.2 kb), providing a more expansive UTR workspace upon 
which favored regulatory interactions between various trans-acting factors (e.g. 
miRISC) and cis regulatory elements (e.g MRE) may have been molded by evolutionary 
pressures. Specific mechanism aside, the general integrated response of all regulatory 
influences directed through the BACE1 3’-UTR in human cells appears to be reduction 
in transcript translation or stability. 
 
B. BACE1 expression is inhibited by miR-339-5p via target sites in the BACE1 3’-UTR 
In silico analyses identified multiple putative miRNA target sites in the BACE1 
3’-UTR. Of these predicted interactions, miR-339-5p potently inhibited BACE1 3’-UTR 
reporter expression. This functional activity of miR-339-5p was mediated via interaction 
with two poorly conserved target sites in the BACE1 3’-UTR. BACE1 protein levels were 
dramatically decreased following miR-339-5p transfection in U373 cells and less 
potently so in primary human fetal brain cultures. Finally, endogenous miR-339-5p 
regulates basal BACE1 expression in primary human fetal cultures as evidenced by 
elevated BACE1 expression following target protector transfection. Therefore, miR-339-
5p is a putative drug target for AD. Direct miR-339-5p delivery or targeting pathways 
that elevate expression of endogenous miR-339-5p may represent viable therapeutic 
strategies. 
miR-339-5p has been implicated in other physiological and pathological roles 
aside from its regulatory effects on BACE1 expression, including hematopoiesis, 
various cancers and neural tube defects (NTD). More specifically, miR-339-5p 
expression was shown to vary during the course of in vitro erythroid differentiation and 
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is predicted to target gene products (EpoR and STAT-5) previously implicated in 
erythroid differentiation [416].  
The role of miR-339-5p in cancer is still unsettled and may vary by tissue origin. 
miR-339-5p expression is significantly upregulated in B-cell precursor acute 
lymphoblastic leukemia [417]. In contrast, its expression is significantly decreased in 
highly invasive breast cancer cell lines (MDA-MB-231 and MDA-MB-468) as compared 
to poorly invasive cell lines (MCF7) [418]. Reduced expression was also observed in 
breast cancer tissue with lymph node metastasies as compared to breast cancer tissue 
without node metastases. This study also showed that miR-339-5p had no effect on cell 
proliferation but that overexpression inhibited breast cancer cell migration while 
inhibition enhanced migration. This effect may be mediated by the inhibitory effect of 
miR-339-5p against BCL6. Finally, endogenously expressed miR-339-5p in colorectal 
cancer cell lines and glioblastoma multiforme cell lines apparently reduces susceptibility 
of malignant cells to cytolysis by cytotoxic T lymphocytes (CTL) by inhibiting expression 
of ICAM1 [419,420]. ICAM1 expression in malignant cells is necessary for proper 
adhesion of CTL to antigen-presenting malignant cells. In toto, these studies suggest 
that miR-339-5p suppresses the malignant potential of transformed cells in some forms 
of cancer but not necessarily others. 
miR-339-5p may play a detrimental role in NTD. A NTD-prone animal model, 
Splotch (Pax3 -/-), that can be rescued from NTD development by folate 
supplementation was shown to have reduced expression of a lysine-specific 
demethylase, KDM6B [421]. Repressed KDM6B expression was shown to inhibit gene 
expression of several genes essential for normal neural tube formation (Hes1 and 
Neurog2) by promoting histone methylation at the promoters of these genes. Reduced 
expression of KDM6B in Splotch animals was likely mediated by increased expression 
of several miRNA, including miR-339-5p, that repressed KDM6B levels via interactions 
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with its 3’-UTR. Folate supplementation reversed dysregulated miR-339-5p expression, 
KDM6B expression, promoter methylation and Hes1 and Neurog2 expression in these 
animals [421]. 
 
C. Other BACE1-targeting miRNA 
As with APP, there is likely an extensive network of miRNA that act in 
collaboration with miR-339-5p to modulate BACE1 expression. While the full repertoire 
has not been elucidated, several BACE1-targeting miRNA have been described in the 
literature. miR-107 regulates BACE1 expression via interaction with a 3’-UTR target site 
and is downregulated early in the temporal cortex of the AD brain [266,273]. miR-107 
also associates with progranulin (PRGN) mRNA in the RISC complex and 
downregulates expression via interaction with a target site in the PRGN CDS [325]. This 
interaction is relevant because mutations in PRGN have been previously linked to 
frontotemporal dementia (FTD) [422,423]. miR-29a/b both downregulate BACE1 
expression via 3’-UTR target sites [189], and both have been reported to be 
downregulated in the AD brain [189,272]. Surprisingly, miR-29b has also been shown to 
downregulate PRGN expression but via interactions in the 3’-UTR, as compared to the 
CDS for miR-107 [424]. miR-29c also downregulates BACE1 expression in both cell 
culture and in vivo miR-29c transgenic animal models via a 3’-UTR target site [425]. 
miR-124 overexpression downregulates BACE1 expression while inhibition elevates 
BACE1 levels [333]. This finding has significant implications because miR-124 is one of 
the most abundant neuronal miRNAs and is decreased in the AD brain [265,274]. 
Additionally, it functions to regulate neuronal APP mRNA splicing as described above 
[274]. Finally, mouse (mmu) miR-298 and miR-328 also downregulate BACE1 via 
mouse BACE1 3’-UTR target sites [415].  
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III. APP and BACE1-targeting miRNA are dysregulated in the AD brain 
 
A. APP and BACE1-targeting miRNA exhibit correlative expression patterns with their 
target proteins consistent with co-regulation 
Experiments in aim 1 and 2 provided strong evidence that miR-101, miR-153, 
miR-346 and miR-339-5p regulate basal expression of APP or BACE1. Experiments in 
aim 3 added further evidence that these miRNA are physiologically relevant regulators 
of APP and BACE1 levels. This was first achieved by analyzing expression levels of 
miRNAs and APP or BACE1 during in vitro development of a human primary fetal brain 
mixed culture. These experiments demonstrated that the expression pattern of miR-346 
and, to a lesser extent, miR-153 correlated with the expression patterns of their APP 
target in a manner concordant with their expected regulatory effect on expression. 
Stated alternatively, the data support the supposition that changes in miR-153 and miR-
346 levels during in vitro development of this culture system aid in driving changes in 
APP or BACE1 expression.  
More specifically, miR-153 levels were highest at a time point in culture (DIV18) 
when APP levels were lowest. Therefore, it might seem reasonable to hypothesize that 
miR-153 contributes to the decrease in APP levels at later time points in culture. It is 
important to note, however, that the correlation coefficient for this analysis was non-
significant, as was the trend for increased miR-153 levels across time points. So, while 
the expression patterns are concordant with miR-153 repression of APP expression, 
statistical analysis does not support this interpretation. Analysis of miR-153 expression 
levels across various organs at different developmental time points in relation to 
another target, SNCA, demonstrated that miR-153 and SNCA were co-expressed rather 
than inversely expressed [342]. The study concluded that miR-153 was expressed as a 
component of a feedforward loop to fine-tune SNCA expression rather than completely 
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block expression. Further experiments would be required to determine whether a similar 
regulatory relationship exists between miR-153 and APP. 
In contrast, miR-346 patterns very similarly mirrored the pattern of APP levels 
across time in culture. Expression levels across time were significantly different for both 
miR-346 and APP, with highest levels at DIV 7. Correlation analysis of miR-346 and 
APP levels produced a non-zero correlation coefficient suggesting co-regulation. Since 
miR-346 stimulates APP expression, a reasonable hypothesis is that APP levels during 
culture development may be significantly driven by changes in miR-346 levels with time. 
 
B. APP and BACE1-targeting miRNA are expressed at functionally relevant levels in 
human brain 
Data from aims 1 and 2 demonstrate that miR-101, miR-153 and miR-346 
regulate APP levels and miR-339-5p regulates BACE1 levels in multiple human cell 
cultures. However, for these miRNA to be targeted therapeutically in AD, they must be 
expressed at relevant levels in the human brain. Therefore, absolute quantification 
miRNA expression analyses were performed on control specimens from two separate 
brain specimen cohorts. miR-124 exhibited highest expression levels of all the miRNAs 
tested. This is consistent with previous studies that have reported miR-124 as either the 
most abundant miRNA in brain or somewhere among the top ten [225,331,426]. Levels 
of miR-101 were significantly lower than miR-124 but still expressed at very high levels 
in the human brain. Global miRNA analyses in the human and rodent brain have also 
found that miR-101 is among the top 20 most abundant miRNA [225,426–428]. miR-
153 levels were lower than miR-101 levels but still present at significantl levels. miR-
346 and miR-339-5p levels were significantly lower than miR-153 levels. However, the 
actual copy counts per cell for each of these miRNA are still likely high enough to 
mediate regulatory effects. This statement is based upon the fact that expression levels 
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here were measured in post-mortem brain specimens, where miRNA decay is known to 
be rapid [255]. Given that PMI were fairly high in some specimens, especially in cohort 
2, it is likely that miRNA copy counts in living CNS cells are much higher than detected 
here.Consistent with the data reported here, studies suggest that miR-346 is highly 
enriched in the human brain with significantly higher expression than in other tested 
tissues [429]. Therefore, all miRNA examined were expressed and detectable in the 
human brain to varying degrees. 
The precise level of miRNA expression necessary for functional regulation is 
likely to vary for each combination of miRNA and mRNA target and their specific 
environmental context. Titration experiments have demonstrated that miRNA efficacy is 
influenced both by the levels of target expression as well as miRNA levels, such that 
target thresholds are generated around which target levels are highly sensitive to 
miRNA effects [241,242]. However, in some conditions as few as 100 miRNA copies 
per cell have been reported to be sufficient for repression [242]. By this standard, 
expression levels of miR-101, miR-153, miR-346 and miR-339-5p in the human brain 
would be sufficient to mediate their regulatory effects on APP and BACE1 expression. 
To confirm this would require in vivo miRNA inhibition experiments in animal models.   
 
C. APP and BACE1-targeting miRNA are dysregulated in AD brain specimens 
Given that miR-101, miR-153, miR-346 and miR-339-5p regulate APP and 
BACE1 expression and subsequent Aβ production, they might be considered novel 
drug targets for AD. If their expression is also dysregulated in AD, they represent even 
more attractive candidates since therapeutic targeting would also correct disease-
specific derangements in their expression levels. Therefore, expression analyses for 
these miRNA were extended to analyze for differential expression in AD samples 
versus controls. Both absolute and relative quantification schemes were employed to 
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ensure that normalization strategy did not bias results. Two separate and independent 
cohorts were analyzed. The first cohort consisted of low PMI specimens from non-
demented patients and patients with advanced AD pathology (Braak stage VI). The 
second cohort consisted of specimens spanning the range of Braak stages (control, 
Braak stage I/II[early AD], Braak stage III/IV[definite AD], Braak stage V/VI [severe AD]) 
but with significantly longer PMI on average compared to cohort 1. 
Both miR-101 and miR-346 expression levels were significantly decreased in 
AD specimens compared to control specimens in cohort 1. This trend remained 
significant when the control specimens were compared among a subset of AD patients 
that had not been treated with AD therapeutics (NoRx). Also, the trend was observed 
using both relative and absolute quantification strategies, indicating that the difference 
could not be explained by normalization bias. Decreased miR-339-5p expression was 
also observed in AD specimens from this cohort, but only with absolute quantification 
and not relative quantification strategies. 
Interestingly, decreased miR-101 expression in AD specimens is a consistently 
observed phenomenon, having been reported in three independent microarray-based 
studies [189,268,430]. On the other hand, to the author’s knowledge there are no 
reports in the literature of differentially expressed miR-346 or miR-339-5p in the AD 
brain. One potential explanation is that most studies have employed global miRNA 
analyses that must be statistically corrected for a high number of multiple comparisons. 
Therefore, the statistical power of these analyses may have been too low to detect the 
decrease observed here. Alternatively, CNS expression levels of miR-346 and miR-
339-5p may be too low to readily detect using probe-based microarray protocols.  
Importantly, the finding of decreased miR-346 expression in AD specimens was 
also observed in independent cohort 2. Surprisingly, no differences in miR-101 or miR-
339-5p levels were observed in cohort 2 samples. However, the specimens in this 
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cohort are very different in that the AD specimens have on average less pathology and 
were obtained at earlier stages of disease progression than the average AD specimen 
from cohort 1. Therefore, it may not be reasonable to expect cohort 2 to exactly 
replicate the expression patterns in cohort 1.  
In cohort 2, miR-153 levels were significantly decreased in postmortem brain 
specimens containing more advanced NFT pathology (Braak stage III – VI) as 
compared to specimens with none or only mild NFT pathology. Interestingly, APP levels 
were significantly increased in Braak stage III/IV specimens. This raises the intriguing 
possibility that the decrease in miR-153 in these specimens may at least partially 
underlie the elevated APP levels. One might question why dysregulated expression of 
miR-153 and APP is not represented progressively across Braak stages. One 
consideration in response is that all these specimens were derived from the frontal 
cortex (BA9) – a region that only begins to become invested with neurofibrillary 
pathology (the basis for Braak staging) in stages III and IV of the disease [13]. A second 
consideration is that changes in miR-153 and APP expression would be expected to 
contribute to amyloid pathology in the AD brain. The development of amyloid and 
neurofibrillary pathology do not initially overlap anatomically and do not progress with 
direct linear correlations between each other in the AD brain [12]. Therefore, one might 
not expect dysregulation of APP and miR-153 to vary linearly with Braak staging.  
This author is not aware of any previous study that has identified miR-153 as 
being dysregulated in AD. One study specifically measured miR-153 levels in AD brain 
using a DNA dot blot array but was unable to detect any miR-153 expression in 
specimens due to low sensitivity [265]. Since most of these studies did not segment 
brain specimens by severity of NFT pathology (Braak staging), one would not 
necessarily expect that the decrease in miR-153 expression observed here would be 
replicated in these studies. 
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Despite reports of elevated BACE1 expression in AD brain specimens 
[189,431], no significant differences in BACE1 or APP expression were observed in 
either cohort. As such, no correlations between miRNA expression and APP or BACE1 
expression were present. However, built in redundancies that homeostatically control 
gene expression are likely to be utilized by cells, especially in chronic pathological 
conditions like AD, to reduce the impact of changes in any given regulator of gene 
expression. Given this layer of complexity, it may not be reasonable to expect a simple 
inverse relationship between miRNA and target expression patterns in the AD 
specimens analyzed here. 
Certain caveats in this analysis should be addressed. First, the sample size here 
is small (n=5 – 10 per group for cohort 2; n=5 – 15 for cohort 1) and the reliability of the 
findings would be greatly aided if they were observed in independent cohorts of larger 
sample size. Second, RNA integrity of some samples in cohort 2 was rather low due to 
prior processing of specimens, possibly introducing bias into the analysis. However, 
specimens in the late stage AD categories (Braak stage III – VI) were not preferentially 
represented among the low RNA integrity extracts. The low integrity extracts also did 
not demonstrate detectably higher Ct values or lower normalized miR-153 expression 
values (data not shown). Again, replication of these findings in an independent cohort of 
low PMI specimens and high RNA quality extracts would address these concerns. It 
should also be noted that procuring a large sample of high quality, low PMI AD brain 
tissue spread across Braak stages is a significant challenge. A final caveat is that one 
cannot rule out that the “dysregulation” of miR-101, miR-346, miR-339-5p and miR-153 
along with APP in cohort 2 might be an epiphenomenal manifestation of cell type 
distribution changes that occurs during the progression of AD. During the course of 
disease, neurons are lost and astrogliosis results in increased relative numbers of glia 
to neurons [432]. Therefore, changes at the molecular levels may simply reflect 
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changes in cell types. However, both APP [433] and miR-153 [342] are more highly 
expressed in neurons than astrocytes suggesting that the changes observed in cohort 2 
cannot be solely explained by changes in cell type distribution. Clarification could be 
provided by the analysis of miR-101, miR-346, miR-339-5p and miR-153 by in situ 
hybridization (ISH) and APP by immunohistochemistry (IHC) in sections from 
specimens across Braak stages. ISH and IHC allows for cellular level resolution of 
miRNA and protein levels, respectively.  
Other studies have profiled miRNA expression in the AD brain [189,265–
268,274,276] and in peripheral blood mononuclear cells [269] and identified miRNA that 
are dysregulated (e.g. miR-107, miR-29a/b, miR-106b, miR-124, etc.) [see [270] for 
review]. miR-107, miR-29b and miR-124 were all assayed in cohort 1 of this study as 
well. While all demonstrated a decreasing trend in expression from these AD 
specimens, these trends were not statistically significant. This either suggests that the 
sample size in this study was too low to detect true expression changes or that the AD 
cohorts analyzed here have different underlying molecular etiologies contributing to 
miRNA dysregulation as those analyzed in earlier studies.  
It is important to point out that not all aspects of study design were completely 
optimal in the brain cohort analyses presented here. Great lengths were taken to obtain 
cohort samples isolated following short PMI with high quality RNA extracts. Also, both 
relative and absolute quantification strategies were employed to prevent bias 
associated with a specific normalization method. These strategies were successful in 
allowing the detection of statistically significant changes in miRNA expression levels 
between AD and control specimens. However, these studies were necessarily limited to 
inter-subject comparisons between control specimens and diseased specimens. A more 
robust study design would allow for within-subject comparisons between affected and 
188 
 
unaffected regions to normalize for inherent variation in specimen characteristics and 
PMI.  
In an optimally designed study, tissue from the entorhinal cortex (EC) and 
dentate gyrus (DG) would be analyzed from each subject. The entorhinal cortex is one 
of the cortical regions first affected in AD, as determined by previous functional imaging 
and neuropathological observations [12,13,434,435]. Therefore, derangements in 
miRNA expression that contribute to AD pathogenesis or progression would be 
expected to occur most significantly and at the earliest time points in the EC. In 
comparison, the DG exhibits age-dependent decreases in functionality with age but, 
unlike the EC, is relatively spared functional deficits and pathological abnormalities 
associated with AD [4]. Importantly, the EC and DG share the same vascular supply 
and should experience the same levels of hypoperfusion or oxygen deficit that occur 
immediately prior to and after death. Given that the physiological changes associated 
with death can dramatically alter gene expression and are highly variable depending on 
the cause death, within-subject comparisons of differential gene expression in the EC 
versus the DG would be most likely to discriminate betwen true miRNA expression 
changes associated with AD from noise accompanying the death process. Such 
approaches have been successfully used in microarray studies of differential mRNA 
expression in AD [436,437]. A two-way mixed model ANOVA to identify miRNA 
expression changes differentially expressed in EC relative to DG specific to AD-derived 
specimens could then be implemented. 
 
IV. Special considerations for therapeutically targeting miR-101, miR-153, miR-
346 and miR-339-5p in AD 
The results of this dissertation suggest that miR-101, miR-153, miR-346 and 
miR-339-5p represent novel targets for the therapeutic modulation of APP, BACE1 and 
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Aβ levels in AD. These are especially attractive candidates given that their levels are 
decreased in at least a subset of AD patients. Assuming that this decrease is 
pathological and not compensatory, modulating their levels would produce salutary 
effects not only on Aβ but also on other mRNA targets whose levels might be deranged 
as a result. Prior to pursuing therapeutic modulation of any of these miRNA, validation 
of beneficial effects on AD-like pathology or cognition in appropriate AD animal models 
would be instructive. 
An important consideration when manipulating miRNA levels is that miRNA 
targeting can be quite promiscuous (i.e. hundreds of predicted targets for each miRNA). 
This might be seen as both a negative and positive attribute from the perspective of 
miRNA therapeutics. miRNA level manipulation might produce unanticipated side 
effects resulting from regulatory actions on gene products outside of AD-implicated 
biological pathways. However, recent studies suggest that many predicted miRNA 
target sites may not be physiologically active and instead interact with and competitively 
sequester away miRNA from bona fide targets [246,247,438]. Further, a majority of 
miRNA:mRNA interactions lead to only subtle effects of protein output [245]. Therefore, 
the extent of unwanted effects resulting from miRNA promiscuity may not be as 
extensive as first appears based on the number of predicted interactions. miRNA level 
manipulation might also produce synergistic salutary effects if multiple gene products 
implicated in the same biological pathway or pathological process are targeted by a 
given miRNA either by chance or as a result of evolutionary pressures. In this case, 
therapeutically modulating the levels of a single miRNA may have more profound 
disease-antagonizing effects than miRNA targeting a single transcript. Potential 
examples of this scenario have been highlighted above, such as miR-153 targeting both 
APP and SNCA or miR-101 targeting both APP and autophagy pathways.  
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An analysis of predicted transcript targets of miR-101 listed in Table 9 revealed 
many targets with sites more favorable than the miR-101 site in APP. This list may at 
first glance suggest that miR-101 off-targeting effects would be too great for therapeutic 
manipulation. However, among these targets included tumor suppressor genes, 
autophagy genes and genes involved in neurodegenerative processes. For these 
specific targets, therapeutically elevating miR-101 expression might be expected to 
have synergistic effects on amyloidogenic processing of APP. Therefore, the 
anticipated results of therapeutically modulating miRNA expression cannot be assumed 
by default to be deleterious. Instead, careful observation of phenotypic changes in 
animal models following therapeutic modulation would be necessary to discriminate 
deleterious versus beneficial outcomes of off-target effects. 
Strategies that increase intracellular levels of miR-101, miR-153 and miR-339-
5p and that decrease levels of miR-346 or inhibit miR-346 interaction with the APP 
transcript in the human brain would be necessary to decrease APP or BACE 1 levels. 
Combining miR-346 inhibition with MPAC therapy would also be expected to have more 
robust APP-modulating effects, as described above. Direct delivery of miRNA mimics, 
antisense miRNA inhibitors or miRNA target protectors into cells is one strategy. Direct 
delivery of these therapeutics by systemic injection can be achieved for organ systems 
such as the liver [439], heart [440] and lungs [441] where parenchymal cells are in close 
communication with the systemic blood circulation. Modifications that stabilize the 
oligonucleotides in circulation (e.g. 2’O-methyl modifications, phosphothiorate linkages, 
locked nucleic acids (LNA), peptide nucleic acids) or promote cellular uptake (e.g. 
cholesterol conjugation) are generally employed [438,442,443]. As an example, liver-
expressed miR-122 promotes hepatitis C virus (HCV) RNA replication and its 
accumulation in hepatocytes [444]. This has been exploited therapeutically to reduce 
HCV viral load in infected chimpanzees by inhibiting miR-122 with intravenously 
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injected LNA antisense inhibitors [445,446]. This LNA-based anti-HCV therapeutic 
(miravirsen) is now being developed for use in humans and is the first miRNA-based 
therapeutic to enter clinical trials (ClinicalTrials.gov). Other strategies for delivering 
miRNA mimics or inhibitors in the periphery include loaded nanoparticles [447,448] and 
transgene-expressing viral particles [449,450], among others. 
Delivery of oligonucleotide-based therapeutics to the CNS remains difficult 
because few viable strategies have been devised to effectively mobilize the molecule 
across the blood-brain barrier (BBB). This would remain the biggest impediment to any 
attempt to modulate levels of miR-101, miR-153, miR-346 or miR-339-5p 
therapeutically in AD. Most methods for delivery in the brain experimentally require 
direct intracranial injection, either as synthetic nucleotides [414] or transgene-
expressing viral particles [451]. A recent, innovative strategy employs dendritic cell-
derived exosomoes engineered to express Lamp2b-rabies virus glycoprotein (RVG) 
fusion protein [194]. The exosome preparation is then loaded with small RNA molecules 
by electroporation, followed by systemic intravenous administration in mouse. The RVG 
peptide directs the exosome across the BBB with specific uptake by CNS neurons 
[194]. This study demonstrated that BACE1 expression was specifically knocked down 
in the mouse brain following systemic administration of BACE1 siRNA-loaded 
exosomes [194]. Such a strategy might be pursued for delivery of miRNA therapeutics 
in the human CNS. 
An alternative strategy for modulating miR-101, miR-153, miR-346 and miR-
339-5p activity is to identify small molecules that either inhibit or augment specific 
miRNA function, either by altering expression or otherwise modifying biological 
behavior. Of course, this is not a straightforward proposition and rational design of small 
molecules for this purpose may be impossible. Recent high throughput screening 
approaches have identified small molecules from large libraries that do exhibit miRNA 
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modulating properties [452,453]. Additionally, two recent studies have demonstrated 
that treating transformed cell lines with chromatin-modifying drugs can induce miR-153 
expression by demethylating the miR-153 promoter and promoting histone acetylation 
[373,454]. How these manipulations would translate to neurons, where miR-153 
expression is relatively high and chromatin structure might already favor transcription, is 
yet to be determined. Regardless of application to neurons, these studies demonstrate 
proof-of-principle for modifying miR-153 and potentially other miRNA therapeutically by 
small molecules.  
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CHAPTER 5: FUTURE DIRECTIONS 
While the results presented here are compelling, functional data are restricted to 
the in vitro setting. Several future studies are therefore essential for further evaluating 
the therapeutic suitability of miR-101, miR-153, miR-346 and miR-339-5p in AD. These 
experiments would explore the effect of manipulating miRNA levels in AD animal 
models. Appropriate AD animal models for these experiments must fulfill certain criteria. 
First, the animal models must obviously replicate aspects of AD pathology. Second, the 
animal models would ideally express human forms of APP and BACE1 mRNA, since 
some target sites identified above are poorly conserved across species (e.g. miR-346 
target site in APP 5’-UTR and miR-339-5p target sites in BACE1 3’-UTR). Finally, the 
animal models should express the full length transcripts so that 5’-UTR and 3’-UTR 
miRNA target sites are expressed. Most AD transgenic mouse models primarily employ 
overexpression of mutant human APP (hAPP), mutant human presenilin, mutant human 
tau or a combination thereof. Most also do not express full-length hAPP cDNA 
[455,456]. Therefore, the most commonly used AD animal models would not be 
appropriate for testing the therapeutic suitability of miR-101, miR-153, miR-346 and 
miR-339-5p.  
An appropriate AD model for testing in vivo modulation of miR-101, miR-153 
and miR-346 is the R1.40 model. This model was created by genomic integration of a 
yeast artificial chromosome encoding the complete hAPP gene sequence containing 
the FAD Swedish mutation, plus large tracts of flanking DNA on either side of the hAPP 
gene [457]. Crucially, this model overexpresses full-length APP transcripts, including 
the 5’-UTR and 3’-UTR, and is driven by the natural human APP promoter. Therefore, 
this model would allow for direct assessment of miRNA modulation on hAPP 
expression. Due to the presence of the Swedish mutation, these animals preferentially 
produce Aβ42 at high levels and develop cortical neuritic plaques and dystrophic 
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neurites that exhibit some degree of tau hyperphosphorylation [457]. These animals 
also exhibit deficits in long-term retention memory and working memory that correlates 
with the levels of Aβ pathology [459]. Therefore, all criteria are fulfilled by this model 
system.  
For testing miR-339-5p modulation of BACE1 expression in vivo, a bacterial 
artificial chromosome transgenic has been created that contains the complete human 
BACE1 gene and large flanking regions [460]. When crossed with Tg2576 mice, the 
resulting mice demonstrate enhanced AD pathology. Therefore, this animal could be 
potentially used as a model system for testing therapeutic modulation of miR-339-5p. 
Experiments utilizing these animal models would test for corrections of AD 
pathology and cognitive deficits following delivery of miRNA mimics or inhibitors. 
Methods for delivery have been described above and include direct intracranial injection 
of synthetic molecules, transgene-expressing viral particles, loaded nanoparticles, or 
neutral lipid emulsions and systemic, intravenous injection of miRNA-loaded exosomes 
engineered for CNS delivery. Following delivery, brain specimens would be analyzed 
for changes in APP or BACE1 expression and the extent of AD-like pathology. 
Improvements in cognitive functioning could also be tested using behavioral paradigms, 
such as the spontaneous alteration Y-maze test and Morris water maze, as previously 
described [459]. 
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CHAPTER 6: SUMMARY 
This dissertation tested the hypothesis that miRNA are relevant regulators of 
APP and BACE1 expression. The results demonstrate that miR-101, miR-153 and miR-
346 regulate APP expression in cultured cells from the fetal human brain by interacting 
with specific sites in the APP 5’-UTR and 3’-UTR. For miR-101 and miR-153, this effect 
on APP expression modulates Aβ production. While miR-101 and miR-153 inhibit APP 
expression, miR-346 stimulates APP expression through a mechanism that may involve 
competition with components of the iron regulatory system. This work also 
demonstrates that miR-339-5p regulates BACE1 expression via specific sites in the 
BACE1 3’-UTR and is expected to modulate Aβ production. Expression levels of miR-
153 and miR-346 co-vary with their target, APP, during the course of in vitro 
development of primary human brain cultures, suggesting co-regulation. miR-101, miR-
153, miR-346 and miR-339-5p are all expressed to varying degrees in the human brain, 
with miR-101, miR-346 and miR-153 dysregulated in the AD brain at different stages of 
the disease. Based on their Aβ-modulating properties, these miRNA might be viable AD 
drug targets, with miR-101, miR-153 and miR-346 especially attractive based on 
dysregulated levels in the AD brain. In the future, a series of feasible experiments in 
relevant AD animal models should further clarify the suitability of miR-101, miR-153, 
miR-346 and miR-339-5p as bona fide therapeutic targets. 
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APPENDIX  
Immunocytochemical characterization of primary human fetal brain cultures 
 
Note: Most of the experimentation described in this appendix was performed by Dr. Ray 
Balmiki, with additional data analysis provided by the author.  
 
Method 
Human fetal brain cultures were fixed in 4% paraformaldehyde for 15 minutes, 
washed three times with chilled PBS, and then permeabilized with 0.12% Triton X-100 
(Sigma-Aldrich, St Louis, MO) for 10 minutes. Permeabilized cells were blocked with 
10% horse serum for 15 minutes followed by overnight incubation with primary 
antibodies.  
Primary antibodies used in this study include a mouse pan-neuronal antibody 
cocktail (Millipore) active against neurites, neuronal nuclei and neuronal cell bodies, 
rabbit anti-GFAP (Sigma-Aldrich, St Louis, MO) for astrocyte labeling, and rabbit anti-
nestin (Sigma-Aldrich, St Louis, MO) for neural stem cell labeling. Cells were incubated 
for 1 hr in secondary antibodies: biotin-conjugated donkey anti-mouse (Jackson 
ImmunoResearch, West Grove, PA) and Cy3-conjugated donkey anti-rabbit (Jackson 
ImmunoResearch, West Grove, PA). Fluorescein-conjugated streptavidin (Jackson 
ImmunoResearch, West Grove, PA) was employed to label biotin-conjugated 
secondary antibody. Nuclei were visualized using Hoechst stain (Sigma-Aldrich, St 
Louis, MO) and labeled cells were examined under a Leica DMIL HC inverted 
fluorescence microscope (Leica Microsystems, Germany). Images were captured using 
a SPOT RT-SE digital camera (SPOT Imaging, Sterling Heights, MI). 
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Results 
To better characterize the distribution of cellular phenotypes in primary human 
fetal brain cultures, cells were fixed at specific time intervals during culture ranging from 
day in vitro (DIV) 8 to DIV 24. One set of cells was co-labeled with the combination of a 
pan-neuronal antibody cocktail designed to label neurites, cell soma and nucleus and 
anti-GFAP. A second set was co-labeled with anti-nestin and anti-GFAP.  
Early cultures (i.e. DIV 8) consisted almost entirely of cells co-expressing GFAP, 
nestin and neuronal markers (Figure A1 and A2). Later stage cultures (e.g. DIV 20) 
consisted of a mixture of cells. Some cells co-expressed GFAP and neuronal markers 
(Figure A1) or GFAP and nestin (Figure A2). Other cells expressed only neuronal 
markers, GFAP or nestin.  
Given that radial glia represent the predominant neural stem cell in the 
developing human cortex [461] and that nestin is a known marker of neural stem cells 
[462], the late stage culture likely contains a mixture of immature neural stem cells 
(GFAP-, nestin-, and neuronal marker-positive) and differentiated neurons and 
astrocytes (positive for a single marker). The persistence of neural stem cells in the 
culture might be explained by the maintenance of bFGF in the medium throughout 
culture. A previous study has also described a similar mixture of cultured cells derived 
from human fetal brain parenchyma [463]. Importantly, this primary human fetal brain 
culture closely mimics the in vivo fetal brain cellular network.  
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Figure A1: Immunocytochemical characterization of neuronal and glial markers in 
human primary fetal brain cultures during in vitro development. Primary human 
fetal brain cultures at DIV 8 to DIV 24 following continuous bFGF exposure were co-
labeled with a pan-neuronal antibody cocktail and anti-GFAP Arrows point to cells only 
labeled with the pan neuronal cocktail. Arrowheads point to cells only labeled by anti-
GFAP.  
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Figure A2: Immunocytochemical characterization of neuronal and 
neuroprogenitor markers in human primary fetal brain cultures during in vitro 
development. Primary human fetal brain cultures at DIV 8 to DIV 24 following 
continuous bFGF exposure were co-labeled with a pan-neuronal antibody cocktail and 
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anti-nestin Arrows point to cells only labeled with the pan neuronal cocktail. Arrowheads 
point to cells only labeled by anti-nestin.  
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